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Current transfusion alternatives  
in elective orthopaedic surgery
10 | Chapter 1
Total hip and knee prosthesis surgery is performed worldwide about two million times 
annually (approximately 50.000 in the Netherlands). These surgeries may result in significant 
intra- and postoperative blood loss (800 to1500mL) with a potential need for allogeneic 
Red Blood Cell (RBC) transfusions to compensate for the resulted anaemia. Although blood 
transfusions are relatively safe, transfusion reactions such as fever, haemolysis, antibody 
formation, Transfusion Associated Circulatory Overload (TACO), Transfusion Related Acute 
Lung Injury (TRALI), or transmission of infectious agents may occur. Furthermore, Natural 
Killer (NK) activity was found to be decreased in patients after an allogeneic RBC transfusion 
compared to no RBC transfusion or peri-operative autologous wound blood re-infusion 
[1]. It has been postulated that, immuno-modulatory effects of blood transfusions may 
result in an increased susceptibility for infections in the postoperative period [2-7]. In the 
field of orthopaedic surgery, there is an ongoing trend to aim for optimal Patient Blood 
Management (PBM). PBM is a new concept in Transfusion Medicine that is based on three 
approaches (pillars): 1. optimising the patient’s own blood; 2. minimising surgical blood loss 
and bleeding; and 3. harnessing and optimising the patient-specific physiological reserve 
of anaemia (including restrictive transfusion thresholds) (http://www.health.wa.gov.au/
bloodmanagement/home.health_professionals.cfm). This approach includes pre-operative, 
intra-operative and post-operative strategies for managing the patient, such as alternatives 
for RBC transfusions, but also surgical and anaesthesiological strategies. A comprehensive 
overview of blood conservation strategies in major orthopaedic surgery in the European 
setting is published in 2009 by Munoz et al [8]. In this overview, several of these strategies 
are discussed, such as correction of perioperative anaemia, pharmacological and non-
pharmacological measures to reduce blood loss, preoperative autologous donation, and 
perioperative blood salvage. Based on the efficacy and safety of these strategies in literature, 
recommendations are offered. However, some recommendations are not supported by a 
high level of evidence due to a lack of appropriate data.
tranSfuSiOn PraCtiCE
A large variation in transfusion practice is present. Recently, in the Austrian benchmark 
study, Gombotz and colleagues found a transfusion rate varying from16 to 85% for patients 
undergoing primary total hip replacement (THR) and a 12 to 87% transfusion rate for 
patients undergoing primary total knee replacement (TKR) surgery [9]. The Orthopaedic 
Surgery Transfusion Haemoglobin European Overview (OSTHEO) study of Rosencher and 
co-workers assessed standard practice in blood management in six countries in Europe (225 
centres, n=3996 patients) and found that, despite existing guidelines, a large percentage 
(21%) of the pre-transfusion Hb levels were greater than or equal to 10 g/dL and 10% 
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guidelines in daily practice, which is often difficult to achieve. This is not only relevant for 
implementing transfusion thresholds, but also for the number of transfusions at each event 
to reach a particular target Haemoglobin (Hb) level. Barr and co-workers investigated red 
blood cell transfusion practice in Northern Ireland in 2005 and still found a two-unit instead 
of single-unit transfusion practice in medical and surgery patients (n=1474) [11].
BlOOd tranSfuSiOn PrOtOCOlS
An important blood saving strategy is the use of a restrictive transfusion protocol. In 1988, the 
NIH published consensus guidelines for red blood cell transfusions [12]. Since then, several 
guidelines have been published, recommending that a range of Hb levels between 6 and 10 
g/dL can be used, depending on the presence of serious co-morbidity [13-15]. These clinical 
practice guidelines, however, have based their recommendations on data from published 
reports on series of patients for whom red cell transfusions were withheld (for instance 
Jehovah’s witnesses), and observational studies, rather than on the results of clinical trials. 
Since June 2004, the 4-5-6 Flexinorm transfusion trigger (Hb values in mmol/L), based on 
the NIH guidelines, in surgical setting was recommended in the Dutch national Consensus 
guideline for Blood Transfusion (CBO) [16]. This transfusion trigger policy is based on 
parameters as Hb level, age and condition of the patient (ASA criteria). In 2010, a Cochrane 
review of Carless and co-workers reported on seventeen Randomised Controlled Trials 
(RCTs) including surgical and medical patients, and concluded that a restrictive transfusion 
policy can reduce the need of receiving a RBC transfusion (further mentioned as transfusion 
avoidance) with 37% (RR 0.63 [95% CI 0.54 to 0.74]; however with a non-significant mean 
RBC reduction (further mentioned as RBC sparing) of 0.75 RBC unit [95% CI 0.20 to 1.3]). 
However, methodology was poor and significant heterogeneity between studies was 
present [17]. Only one study (Lotke 1999) reported on elective orthopaedic surgery patients 
who also donated pre-operatively 2 units of autologous blood (knee replacement surgery, 
n=152), which resulted in an increased allogeneic transfusion avoidance of 74% (RR 0.26 
[95% CI 0.17 to 0.40]).
CurrEnt altErnativES fOr rEd BlOOd CEll tranSfuSiOnS
Many alternatives for an allogeneic RBC transfusion are available. Not all interventions are 
widely applied in the Netherlands. Next to efficacy, important factors that are of influence 
are costs and user friendliness. Based on recent randomised controlled studies, the efficacy 
of the different modalities will be discussed, first in general and in more detail for the elective 
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orthopaedic surgery patients. These alternatives for an allogeneic blood transfusion can be 
subdivided in two main groups:
a. non-pharmacotherapeutical interventions:
1. pre-operative alternatives: Preoperative Autologous Donation (PAD) 
2. peri-operative alternatives: 
a. Acute Normovolaemic Haemodilution (ANH), in which one or several units of whole 
blood is taken just before surgery and at the same time (=isovolaemic) the lost blood 
volume is replaced by normal saline or colloids. The retained whole blood is then 
transfused back to the patient during or after surgery;
b. use of the cell saver, that collects autologous wound blood during (and sometimes 
after) surgery. The shed blood is washed, concentrated and then re-infused.
3. post-operative alternatives: devices that collect and re-infuse autologous wound blood 
after surgery (non-washed, filtered by several types of devices) by means of a wound-
drainage and re-infusion system.
B. Pharmacotherapeutical interventions
This concerns the pre-operative use of Erythropoietin (Epo) and the peri-operative use of 
anti-fibrinolytics (e.g. aprotinin, tranexamic acid) and fibrin glue. The use of (intravenous) 
iron as a new modality will be discussed in chapter eight of this thesis.
CurrEnt EvidEnCE On tranSfuSiOn altErnativES in thE general 
surgical POPulatiOn
ad a non-pharmacotherapeutical interventions
A Cochrane review by Henry and co-workers (2010) reported on 13 trials (n=1506) and 
concluded that Pad as a single intervention resulted in a significant transfusion avoidance of 
68%. However, autologous donors were more likely to undergo transfusion with allogeneic 
and/or autologous blood (OR 1.24; 95% CI 1.02 to 1.51). The authors concluded, that overall 
transfusion rates were very high, raising the question of the true benefit of PAD.
 In 2004, two systematic reviews reported on the use of anh in elective surgery [18,19]. 
Carless and co-workers performed a systematic review on several autologous transfusion 
techniques (PAD, ANH and cell saver). Of 30 trials, ANH resulted in a significant transfusion 
avoidance of 31%. Mean RBC use was reported in 7 trials resulting in a significant mean RBC 
sparing of 1.9 units. However, studies were small, and methodology was judged as poor. 
Also, the blood sparing effect was less when a transfusion protocol (in 60%) was used. [18] 
Segal and co-workers compared 42 RCTs on ANH, but did not find a significant reduction 
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compared to another blood conservation method (mostly PAD). They concluded that use of 
ANH can not be encouraged [19].
 The effect of washed autologous salvaged blood (by means of cell saver) or non-
washed salvaged blood (by means of post-operative re-infusion systems) on RBC use was 
investigated In a Cochrane review [20]: 75 randomised studies up to 1 June 2009 were 
analysed. The authors concluded a significant overall transfusion avoidance of 38% and 
mean RBC sparing of 0.68 RBC unit.
table 1. Transfusion avoidance and mean Red Blood Cell (RBC) reduction of transfusion alternatives in 
the general surgical population




rr [95% Ci] Mean rBC 
reduction/patient 
[95% Ci]
Henry (2010) [37]# PAD 68% 0.32 [0.22 to 0.47] NA
Carless (2004) [18]# ANH 31% 0.69 [0.56 to 0.84] 1.9 [1.1 to 2.7]
Segal (2004) [19] ANH 4% (NS) 0.90-1.01 [NA] NA
Carless (2006) [20]# Autologous blood 
salvage
38% 0.62 [0.55 to 0.70] 0.68 [0.49 to 0.88]
Laupacis (1998) [21] Epo (cardiac surgery) 75% 0.25 [0.08 to 0.82] NA
#=Cochrane review
Abbreviations: CI=Confidence Interval; PAD=Preoperative Autologous Donation; ANH=Acute Normovolaemic 
Haemodilution; NA=Not Available; NS=Not Significant; Epo=Erythropoietin.
ad B Pharmacotherapeutical interventions
In a meta-analysis by Laupacis and co-workers [21] , Epo resulted in a significant transfusion 
avoidance (with or without the combination with PAD) with the largest effect (75% 
avoidance) in cardiac surgery patients (Table 1). A systematic review on the use of anti-
fibrinolytics for minimising perioperative allogeneic blood transfusion and on their adverse 
events was published in 2007 and updated in 2011 by Henry and co-workers, comparing 
aprotinin, TraneXamic Acid (TXA) and Epsilon AminoCaproic Acid (EACA). [22] That review 
of over 250 clinical trials reported on the use of anti-fibrinolytic drugs in major surgery and 
found that these reduced bleeding, as well as the need for transfusions of red blood cells. 
Consequently, the need for revision surgery because of bleeding (in cardiac surgery) was 
reduced as well. This update was especially focussed on safety, since the results of the BART 
study (2008), a study in cardiac surgery patients comparing aprotinin to TXA and to EACA, 
showed that aprotinin was significantly associated with increased mortality compared to 
the lysine analogoues TXA and EACA. This resulted in abandoning the use of aprotinin in 
patients [23]. This finding suggests a potential bias of under-reporting adverse events, since 
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only 18 of 76 trials of aprotinin reported adverse events. Also, more studies with positive 
effects were published, resulting in asymmetric funnel plots, suggesting publication bias. 
The explanation for the increased mortality rates after aprotinin in comparison to lysine 
analogues might be due to a direct adverse effect by aprotinin or due to a protective effect 
of the lysine analogues. The lysine analogues TXA and EACA appeared to be safe. 
 
Current evidence on transfusion alternatives in elective hip-and knee replacement surgery 
patients
ad a non-pharmacotherapeutical interventions:
ad 1 Preoperative alternatives
Preoperative autologous donation (PAD)
Five trials reported on orthopaedic surgery patients (n=425) and showed a significant 
transfusion avoidance of 79%. However, autologous orthopaedic donors were more likely 
to have an increased overall transfusion rate with allogeneic and/or autologous blood (OR 
1.78; 95% CI 0.61 to 5.20). In The Netherlands, PAD is predominantly collected at Sanquin 
Blood Supply (donor centres). Only one hospital, the Sint Maartenskliniek, a specialised 
orthopaedic centre in Nijmegen, has implemented this procedure as an in-house procedure 
within their own hospital setting.
 The modality of PAD is relatively expensive and complex and needs a fixed surgery 
date (the patient needs to visit the centre several times to donate blood). In addition, the 
likelihood for mistakes by switching of blood products is high [24]. The British guidelines 
only advise PAD in exceptional cases if the normal donor stock is not sufficient as in cases 
of rare blood group typing and/or antibodies against public antigens etc [25]. The new CBO 
Guidelines (Richtlijn Bloedtransfusie) 2011 advises a limited use of PAD due to the complex 
logistics, the relative high costs, the lack of additional safety and the waste of plasma 
products (side product of PAD) and recommends for it’s use for certain indications, like lack 
of compatible blood units in case of rare blood groups or antibodies to public or multiple 
red blood cell antigens and the occurrence of former haemolytic transfusion reactions with 
unknown cause. 
ad 2a acute normovolaemic Haemodilution (anH)
ANH is not often applied in the Netherlands, possibly due to its logistical difficulties. In the 
two systematic reviews of Carless and Segal, ANH was investigated in 6 and 13 orthopaedic 
trials, respectively. Both did not report a significant benefit of ANH on transfusion avoidance. 
Compared to another blood sparing modality (PAD or TXA), ANH was less effective in 
orthopaedic patients [19]. As a transfusion alternative, ANH is therefore not recommended 
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ad 2B en 3
autologous re-infusion (cell saver and post-operative re-infusion systems)
In a Cochrane review [20] evaluating all randomised studies up to 1 June 2009, in which 
the effect on RBC use of washed shed blood (by means of cell saver) or non-washed shed 
blood by means of post-operative re-infusion systems was investigated, 36 studies reported 
on orthopaedic surgery (6 of which had been conducted in the Netherlands). The authors 
concluded a significant transfusion avoidance of 54% and a significant mean RBC sparing of 
0.82 RBC unit per patient as well. The outcomes were similar using washed or non-washed 
blood. The authors also concluded that the methodological quality was poor and that the 
findings could have been influenced by bias. There was a lack of concealment, meaning that 
allocation of the randomisation was not centralised, but often on location by drawing an 
opaque envelope. This method can be susceptible to bias, because it can not be ruled out 
that the envelopes are drawn in the proper order [26]. 
table 2. Transfusion avoidance and mean red blood cell (RBC) reduction of transfusion alternatives in 
the elective knee-and hip replacement surgical population




rr [95% Ci] Mean rBC reduction /
patient [95% Ci]
Henry (2010) [37]# PAD 79% 0.21 [0.11 to 0.43] NA
Carless (2004) [18]# ANH 21% 0.79 [0.60 to 1.06] NA
Segal (2004) [19] ANH 23% to none 0.77 to 1.06 
[0.47 to 1.37]
NA
Carless (2006) [20]# Autologous  
blood salvage
54% 0.46[0.37 to 0.57] 0.82 [-0.27 to -1.36]
Laupacis (1998) [21] Epo with PAD 58% 0.42 [0.28 to 0.62] NA
idem Epo only 64% 0.36 [0.24 to 0.56] 0.14 [-0.04 to 0.31]
Fergusson (submitted) Epo 56% 0.44 [0.31 to 0.64] 0.61 [0.22 to 1.01]
Henry (2011) [22]# APR vs Co
(n=1146)
32% 0.68 [0.5 to 0.89] NA
idem TXA vs Co
(n=1381)
51% 0.49 [0.39-0.62] NA
idem EACA vs Co
(n=304)
0% 1.00 [0.93 to 1.08] NA
#=Cochrane review
Abbreviations: APR=APRotinin; PAD=Preoperative Autologous Donation; ANH=Acute Normovolaemic Haemodilution; 
NA=Not Available; NS=Not Significant; Epo=Erythropoietin; Co=Control group; TXA=TraneXamic Acid; EACA=Epsilon 
AminoCaproic Acid
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ad B. Pharmacotherapeutical interventions
erythropoietin (epo)
Many randomised studies have been published in which the effect of Epo on RBC use has 
been investigated. Older studies report on the effect of Epo on the efficacy of donating PAD. 
In a meta-analysis by Laupacis et al [21] , in orthopaedic surgery, Epo resulted in a significant 
transfusion avoidance of 58% with or 64% without the combination with PAD (11 trials with 
PAD and 3 trials without PAD), but Epo did not significantly reduce the mean RBC use. The 
main reason for this finding was the low mean number of transfusions in the control group 
(0.46 RBC unit/patient), and a subsequent non-significant decrease of 0.14 RBC unit per 
patient after use of Epo. This finding was confirmed by a large European randomised study 
(n=695) (the EEST study) by Weber and colleagues [27], who found a proportion of 12% 
transfused patients in the Epo group which was significantly lower than the 46% transfused 
patients of the control group (p<0.001), but found a non-significant difference in mean RBC 
use (1.25 RBC/patiënt [SD 0.51] versus 1.42 RBC/patiënt [SD 0.70], respectively; p=0.14). 
A recent meta-analysis by Fergusson and co-workers performed on elective orthopaedic 
surgery studies until August 2007 (submitted) resulted in 36 evaluable RCTs of which 
Epo dose varied (>1800 UI/kg or <1800 UI/kg), as well as time of administration (pre-or 
postoperatively), use of PAD, route of Epo administration (subcutaneously or intravenously) 
and use of a transfusion threshold (in 15 trials not reported). Overall, compared to the 
control group, a significant RBC avoidance of 56% was found as well as a significant RBC 
sparing of 0.61 RBC unit. The aggregated risks of DVT was 3.5%, and 0.20% of myocardial 
infarction (MI), 0.29% of stroke, 0.15% of PE and 0.13% of death. It was concluded that Epo 
was a safe blood sparing modality in orthopaedic surgery, however, Epo exceeds the costs 
of an allogeneic blood transfusion [28,29].
anti-fibrinolytics
Since trials on anti-fibrinolytics comprised mostly cardiac surgery patients, which are rather 
different from orthopaedic surgery patients, outcome on RBC use may be quite different 
between these study populations. The results of trials on orthopaedic surgery patients are 
discussed here, and when possible, separately reported:
1. interventional drug versus control group
Of 108 trials of aprotinin compared with a control group, 15 were conducted in orthopaedic 
surgery with a total of 1146 patients. In these patients, the use of aprotinin resulted in a 
significant transfusion avoidance of 32%, however studies were heterogeneous (p<0.001). 
Total blood loss was also reduced by around 400 mL (Mean difference -399 mL [-563 to 
-235 mL]) (n=430; 10 studies), heterogeneity was again significant (p<0.007). Compared to 
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in an increased risk for myocardial infarction or for thrombotic events (stroke, deep vein 
thrombosis or pulmonary embolus).
 Of 65 reported trials on tXa compared with controls, 27 involved orthopaedic surgery 
(n=1381 patients), where a significant transfusion avoidance of 51% was found (RR 0.49, 
however heterogeneity between trials was present (p<0.0007). Total blood loss was 
significantly reduced by 446 mL [95% CI of mean difference 338 to 555 mL], also with 
heterogeneity between trials (p<0.00001).Compared to controls, the use of TXA (pooled 
data) did not result in increased mortality risk nor increased risk of myocardial infarction or 
thrombotic events (stroke, deep vein thrombosis or pulmonary embolus). 
 Of 16 reported trials of EaCa compared with controls, four trials involved orthopaedic 
surgery (n=304 patients) of which the use of EACA did not reduce the need for allogeneic 
RBC transfusions. Two trials reported a marginally effective reduction in total blood loss of 
300 mL [95% CI of mean difference 77 to 523 mL]. Mortality risk, risk of myocardial infarction, 
and thrombotic events were not increased.
2. comparison between anti-fibrinolytics
A. Aprotinin versus TXA
Of 21 trials on aprotinin versus TXA that reported data on the number of patients exposed 
to allogeneic RBC transfusions, only one study [30] was performed in orthopaedic surgery 
patients (knee replacement surgery; n=36). The study consisted of three groups of 12 
patients: controls versus TXA versus aprotinin, respectively) and showed no difference in 
the transfusion rate between all three groups. No adverse outcomes were reported other 
than deep venous thromboses (n=2 in TXA group, n=1 in aprotinin group and n=0 in control 
group). 
B. Aprotinin versus EACA
Of 12 reported trials, three (Amar 2003;n=69 spine, Ray 2005; n=45 hip, Urban 2001; n=60 
spine) were in orthopaedic surgery patients: no significant transfusion avoidance was 
found with aprotinin compared to EACA (RR 0.82; 95% CI 0.48 to 1.40) [31-33]. The relative 
risk, however, was comparable to the risk in cardiac surgery patients, in which a significant 
transfusion avoidance with aprotinin was found (RR 0.82; 95% CI 0.76 to 0.89). Ray and co-
workers performed a study on 45 total hip arthroplasty patients and did not find a difference 
in blood loss between aprotinin and EACA (each 15 patients per group) or in mean RBC 
reduction or transfusion avoidance. 
 Pooled data on adverse events (myocardial infarction, thrombotic events) showed no 
difference between the study- and control groups. In the single hip surgery trial of Ray and 
co-workers [32] no thrombotic events as DVT or PE were found. Six cardiac adverse events 
were reported postoperatively in the intervention groups: two non-ST elevation MI, two 
atrial fibrillation (AF), and two patients with both MI and AF, however this did not reach 
statistical significance compared to the control group in these 45 patients (p=0.08). 
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C. TXA versus EACA
Of 8 reported trials (n=2003), only one orthopaedic study (knee replacement surgery; 
n=127) compared TXA (n=35) with EACA (n=32) and placebo (n=60) and found no difference 
in blood loss between TXA and EACA or in transfusion avoidance or mean RBC reduction or 
in adverse events [34].
 
Conclusions on the role of anti-fibrinolytics in orthopaedic blood management 
Compared to controls, both aprotinin and TXA, but not EACA showed significant transfusion 
avoidance. Compared to one another, only three orthopaedic trials on knee- and hip 
replacement surgery, were available: no advantage of aprotinin compared to the lysine 
analogues could be found regarding blood loss and the need for RBC transfusions. None 
of these studies reported on mortality and only one study reported more cardiac adverse 
events [32]. Since data are lacking, and numbers were small, no valid conclusions can be 
drawn regarding the blood sparing effect or regarding adverse events in orthopaedic 
surgery due to the low numbers of study patients. 
Fibrin glue
Carless and co-workers (2009) concluded in a Cochrane review that especially in orthopaedic 
surgery, where blood loss is often substantial, fibrin sealants appeared to demonstrate their 
greatest beneficial effects by significantly reducing blood loss and transfusion avoidance by 
32% (RR 0.68; 95% CI 0.51 to 0.89), but large RCTs were lacking [35]. Therefore, the authors 
support initiating well-conducted large clinical trials on this matter.
SCOPE Of thiS thESiS
As discussed, several transfusion alternatives are available to reduce RBC use in elective 
orthopaedic surgery. Since the patient population eligible for knee-or hip replacement 
surgery is exponentially growing, expecting more than 100.000 of these type of surgeries 
in 2030 in the Netherlands [36], optimising peri-operative blood management is not only 
highly relevant with respect to patient risk and benefit, but also important in terms of cost 
effectiveness. 
 However, we found that insufficient evidence was published to provide a strategy for 
the optimal use these transfusion alternatives: most studies compared only one transfusion 
alternative with controls, which is inconsistent with daily practice; or studies were of older 
date, comparing transfusion alternatives as PAD with ANH, both are not widely applied 
anymore, especially not in the Netherlands; or studies did not use a transfusion protocol or 
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To gain insight in the transfusion policy, we first evaluated RBC use during 6 months in the 
orthopaedic ward in the LUMC in 2000 (January to July). We found that a 68% reduction 
could be reached if a restrictive transfusion policy would be implemented. This was the 
reason to start a Randomised Controlled Trial (RCT), to investigate the effect of a restrictive 
transfusion trigger on mean RBC use and transfusion avoidance. To anticipate on a study to 
evaluate the use of postoperative autologous wound blood we compared the feasibility and 
effectiveness of different types of post-operative re-infusion devices, that were available in 
2003, and to explore their possible use in a larger trial on the combined use of transfusion 
alternatives. Finally, we were fully prepared to study the effect of combinations of the 
mostly applied transfusion alternatives, while using a strict transfusion threshold, currently 
recommended in blood management protocols. The aim of this thesis is to optimise 
Patient Blood Management by providing evidence for cost-effective measures in elective 
orthopaedic surgery. 
OutlinE Of thiS thESiS
Chapter 2 describes the results of a RCT on the effect of a restrictive trigger on RBC sparing. In 
three hospitals, a restrictive transfusion policy was compared with standard care transfusion 
policy. A randomised comparison of transfusion triggers in elective orthopaedic surgery 
using leucocyte-depleted red blood cells was performed. The clinical consequences of this 
restrictive transfusion policy on post-operative complications and well-being are discussed 
in Chapter 3. Quality of Life and fatigue scores in relation to postoperative haemoglobin 
levels were analysed in Chapter 4. 
 In Chapter 5 we investigated the efficacy and feasibility of two types of postoperative 
drainage and re-infusion systems and compared these to a control group. To evaluate the 
immuno-modulatory effects of salvaged blood in the post-operative patient, we analysed 
the effect of autologous salvaged blood re-infusion on the patients’ cytokine gene 
expression profiles compared to the effect of surgery itself (Chapter 6). 
 Chapter 7 reports the combined strategies of Epo and autologous salvaged blood 
on RBC use compared to a control group under a restrictive transfusion policy (TOMaat 
study). In Chapter 8, future trends and ongoing studies are discussed in order to aim for 
an optimal and Tailor Made Patient Blood Management Program for elective orthopaedic 
surgery patients. In the final chapter, Chapter 9, an implementation protocol is described 
to investigate the barriers and facilitators for implementation of the TOMaat study results in 
daily practice. 
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aBStraCt
Objective: In elective orthopaedic hip- and knee replacement surgery patients, we studied 
the effect of implementation of a uniform transfusion policy on RBC usage. 
Study design and methods: A randomized, controlled study. A new uniform, restrictive 
transfusion policy was compared with standard care, which varied among the three 
participating hospitals. Only prestorage leukocyte-depleted RBC(s) were used. Primary 
end-point was RBC usage, related to length of hospital stay. Secondary end-points were Hb 
levels, mobilisation delay and postoperative complications. 
results: 603 patients were evaluated. Adherence to the protocol was over 95%. Overall 
mean RBC usage was 0.78 U/patient in the new policy group and 0.86 U/patients in the 
standard care policy group (mean difference 0.08; 95% CI [-0.3; 0.2]; p=0.53). In two hospitals 
the new transfusion policy resulted in a RBC reduction of 30% (0.58U RBC/patient) (p=0.17) 
and 41% (0.29 U RBC/patient) (p=0.05), respectively. In the third hospital, however, RBC 
usage increased by 39% (0.31 U RBC/ patient) (p=0.02) with the new policy, due to a more 
restrictive standard care policy in that hospital. Length of hospital stay was not influenced 
by either policy. 
Conclusions: Implementation of a uniform transfusion protocol for elective lower joint 
arthroplasty patients is feasible, but does not always lead to a RBC reduction. Length of 
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intrOduCtiOn
Concerns about transfusion-associated complications have stimulated the use of drugs and 
devices to reduce peri-operative blood transfusions [1-3]. To value such interventions they 
must be compared with an appropriate and uniform use of allogeneic RBC transfusions. 
In itself, one of the tools to accomplish a reduction in allogeneic RBC transfusions is a 
standardized protocol for the use of a restrictive transfusion trigger. Studies on the use of such 
a protocol in (orthopaedic hip fracture) surgery report an allogeneic RBC reduction between 
40 and 80%, depending on the type of restriction used [4-6]. In elective orthopaedic surgery, 
a randomized study in which different transfusion trigger protocols are compared has never 
been performed. Additionally, except for studies in paediatric and neonatal patients, all 
previous studies that compared different transfusion triggers used non leukocyte-depleted 
RBC units [4,5,7]. We only used pre-storage leukocyte-depleted (LD) RBC(s) and conducted 
a randomized controlled trial among elective orthopaedic surgery patients in three Dutch 
hospitals to investigate the effect of a new, restrictive transfusion protocol compared with 
the standard care on the magnitude of reduction in RBC transfusions and its effects on 
length of hospital stay (LOHS), postoperative complications and rehabilitation. 
PatiEntS and MEthOdS
Outcome measures
Primary objective was to investigate whether or not a reduction of RBC usage was associated 
with a prolonged hospital stay.
 Primary outcome was RBC usage. With the new transfusion policy we aimed at a 
reduction of 40% in RBC use without increasing hospital stay. Secondary end-points were: 
postoperative Hb values (g/dL) at day +1, day +4 and day +14, mobilization delay (days) and 
postoperative complication rate. 
Inclusion criteria:
All patients of 18 years and older scheduled for a primary or revision total hip replacement 
(THR)- or total knee replacement (TKR) surgery of three Dutch participating hospitals were 
eligible for inclusion. 
Exclusion criteria:
Refusal of allogeneic transfusions (e.g. Jehovah’s witnesses). 
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Study design
A randomized open study stratified by hospital, type of surgery and risk group. Eligible 
patients were informed during the preoperative intake at the orthopaedic outpatient 
clinic and after obtaining informed consent were randomly assigned to a new transfusion 
policy (protocol A) or standard care (protocol B). The new policy, which was risk level 
based and uniform among the three participating hospitals, is described in Table 1, and 
was meant to include the more restrictive transfusion policy. In this policy, age and co-
morbidity were determinants for the used risk levels for transfusion. Three clinical risk 
groups (low, intermediate and high) were defined: age groups less than 50 years, 50 to 70 
years, and older than 70 years or presence of significant co-morbidity (i.e. cardiovascular 
and pulmonary disease, and/or insulin dependent diabetes). The standard care policies, 
which varied among hospitals, are described in Table 2, and were supposed to include 
the more liberal transfusion policies. Randomization took place as follows: all patients 
were stratified by hospital, type of surgery (primary/revision THR/TKR) and risk group. For 
each stratum a separate randomization list was created, using blocks of variable length to 
avoid predictability of the random treatment assignment towards the end of each block. 
Treatment allocation was random using a uniform distribution for a pregenerated list of 
sufficient length, based on the maximum expected sample size in each stratum. For each 
subject to be randomized, a sheet of paper with all relevant stratification and group-
allocation information was produced and placed in a sealed opaque envelope. Batches 
were created according to the stratification factors. After receiving informed consent, the 
patient was preoperatively allocated by the research nurse to one of the groups by opening 
the first sealed envelope from the appropriate stratum.
 Due to a universal leukocyte-depletion policy in the Netherlands, our data comprises only 
pre-storage LD- RBC(s). Intra-operative transfusions were guarded by the anaesthesiologist 
and post-operative transfusions by the orthopaedic surgeon. Both were informed about 
the treatment assignment in order to avoid protocol violations, but they were not involved 
in the coordination and evaluation of the study. The chart data were written on the Clinical 
Research Form and placed in the database by the research nurse, who had access to the 
medical records in which the study assignment was noted. The study investigators, however, 
were blinded for the randomization arm. Transfusion trigger deviations were regarded as 
protocol violations. The following postoperative complications were scored: infections, 
ICU stay, transfusion reactions (defined by the national hemovigilance association), neuro-
psychiatric, cardiovascular, haemorrhagic and drug related complications, and death. 
Post-operative infections were defined according to the CDC criteria [8]. Wound infections 
were scored according to Gaine et al [9]. Mobilisation was defined according to the hospital 
protocols (hospital number 1: mobilisation from day +2 onwards, hospitals number 2 and 
3: mobilisation from day +1 onwards) and was recorded by the orthopaedic surgeon on the 
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patient: they had to be ambulated with a crutch and had to be able to walk a staircase with 
ease. Hospital number 2 used a short-stay protocol for the most healthy and mobile patients. 
Follow up ended at the outpatient clinic 14 days after surgery or (in case of a hospital stay 
of more than 14 days) at final discharge. All patients provided informed consent, and the 
trial was conducted according to good clinical practices and the Declaration of Helsinki. The 
study was approved by the Medical Ethical Committees of the three participating hospitals.
table 1. Transfusion policies: new, uniform restrictive transfusion policy (Protocol A)
low risk group (patients younger than 50 years of age)
Within 4 hours of surgery After 4 hours of surgery
If Hb ≥6.4 g/dL: 0 RBC If Hb ≥6.4 g/dL: 0 RBC 
4.8 - <6.4: 1 RBC 5.6 - <6.4: 1 RBC
<4.8: 2 RBC(s) <5.6: 2 RBC(s)
intermediate risk group (patients from 50 to 70 years of age)
Within 4 hours of surgery After 4 hours of surgery
If Hb ≥7.2 g/dL: 0 RBC If Hb If Hb ≥8.1g /dL: 0 RBC
6.4 - <7.2: 1 RBC 7.2 - <8.1: 1 RBC
 <6.4: 2 RBC(s) <7.2: 2 RBC(s)
high risk groupa (see below)
Within 4 hours of surgery After 4 hours of surgery
If Hb ≥8.9 g /dL: 0 RBC If Hb If Hb ≥9.7 g /dL: 0 RBC
8.1 - <8.9 1 RBC 8.9 - <9.7: 1 RBC
7.2 - <8.1: 2 RBC(s)  8.1 - <8.9: 2 RBC(s)
<7.2: 3 RBC(s)  <8.1: 3 RBC(s) 
Hb values were originally in mmol/L (e.g. 4.0 / 5.0 / 6.0 mmol/L) which is common use in the Netherlands
aHigh risk includes one or more of the following:
(i) any heart rhythm different than sinus rhythm.
(ii) unstable cardiac ischemia (by history or ECG) 
(iii) myocardial infarction < 6 months 
(iv) heart failure
(v) heart valve disease
(vi) age ( from 70 years onwards)
(vii) serious peripheral arterial disease, including large vessel surgery (aortic aneurysm, peripheral vessels).
(viii) cerebral arterial disease (CVA or TIA in history)
(ix) hypertension with left ventricular hypertrophy (LVH) (shown on ECG/ echocardiogram)
(x) serious pulmonary disease, expressed in polyglobulism (emphysema / pulmonary fibrosis)
(xi) insulin dependent diabetes mellitus
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table 2. Transfusion policies: standard care transfusion policies (Protocol B)
hospital number 1 (university Medical Center):
Peri-operative transfusion policy (day 0): 
 if Hb between 8.1 and 9.7 g /dL and dependent on blood loss: 1-2 RBC(s).
Post operative transfusion policy (from day 1):
 if Hb <9.7 g /dL : 2 RBC(s), independent of age, risk status
hospital number 2 (general hospital):
Peri-operative transfusion policy (day 0): 
 I keep Hb >6.4 g/dL in case of age < 60 years and ASAa class 1
 II keep Hb >8.1 g.dL in case of age ≥ 60 years and ASAa class 1, 2, 3
 III keep Hb >9.7 g/dL in case of ASAa class 4 or serious cardiopulmonary disease
aAmerican Society of Anesthesiologists
Post operative transfusion policy (from day 1):
 I keep Hb > 9.7 g/dL in case of co-morbidity as: IC / CCU admission, uremia, serious heart-, lung- or vessel  
  disease: 
 II If no co-morbidity exists, the transfusion trigger is age-dependent:





hospital number 3 (general hospital):
Peri-operative transfusion policy (day 0): 
 if Hb <9.7 g/dL and dependent on (expected) blood loss: 2 RBC(s) 
Post operative transfusion policy (from day 1):
  I Patients with cardiac history:
   if Hb <9.7 g/dL: 2 RBC(s)
  II Patients without cardiac history if symptomatic (nausea, dizziness, tachycardia, general malaise,  
  paleness):
   if Hb 7.2 g/dL – 8.1 g/dL: 2 RBC(s)
  III If Hb ≤7.2 g/dL: 2 RBC(s)
Sample size calculation
The initial sample size calculation (power 0.90; alpha 0.05) was based on pilot data of hospital 
number 1, from which a 40% RBC reduction (in terms of RBC units divided by the total 
patients in each randomization group) was expected by introducing the new transfusion 
policy. Since the main statistical analysis is a comparison of group means, the reduction for 
which the study was powered, was transformed to an absolute reduction from an estimated 
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other group. A t-test with adjustment for possibly non-normally distributed data needed 
2 groups of 125 patients to achieve 90% power for a treatment effect of 1 RBC unit at a 
pooled SD of 2.4, while at the same time powering with 90% for equivalence in length of 
stay with a delta of at most four days between the groups. At the time the study protocol 
was designed a mean hospital stay of 10 to 12 days was usual, therefore a prolongation of 
hospital stay of more than four days was not acceptable from a clinical point of view. To 
adjust for non-evaluable patients, each of 3 hospitals had at least to randomize 100 patients. 
An interim analysis was performed after the first 125 patients became evaluable. A formal 
stopping rule was pre-specified to enable the trial to stop for futility as well as efficacy, using 
a simple Bonferroni correction for multiple testing (alpha=0.025). This pre-specified rule 
also included the condition of a maximal prolongation of hospital stay of four days in the 
new policy group, which was expected to include the most restrictive transfusion policy: 
so if RBC use was significantly lower in the new policy group, but hospital stay increased 
by more than four days, the new transfusion policy was considered not to be clinically nor 
economically beneficial. A much lower percentage of patients who were actually transfused 
(33% in stead of the expected 75%, which was calculated from the pilot study), irrespective 
of hospital and trial arm, resulted in an adjustment of the group sizes, leading to two groups 
of 300 evaluable patients. 
Statistical analysis
Analysis was performed on an intention-to-treat basis and for the parametric analyses 
stratified by all stratification factors in the design. Frequencies were described as mean and 
SD, and in addition median and interquartile range in case of a non-normal distribution. 
Analysis of laboratory parameters between patients and other numerical end-points was 
performed with the ANOVA-test for between-group comparisons and by a paired t-test (or a 
mixed model) for within-patients effects. Differences between the groups in the number of 
RBC transfusions and the total number of units RBC transfusions given were analysed with 
the non-parametric Mann-Whitney test. Categorical end-points were tested using the Chi-
square test or Fisher’s Exact test. LOHS and age were analysed as a continuous variable. In 
case of heterogeneity between the three hospitals concerning the primary and secondary 
end-points, subgroup analyses by hospital will be performed. 
 Regarding the primary end-point, a P-value of less than 0.05 was considered statistically 
significant. For the analysis of the secondary end-points we used a Bonferroni correction to 
adjust for multiple testing (significant P-value of less than 0.01). Data were analysed using 
the SPSS statistical program (version 11.0) for Windows (SPSS Inc, Chicago, IL, USA).
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rESultS
Patient enrolment and baseline characteristics 
From 2001 to 2003, 713 patients were assessed for eligibility of which 619 consecutive 
patients were included. Sixteen patients were not analysed because of the following 
reasons: cancellation of surgery in seven, death before surgery in one, consent withdrawn 
before surgery in six and charts missing in two cases (Figure 1: Flow chart). 
 Baseline characteristics of the excluded group were comparable with the analysed 
group (data not shown). The included patients were equally assigned to the randomization 
groups within each hospital.
 Baseline characteristics between the two randomization groups (protocol A and protocol 
B) were comparable, except for female patients, who were represented more in the new 
policy group (P=0.01) and for patients with rheumatoid arthritis, who were represented 
more in the standard care group (P=0.02) (Table 3). 
 The baseline characteristics between hospitals were comparable, except for hospital 
number 1, the university medical centre, who included a significantly higher proportion 
of Rheumatoid Arthritis (RA) patients (31.7% versus 9.2% and 3.3% in the other hospitals, 
respectively; P<0.001). Also, hospital number 1 included patients with a lower mean age 
(SD) than the other hospitals (67.1 (11.7) versus 71.1 (9.8) and 70.5 (9.9); p<0.001). This age 
difference can be explained by the larger RA patient population, who are generally younger 
when indicated for joint replacement surgery. Co-morbidities such as hypertension, 
myocardial infarction, heart failure, diabetes, stroke, peripheral arterial disease and 
arrhythmia were all comparable among hospitals, as well as use of medication (steroids, 
non-steroidal anti-inflammatory drugs (NSAID’s), anticoagulants etc). Autologous re-
infusion by cell saver was used in two hospitals in a total of 9 cases (2% of total; twice in 
hospital number 2 and seven times in hospital number 3). 
Primary outcome
RBC usage
Overall RBC usage in the group with the new policy was 0.78 U/patient (SD 1.4) and 0.86 U 
/patient (SD 1.6) in the standard care group, with an overall mean difference of 0.08 (95% 
CI of mean difference [-0.3, 0.2]; P=0.53). LOHS was comparable between the groups (mean 
difference of - 0.6 days (95% CI of mean difference [-1.2, 0.5]; P=0.21)) (Table 4).
Secondary outcome
Results of all categorical, secondary end-points were not significantly different between the 




















- Not meeting inclusion criteria (n=17)
- Refused to participate (n=65)

















































The flowchart shows the progress of all participants in the trial, from the time they are assessed for 
eligibility until the end of their involvement. In hospital #1 and hospital l#2, the new policy (protocol A) 
was the most restrictive policy, as expected. In hospital #3 the standard care policy (Protocol B) turned 
out to be the most restrictive policy.
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table 3. Patient characteristics (by type of policy and of total group)
Parameter







Evaluated 299 304 603
Females (%) 215 (71.9) 186 (61.2)d 401 (66.5)
Mean age (years) 70.7 (10.2) 70.3 (9.7) 70.4 (9.9)
Mean weight (kg) 78.1 (13.4) 79.0 (13.2) 78.6 (13.2)
Smoking 43 (14.3) 47 (15.5) 90 (15.2)
THR 167 (55.9) 172 (56.6) 339 (56.2)
TKR 111 (37.1) 113 (37.2) 224 (37.1)
Revision THR 18 (6.0) 16 (5.2) 34 (5.6)
Revision TKR 3 (1.0) 3 (1.0) 6 (1.0)
Low riska 14 (4.7) 12 (3.9) 26 (4.3)
Intermediateb 80 (26.8) 81 (26.6) 161 (26.7)
High riskc 205 (68.6) 211 (69.4) 416 (69.0)
Rheumatoid arthritis 24 (8.0) 43 (14.1)e 67 (11.1)
COPD 21 (7.0) 25 (8.3) 46 (7.6)
Mean pre-operative Hb (g/dL) 13.7 (1.4) 13.7 (1.4) 13.7 (1.3)
Mean pre-operative Hct (L/L) 0.41 0.41 0.41
Percentages are within policy group.
a low risk: patients younger than 50 years of age without risk factors indicated in Table 1
b intermediate risk: patients from 50 to 70 years of age without risk factors indicated in Table 1
c high risk: see definition in Table 1. 
d P=0.01
e P=0.02
Subgroup-analysis at individual hospital
Due to heterogeneity of the effects on primary outcome across the three hospitals (P=0.008), 
we performed a subgroup-analysis by hospital.
Primary outcome 
RBC use and the proportion of transfused patients were highest in hospital number 1 (Table 
5). In two hospitals (number 1 and 2), the new policy (protocol A) was more restrictive than 
the standard care, but resulted in a non-significant RBC reduction of 30% in hospital number 
1 (P=0.17) and a nearly significant reduction of 41% in hospital number 2 (P=0.05). In the 
third hospital, however, the standard care was more restrictive, which led to an increase of 
39% in RBC usage (P=0.02) and to an increase in the proportion of transfused patients as 
well (P=0.001). The effect on RBC use differed significantly per hospital (test on interaction; 
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compared to the high risk group, the effect size (this is the difference between the new 
policy and standard care) was larger in the lowest risk group, namely -4.9 RBC(s) (95% CI 
[-7.1, -2.7]; P<0.001) and -2.1 RBC(s) (95% CI [-3.2, -1.0]; P<0.001) in the intermediate risk 
group. In hospital number 2 and 3, no clinical significant interaction with a particular risk 
group was found. Within each hospital, mean duration of surgery and median blood loss 
were comparable between randomization groups. Total LOHS differed between hospitals 
due to the different hospital protocols. Hospital number 2 used a short-stay protocol, which 
resulted in the shortest LOHS. Due to a non-normal distribution of data, median values are 
shown, which were comparable within randomization groups. In all hospitals, LOHS was not 
affected by any transfusion protocol.
table 4. Results of primary and secondary end-points by randomized group
Parameters new policy (Protocol a)
n=299
Standard care (protocol B)
n=304
RBC (units) / patient 0.78 (1.4) 0.86 (1.6)a
LOHS (days) 9.6 (5.0) 10.2 (7.4)b
Hb day +1 (g/dL) 10.5 (1.6) 10.3 (1.4)
Hb day +4 (g/dL) 10.5 (1.1) 10.5 (1.1)
Hb at discharge (g/dL) 11.4 (1.1) 11.4 (1.3)
Infections 18 (6.0 %) 31 (10.1%)
Cardiovascular complications 34 (11.4%) 23 (7.6%)
Respiratory complications 6 (2.0%) 15 (4.9%)
Neuropsychiatric complications 11 (3.7%) 13 (4.2%)
Hemorrhage 10 (3.3%) 12 (3.9%)
Delayed mobilisation 22 (7.4%) 36 (11.8%)
Mortality 1 (0.3%) 2 (0.7%)
Composite complications 99 (33.1%) 104 (34.2%)
For continuous variables mean (SD) is shown, for categorical variables numbers (percentages) are shown. Percentages are 
calculated within randomized group (columns)
a mean difference 0.08 (95% CI of mean difference: -0.3 to 0.2; P=0.53)
b mean difference -0.6 (95% CI of mean difference: -1.2 to 0.5; P= 0.21)
For all categorical complications (infections etc) no difference between groups was found (P-values were all >0.05).
Secondary outcome
Mean post-operative Hb levels were comparable between hospitals and within each 
hospital between randomization groups. For hospital number 1 mean values were: 9.8 g/dL 
(SD 1.3) at day +1, 10.3 g/dL (SD 1.1) at day +4 and 10.9 g/dL (SD 1.1) at day +14. For hospital 
number 2 these values were: 10.8 g/dL (SD 1.6), 10.9 g/dL (SD 1.1) and 11.8 g/dL (SD 1.3), 
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respectively and for hospital number 3 these values were: 10.5 g/dL (SD 1.3), 10.3 g/dL (SD 
1.1) and 11.3 g/dL (SD 1.1), respectively.
table 5. Subgroup analysis of primary outcome measurements at individual hospital
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In hospital#1 and hospital#2, the new policy was the most restrictive policy, as expected. In hospital #3 the standard care 
policy turned out to be the most restrictive policy.
a Mean RBC use (U/patients) (SD): in hospital #1 was 1.34 (2.2) with the new policy and 1.92 (2.4) with standard care. In 
hospital #2 mean RBC use was 0.42 (1.0) and 0.72 (1.2), respectively and in hospital #3 mean RBC use was 0.80 (1.2), and 0.49 
(1.1) (P=0.02), respectively.
b LOHS must not be prolonged for more than four days in the most restrictive policy group.
c P=0.001
In 203 patients (33.7%) a postoperative complication was observed, which was highest in 
hospital number 1 (83/123=67%). Between transfusion policies, differences were found in 
composite complications in hospital number 2, which were slightly more represented in 
the standard care group that had the most liberal policy (n=35 versus n=21 in the new 
policy group; P=0.04) (Table 6). In hospital number 1, respiratory complications were 
more observed in the standard care group, that had the most liberal transfusion policy 
(n=13 versus n=3 in the new policy group; P=0.008). Furthermore, delayed mobilization 
(i.e. different from the standard ambulation protocol) was reported more frequent in the 
standard care group of hospital number 3 (n=18 versus n=8 in the new policy group; P=0.04), 
which contained the most restrictive transfusion policy. Infections occurred in 47 (7.8%) of 
all patients, which were mostly urinary tract infections (24 cases); 16 patients had wound 
infections, of which 5 were deep prosthetic infections. The remaining wound infections 
consisted of mostly superficial wound infections, which resolved uneventful: mild, grade 2 
infections (haematoma with or without evident inflammation, but no bacterial growth) and 
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table 6. Subgroup analysis of secondary outcome measurements at individual hospital
Secondary end-points new policy (Protocol a)
n=299
Standard care (Protocol B)
n=304
Composite complicationsa
 Hospital #1 (n=123)
 Hospital #2 (n=206)








 Hospital #1 
 Hospital #2 








 Hospital #1 
 Hospital #2 



























Stated values are numbers of patients
a patients could experience more than one complication
b P=0.04
c P=0.008 (significant P-value of less than 0.01 (Bonferroni correction for multiple comparisons)).
d P=0.04 
no evident inflammation) and one grade 4 infection (evident inflammation and bacterial 
growth). Furthermore, one patient suffered from a pneumonia and in six patients a systemic 
bacterial infection (n=3) or a localized infection (n=3) was found. One patient had two 
infections. Respiratory complications were pulmonary embolism in one, pneumonia in 
one, five cases of transfusion associated cardiac overload (TACO), three cases of respiratory 
insufficiency due to opiates for pain reduction, bronchospasm in COPD in two and shortness 
of breath without evident clinical substrate in nine cases. Of all complications, ICU stay of 
more than 1 day (n=3) and transfusion reactions (n=3) were negligible (<1%). Mortality 
was found in three cases, one in each hospital, which all occurred in the groups who were 
transfused with the most liberal policies. The proportion of patients who had a delay in 
mobilisation differed per hospital, but within hospitals, delay was comparable between 
randomization groups in hospitals number 1 and 2. In hospital number 3, however, more 
patients (n=18) were delayed in the group with the most restrictive transfusion policy 
compared to the patients in the group transfused with the most liberal policy (OR 2.4 (95% 
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CI [1.0, 5.8]); P=0.008). Nevertheless, total hospital stay in hospital 3 was comparable in both 
groups. This delay in mobilisation could not be explained by a difference in post-operative 
Hb level of these patients: mean Hb level at day +1 was 10.2 g/dL with delay and 10.5 g/dL 
without delay (NS). Other complications as neuropsychiatric and haemorrhage were not 
different between randomization groups within each hospital.
diSCuSSiOn 
Implementation of a new restrictive transfusion protocol in three different hospitals 
compared with the standard care did not result in an overall significant reduction of 
RBC transfusions, however, this study shows that a uniform transfusion policy can be 
implemented with great reliability, as deviations from the trigger protocol were only 
4.5%. By implementing a new presumably restrictive transfusion trigger, we aimed at a 
reduction in RBC use, but one of the hospitals (number 3) showed an increase instead. This 
can not be explained by a population difference or a staff compliance difference to the 
protocol, because patients characteristics (age, gender) were not different from hospital 
number 2 which was the other general hospital. Hospital 1 and 2 had a liberal standard 
care transfusion policy. However, hospital 3 turned out to have a different more restrictive 
standard care policy. Furthermore that policy did not consider age as a risk factor. Thus, 
their current standard policy resulted in a lower RBC use. As a result, the overall difference in 
RBC use between the original randomization groups was negligible. Due to heterogeneity 
between hospitals in primary outcome we performed a subgroup analysis by hospital. 
Hospital number 1 had a modest RBC reduction, but showed a significant interaction of 
RBC use with risk group. This is explained by the difference in Hb trigger of age-matched 
patients between randomization groups in this hospital: the difference was largest in the 
low risk group (age<50 years): transfusion trigger of 6.4 g/dL with the new protocol and 
9.7 g/dL with standard care. In the intermediate group (age 50-70 years) these were 8.1 g/dL 
and 9.7 g/dL, respectively and 9.7 g/dL in both arms for the high risk group (>70 years). The 
standard care policy advocated to give two RBC(s) per transfusion against one RBC in the 
new protocol. In hospital number 2, a high mean age of the patient population (71.1 years) 
resulted in a large population of high risk patients who were transfused with a trigger of 
9.7 g / dL according to the new, restrictive policy (protocol A) compared a trigger of 10.5 
g/dL according to standard care (protocol B). Despite this small difference, still an overall 
reduction of transfused RBC units was found, but not a reduction of the percentage of 
transfused patients. In none of the three hospitals, the Hb level of the transfusion triggers 
was identical between randomization arms for age-matched patients, except for high risk 
patients (age from 70 years onwards). Hospital number 1 had a trigger of 9.7 g/dL in either 
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transfusion protocol effect was seen in hospital number 3, due to the exclusion of age in the 
standard care protocol (protocol B), which resulted in a more restrictive RBC use compared 
to the new, age-dependent protocol (protocol A). 
 A reduction of RBC use would not be acceptable at the cost of an increased hospital 
stay (due to increased morbidity from anaemia). However, the most restrictive transfusion 
policies were safe and LOHS was not affected by either of the two transfusion policies, 
although ambulation in hospital number 3 was slightly slowed down in the standard care 
group that used the most restrictive transfusion policy. 
 The impact of different transfusion triggers on postoperative complications (e.g. infection 
rate) in elective orthopaedic surgery patients has not been previously reported. Allogeneic 
RBC transfusions were found to be associated with a higher post-operative infection rate 
compared to non- transfused patients [10-15], but these studies were observational and/
or retrospective and performed with non leukocyte-reduced RBC(s). Subgroup-analysis by 
hospital showed that in hospital number 1, respiratory complications were significantly 
higher in the group with the most liberal transfusion policy. This association should be 
further studied in future trials.
 Of the total of respiratory complications, in 14 of 21 cases the respiratory complications 
might be explained by the RBC transfusion itself: 5 cases were classified as transfusion 
related (TACO), whereas in the 9 cases of unclassified hypoxemia, a subclinical TACO or a 
transfusion related acute lung injury (TRALI) might have been present [16]. The occurrence 
of post-operative infections was not significantly different between randomization groups. 
Age appeared no risk factor for post-operative complications, as shown by data of hospital 
number 3, who had a standard care policy that was more restricted and not age-dependent, 
but was not associated with an increase in post-operative complications, although 
mobilisation was significantly delayed in this group. Other factors, such as pre-existent 
cardiovascular disease may play a role, however the current study was not powered to 
identify such an effect. In the FOCUS trial [17], an ongoing randomized, multi-centre study 
on elderly hip fracture patients (from 50 years of age onwards), patients with cardiovascular 
disease or cardiovascular risk factors are studied to investigate the impact of a restrictive 
transfusion trigger in this specific patient population with functional outcome as the 
primary end-point. 
 This study has some limitations. First, our data can not be extrapolated to other hospitals 
in general, as the hospital’s standard care transfusion policy turned out to be very different 
between hospitals and therefore, it is unlikely that these three hospitals do represent 
the overall transfusion policy in the Netherlands. Second, our study was not powered to 
evaluate mortality or cardiovascular outcomes. Third, it is possible that our assessment of 
secondary end-points was biased since the trial and classification of outcomes was not 
blinded. However, the secondary end-points were scored by use of pre-defined objective 
criteria by the orthopaedic residents not performing the surgery. Fourth, to take RBC usage 
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as a primary end-point can be seen as a limitation, because transfusion less blood is the 
intended intervention of a restrictive policy. However, to use another well-accepted primary 
outcome such as mortality or post-operative complications is difficult, because of the low 
prevalence of such end-points in this study population. Although it seemed logically that a 
new, restrictive policy would always result in a RBC reduction, this was not the case in one 
hospital.
 And finally, there is a limitation concerning the un-transfused patients, which is a general 
problem concerning all transfusion medicine trials: due to the early time of randomization, 
prior to surgery, the majority of patients included in the study did not meet any of the 
criteria for transfusion. In our study, this concerns a large part (45 to 80%) of the randomized 
patients. Ideally a patient should only be randomized when a transfusion is inevitable, but 
in practice this is very difficult to perform. However, by comparing the randomized patients 
according to the intention-to-treat principle, both groups remain balanced in terms of the 
levels of all known confounding factors [18]. 
 In conclusion, implementation of a new, intentionally restrictive transfusion protocol 
in elective hip and knee replacement surgery is feasible and safe without lengthening the 
hospital stay. Whether a more restrictive transfusion policy is associated with less post-
operative complications should be investigated in further studies which are powered to 
find this effect.
acknowledgements
The authors thank Tineke van der Heide for data collection and the Orthopaedic staff of the 
Leiden University Medical Center, The HAGA Hospital Leyenburg and the Reinier de Graaf 
Gasthuis for participating in this study.






39A randomized comparison of RBC triggers | 
rEfErEnCES
1. Keating EM. Current options and approaches for blood management in orthopaedic surgery. Instr 
Course Lect 1999; 48:655-65.
2. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood 
transfusion. Transfusion 2003; 43:668-676.
3. Shander A and Goodnough LT. Objectives and limitations of bloodless medical care. Curr Opin Hematol 
2006; 13 (6):462-470.
4. Carson JL, Hill S, Carless P, Hebert P, Henry D. Transfusion triggers: a systematic review of the literature. 
Transf Med Rev 2002; 16(3):187-199.
5. Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB, Henderson KM. Transfusion 
thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database 
Syst Rev 2002; (2):CD002042.
6. Eindhoven GB, Diercks RL, Richardson FJ, van Raaij JJAM, Hagenaars JAM, van Horn JR, de Wolf JThM. 
Adjusted transfusion triggers improve transfusion practice in orthopaedic surgery. Transfus Med 2005; 
15:13-18.
7. Lacroix J, Hébert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, Gauvin F, Collet JP, Toledano BJ, 
Robillard P, Joffe A, Biarent D, Meert K and Peters MJ, for the TRIPICU Investigators, the Canadian Critical 
Care Trials Group, and the Pediatric Acute Lung Injury and Sepsis Investigators Network. Transfusion 
Strategies for Patients in Pediatric Intensive Care Units. New Engl J Med 2007; 356:1609-19.
8. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site 
infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp 
Epidemiol 1992; 13 (10):606-608.
9. Gaine WJ, Ramamohan NA, Hussein NA, Hullin MG, McCreath SW. Wound infection in hip and knee 
arthroplasty. J Bone Joint Surg Br 2000; 82(4):561-565. 
10. Murphy P, Heal JM, Blumberg N. Infection or suspected infection after hip replacement surgery with 
autologous or homologous blood transfusions. Transfusion 1991; 31(3); 212-217. 
11. Fernandez MC, Gottlieb M, Menitove JE. Blood transfusion and postoperative infection in orthopedic 
patients. Transfusion 1992; 32;318-322. 
12. Vignali A, Braga M, Gianotti L, Radaelli G, Gentilini O, Russo A, Di Carlo V. A single unit of transfused 
allogeneic blood increases postoperative infections. Vox Sang 1996; 71(3);170-175. 
13. Duffy G and Neal KR. Differences in post-operative infection rates between patients receiving 
autologous and allogeneic blood transfusion: a meta-analysis of published randomized and 
nonrandomized studies. Transfus Med 1996; 6 (4);325-328. 
14. Triulzi DJ, Vanek K, Ryan DH, Blumberg N. A clinical and immunologic study of blood transfusion and 
postoperative bacterial infection in spinal surgery. Transfusion 1992; 32 (6);p.517-524. 
15. Innerhofer P, Klinger A, Klimmer C, Fries D, Nussbaumer W. Risk for postoperative infection after 
transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic 
patients undergoing primary arthroplasty. Transfusion 2005; 45;103-110.
16. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung 
injury. Report of a clinical look-back investigation. JAMA 2002; 287(15):1968-1971.
17. Carson JL, Terrin ML, Magaziner J, Chaitman BR, Apple FS, Heck DA, Sanders D; FOCUS Investigators. 
Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip 
fracture repair (FOCUS). Transfusion 2006; 46(12):2192-206.
18. Vamvakas EC. Rationale for randomized controlled trials and for intention-to-treat analysis in 
transfusion medicine: are they one and the same? Vox Sang 2008; 95:165-73.

Chapter 3
the impact of a restrictive transfusion 
trigger on post-operative complication 
rate and well-being in elective 
orthopaedic surgery:  
a post-hoc analysis of a  
randomised study
Cynthia So-Osman1, Rob Nelissen2, Ronald Brand3, Frank Faber4, Ron Te Slaa5†, Anne Stiggelbout6 
and Anneke Brand1
From the 1Dept. of Research and Development, Sanquin Blood Bank South West Region, Leiden; 
2 the Dept. of Orthopaedic Surgery, Leiden University Medical Centre (LUMC), Leiden;  
3 the Dept. of Medical Statistics and BioInformatics, Leiden University Medical Centre (LUMC), 
Leiden;  
4 the Dept. of Orthopaedic Surgery, HAGA Hospital, Leyenburg location, The Hague;  
5 Dept. of Orthopaedic Surgery, Reinier de Graaf Hospital, Delft; and 




42 | Chapter 3
aBStraCt
Background: Peri-operative red blood cell transfusions have been associated with 
post-operative complications in patients undergoing elective orthopaedic hip- or knee 
replacement surgery. 
Materials and methods: A post-hoc analysis of data extracted from a randomised study 
on transfusion triggers using pre-storage leukocyte-depleted red blood cells. Patients who 
received the most restrictive transfusion policy (“restrictive group”) were compared with 
patients who received the most liberal policy (“liberal group”). Endpoints were red blood 
cell use, hospital stay, haemoglobin levels, postoperative complications and quality of life. 
results: Of 603 patients, 26.4% patients in the restrictive group and 39.1% in the liberal 
group were transfused (p=0.001). In the restrictive group, fewer postoperative infections 
(5.4 % versus 10.2 %; p=0.03) and respiratory complications (1.7% versus 4.9%; p=0.03) were 
observed, whereas hospital stay, cardiovascular complications and mortality rate were not 
different in both groups. Quality of life scores were not associated with type of transfusion 
policy, the number of red blood cell transfusions or the transfusion status. 
Conclusion: A restrictive transfusion protocol was not associated with worse outcome 
and showed a trend towards fewer postoperative infections and respiratory complications 
compared to a liberal transfusion policy. Well-being was not associated with transfusion 
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intrOduCtiOn 
Reports on the role of allogeneic red blood cell (RBC) transfusions, whether or not leukocyte 
reduced, on post-operative infection rate in orthopaedic surgery are inconsistent [1-6]. 
Since many of these studies were observational or retrospective, selection bias at patient 
inclusion may have occurred. We recently reported the intention-to-treat results of a 
randomised study among elective orthopaedic surgery patients, that compared a new 
uniform, intentionally restrictive, transfusion policy with the standard hospital policy, 
with RBC use as primary endpoint [7]. No differences in RBC use between the randomised 
arms were observed because in one of the three participating hospitals, the new uniform 
study trigger for blood transfusion turned out to be less restrictive than their standard 
trigger, which resulted in an increased RBC use with this new transfusion policy. As well, no 
significant differences in post-operative complications between the original randomisation 
groups was present. In the current post-hoc analysis we investigated the effect of the most 
restrictive transfusion policy in all three participating hospitals, by pooling the patients 
who were randomised to the most restrictive trigger to a restrictive policy group and the 
patients who were randomised to the most liberal transfusion policy to a liberal policy 
group, thereby fully respecting the randomised nature of the data. 
 A second aim of the study was to evaluate the effect of the transfusion policy (restrictive 
or liberal) and of RBC transfusions on postoperative functional well being by measuring 
quality of life (QoL) scores. Previously, we were unable to show any correlation between 
QoL scores and Hb levels in the early postoperative period in this cohort, but, as suggested 
by Wallis, Hb and transfusions should be disentangled and thus separately analysed in QoL 
evaluations [8,9]. 
MEthOdS
Establishing groups for the post-hoc analysis 
In the original study, within each participating hospital, patients were randomized to 
either protocol A (new policy) or protocol B (standard policy) [7]. The new transfusion 
trigger, was risk level based (depending on age and co-morbidity) and uniform among the 
three participating hospitals (Appendix). The new protocol (A) was more restrictive than 
the standard policy (B) for two hospitals and the patients randomized to A were labeled 
“restrictive ” and to B “liberal “. In the third hospital, patients randomized to protocol A 
actually received more RBC transfusions and this group was now labeled “liberal” and the 
standard policy (protocol B) “restrictive”. Only pre-storage leukocyte-depleted (LD-) RBC(s) 
were used. 
44 | Chapter 3
Outcome measures
The original primary outcome variable was the number of transfused RBCs. Postoperative 
complications and QoL were secondary outcome measures and prospectively scored. 
Complications were categorised in: infections, respiratory complications (pneumonia 
excluded), neuro-psychiatric, cardiovascular and haemorrhagic complications, mobilisation 
delay, and mortality. Post-operative infections were pre-defined according to CDC criteria 
[10]. All wounds were prospectively scored for possible wound infection at postoperative 
day 5 according to Gaine and coworkers [11]. Cases of unclassified hypoxaemia were further 
investigated by detailed chart review to investigate their relationship with RBC transfusions 
(e.g Transfusion Associated Circulatory Overload or Transfusion Related Acute Lung Injury) . 
QoL questionnaires were scored preoperatively (time point T1) and at postoperative days +4 
(time point T2) and +14 (time point T3), using the Functional Status Index (FSI), measuring 
functionality in daily living; a Visual Analogue Scale (VAS) for fatigue; and the Functional 
Assessment of Cancer Therapy-Anaemia (FACT-An) subscale, measuring fatigue and other 
anaemia-related symptoms. All scores ranged from 1 to 100, with lower scores indicating 
better functioning. Follow up ended at the outpatient clinic 14 days after surgery or at final 
discharge (if hospital stay was longer than 14 days). Details of the original study and overall 
results have been reported previously [7,9].
analysis and statistical methods
Continuous data are summarized as mean and SD, or median and inter-quartile (IQ) range 
in case of a non-normal distribution. A comparison of laboratory parameters and other 
numerical endpoints (like hospital stay and age) between groups was performed by a Student 
t-test in case of normal distributions and by the non-parametric counterpart (Mann-Whitney) 
in case of non-normal distributions (the number of patients receiving RBC transfusions and 
the total number of units RBC administered). In case of categorical endpoints, comparisons 
were made on proportions using the Chi-square statistic or Fisher’s Exact test. A common 
(pooled) Odds Ratio was computed as an overall effect measure among the three hospitals 
since all tests for heterogeneity were non-significant (p>0.10). RBC use of both groups was 
compared to verify that the restrictive group indeed used fewer RBCs (significant p-value 
of less than 0.05). Pearson correlation coefficients [+ 95% CI] were calculated between FSI, 
Fact-Anemia and VAS scores and number of RBC transfusions for time points T1, T2 and T3. 
If r≥0.20, scores at T2 and T3 were corrected for preoperative scores of FSI, Fact-Anemia 
and VAS, and for peri- and post-operative variables (duration of surgery, surgical blood loss 
and post-operative complications) as possible confounders. Student’s t-tests were used to 
compare the QoL scores with dichotomous variables (transfusion status: yes/no or type of 
transfusion policy: restrictive/liberal). In case of a significant difference between means 
(p<0.05), regression analysis was performed to further evaluate the association of FSI, Fact 
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For the analysis of the post-operative endpoints, we used a Bonferroni correction to adjust 
for multiple testing of seven variables (infections, respiratory complications (pneumonia 
excluded), neuro-psychiatric, cardiovascular and haemorrhagic complications, mobilisation 
delay and mortality) (significant p - value of less than 0.01). Data were analysed using the 
SPSS statistical program (version 15.0) for Windows (SPSS Inc, Chicago, IL, USA).
rESultS
Of 603 included patients, 299 were assigned to the restrictive group and 304 to the 
liberal group. The baseline characteristics (age, sex, type of surgery, co-morbidities, use of 
medication, pre-operative haemoglobin (Hb) level) were balanced in both groups except 
for history of chronic obstructive pulmonary disease (COPD), of which 32 (10.7%) patients 
were in the restrictive group versus 14 (4.6%) in the liberal group (p=0.005) (Table 1). 
table 1. Patient baseline characteristics
Parameter






Females 190 (63.5) 211 (69.4) 0.13
Mean age (years) 70.2 (10.3) 70.7 (9.6)
Mean weight (kg) 79.5 (13.4) 77.7 (13.1)
Smoking 43 (14.4) 47 (15.5)
Total hip replacement (THR) 166 (55.5) 173 (56.9)
Total knee replacement (TKR) 113 (37.8) 111 (36.5)
Revision THR 16 (5.4) 18 (5.9)
Revision TKR 4 (1.3) 2 (0.7)
Low riskc 12 (4.0) 14 (4.6)
Intermediate riskd 81 (27.1) 80 (26.3)
High riske 206 (68.9) 210 (69.1)
Rheumatoid arthritis 27 (9.0) 40 (13.2) 0.11
Chronic Obstructive Pulmonary Disorder 32 (10.7) 14 (4.6) 0.005
Mean pre-operative Hb (g/dL) 13.8 (1.4) 13.5 (1.3) 0.02
Mean pre-operative Hct (L/L) 0.41 (0.04) 0.40 (0.04)
Percentages are within policy group.
a restrictive group: patients assigned to the most restrictive transfusion policy.
b liberal group: patients assigned to the most liberal transfusion policy.
c low risk: patients younger than 50 years of age without risk factors.
d intermediate risk: patients from 50 to 70 years of age without risk factors.
e High risk includes one or more of the following risk factors:
any heart rhythm different than sinus rhythm, unstable cardiac ischaemia (by history or ECG), myocardial infarction less than 
6 months, heart failure, heart valve disease, age from 70 years onwards, serious peripheral arterial disease, including large 
vessel surgery (aortic aneurysm, peripheral vessels), cerebral arterial disease (CVA or TIA in history), hypertension with left 
ventricular hypertrophy (LVH) (shown on ECG/ echocardiogram), serious pulmonary disease, expressed in polyglobulinaemia 
(emphysema / pulmonary fibrosis), insulin dependent diabetes mellitus.
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Clinical endpoints 
The proportion of transfused patients was smaller (26.4%) in the restrictive group compared 
to the liberal group (39.1%, p=0.001), as was the mean RBC use per patient (p=0.003) (Table 
2). No difference in hospital stay (p=0.27) was noted between the groups. Mean duration of 
surgery and median blood loss were comparable between groups (data not shown). 
table 2. RBC use and post-operative clinical endpoints by assigned transfusion policy group
Clinical endpoints







N / proportion transfused patients (in %) 79 / 26.4 119 / 39.1 0.001
RBC use (U/patients) 0.64 (1.4) 1.00 (1.6)d 0.003
LOHS (days) 9.6 (5.1) 10.2 (7.4)e 0.27
Hb day +1 (g/dL) (SD) 10.6 (1.6) 10.3 (1.4) 0.02
Hb day +4 (g/dL) (SD) 10.5 (1.2) 10.5 (1.2) 0.99
Hb at discharge (g/dL) (SD) 11.4 (1.3) 11.4 (1.2) 0.99
Infections 16 (5.4) 31 (10.2) 0.03 2.0 (1.1-3.8)
Cardiovascular complications 30 (10.0) 27 (8.9) 0.63 0.9 (0.5-1.5)
Respiratory complications 5 (1.7) 15 (4.9) 0.03 3.1 (1.1-8.5)
Neuro-psychiatric complications 12 (4.0) 12 (3.9) 0.98 1.0 (0.4-2.2)
Haemorrhage 10 (3.3) 12 (3.9) 0.68 1.2 (0.5-2.9)
Delayed mobilisation 32 (10.7) 26 (8.6) 0.37 1.3 (0.7-2.2)
Mortality 0 (0) 3 (1.0) 0.25
Composite complicationsf 93 (31.1) 110 (36.2) 0.18 1.3 (0.9-1.9)
a restrictive group: patients assigned to the most restrictive transfusion polic.y
b liberal group: patients assigned to the most liberal transfusion policy.
c to estimate complication risk, a common odds ratio (OR) is calculated. 
d 95% CI of difference [0.12, 0.60].
e 95% CI of difference [-1.6, 0.4].
f patients could experience more than one complication
Median RBC use (IQ range) was 0.0 (0-2.0) in the liberal policy group and 0.0 (0-1.0) in the restrictive policy group
Infections occurred in 47 (7.8 %) of all patients, of which 16 patients were in the restrictive 
group (5.4%) and 31 patients in the liberal group (10.2%, p=0.03). Pooled risk estimates 
were calculated for post-operative complications, which resulted in an elevated risk of 
infections (common OR=2.0, p=0.03) and respiratory complications (common OR=3.1, 
p=0.03) in the liberal group, however both were not significant after correction for multiple 
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Table 3 shows that infections (mainly urine tract infections and wound infections) and 
respiratory complications occurred more often in transfused patients, respectively 66% (31 
of 47) and 70% (14 of 20) of patients developing these complications had been transfused. 
Of the patients who developed infections, median RBC use in the restrictive group was 0.5 
units (IQ range 0-2.0) and 2.0 in the liberal group (IQ range 1.0-3.0). Two patients had already 
been treated for a pre-existent infection (jaw and urine tract infection, one in each group). 
table 3. Infections and respiratory complications by assigned transfusion policy group in relation to 
RBC use (yes or no)
Clinical endpoints










infections (total number n=47) 16(8/8) 31(23/8) 0.03
Urine tract infection (UTI) (n=24) 8 (4/4) 16 (12/4)
Wound infection (n=16)





Pneumonia (n=1) 0 1 (0/1)
Systemic bacterial infection (n=3) 1a (0/1) 2 (1/1)
Other (localized) (n=3) 1 (1/0) 2 (1/1)
Of which pre-existent infection (n=2) 1 (1/0) Jaw 1 (1/0) UTI
respiratory complications (total number n=20) 5 (3/2) 15 (11/4) 0.03
TACO (n=5) 2 (2/0) 3 (3/0)
Bronchospasm in COPD (n=2) 1 (0/1) 1 (0/1)
Respiratory insufficiency due to opiates (n=3) 0 3 (2/1)
Pulmonary embolism (n=1) 0 1 (0/1)
Unclassified hypoxaemia (n=9) 2 (1b/1) 7 (6c/1)
Abbreviations: UTI= Urine Tract Infection;  TACO=Transfusion Associated Circulatory Overload; COPD=Chronic Obstructive 
Pulmonary Disease
a this patient also had a deep prosthetic wound infection 
b this case was possibly transfusion related (TACO)
c one case was possibly transfusion related (TRALI)
Patients with respiratory complications received a median RBC use of 1.0 unit in the 
restrictive group (IQ range 0-3.5) and of 2.0 in the liberal group (IQ range 2-2.75). Patients 
with postoperative infections or respiratory complications had significantly longer hospital 
stays compared to compared to patients without these complications: median hospital 
stay 12.0 [9.0-12.0] and 13.0 [10-17] days with infections and respiratory complications 
respectively, compared to 9.0 [7-10] in patients without these complications (p<0.001) (not 
shown). 
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Of five patients, the respiratory complications were related to a RBC transfusion and 
diagnosed as Transfusion Associated Circulatory Overload (TACO). Of nine patients with 
unclassified hypoxaemia, seven had received RBC transfusions. Detailed chart review 
of these seven patients further revealed two possible transfusion related cases. One 73-
year old male with a history of CABG, PTCA and hypertension, who had knee surgery and 
one postoperative RBC transfusion, following a low Hb value of 9.2 g/dL, after which the 
patient developed cardiac failure (possible TACO) that responded well to diuretics (with 
compatible chest X-ray). The other was a 76-year old male patient with a history of CABG 
who received two RBC transfusions for a postoperative Hb value of 9.1 g/dL, with transient 
hypoxaemia, which needed oxygen support and resolved uneventfully (possible TACO or 
TRALI, although chest X-ray was not taken). A third 34-year old patient with a history of 
Still’s disease, had knee surgery followed by massive postoperative blood loss of 2 litre by 
drains, with dyspnoea and tachypnoea and a postoperative Hb of 9.1 g/dL. After the patient 
received 4 RBC transfusions to compensate for the blood loss, he recovered completely. Of 
the remaining four transfused patients with unclassified hypoxaemia a relationship with 
RBC transfusion could not be found, mainly due to lack of chart information. However, in 
all patients hypoxaemia was mild and all patients completely recovered without additional 
mechanical ventilation.
 QoL and fatigue scores were not associated with the type of transfusion policy (non-
significant differences in mean scores between transfusion policy groups or number of 
RBC transfusions, except for FSI scores measuring daily activity which showed a significant, 
but weak correlation r=0.36 (p<0.001) with the number of RBC transfusions at time-point 
T2 (4 days postoperatively). However, this association disappeared after correction for the 
possible confounders pre-operative FSI score (T1), duration of surgery, surgical blood loss 
and post-operative complications, which lowered r to 0.08 (p=0.085). The transfusion status 
(being transfused or not) was also significantly associated with the FSI score at T2, with 
better scores if not transfused, but also with the VAS scores at T2, the FSI score at T3 and the 
Fact-Fatigue score at T2 (all had significant differences in mean scores between transfused 
and non-transfused groups with p-values <0.001). After correction for the four possible 
confounders, in all cases significance was lost. 
diSCuSSiOn
In this post-hoc analysis, we compared a restrictive transfusion policy with a liberal policy 
and evaluated the clinical impact on post-operative complications and well-being. The 
restrictive transfusion policy resulted in an absolute reduction of 0.36 RBC unit per patient 
and a 31% relative risk reduction of proportion of transfused patients (13% absolute decrease 
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performed a meta-analysis of 17 randomised studies on transfusion triggers in a variety of 
patient groups including orthopaedic surgery and found an average relative risk reduction 
of 37% [12]. Although we found only an absolute reduction of 5% (from 36% to 31%) in the 
composite postoperative complication rates, the liberal group had more often infections 
and respiratory complications. The majority of postoperative infections and respiratory 
complications occurred in transfused patients. Estimated risks for these complications were 
respectively doubled and tripled in the groups assigned to the liberal transfusion trigger. 
However, if corrected for multiple testing (p<0.01), the significance between the groups 
was lost. A decreased infection rate with a restrictive transfusion policy was also found by 
Carless and co-workers, who analysed four randomised studies that reported infection rate, 
with a pooled risk ratio of 0.76 (95% CI 0.60 to 0.76). Two of those studies used leukoreduced 
RBCs [12]. 
 The finding of an increased respiratory complication rate with a liberal transfusion policy 
has not been reported earlier. Postoperative pulmonary morbidity has been associated 
with RBC transfusions in cardiac surgery [13]. In our dataset, detailed chart review of seven 
transfused cases with unclassified hypoxaemia revealed a possible transfusion-related 
complication in two, and in a third a complete recovery thanks to the transfusions. Due 
to lack of information (no chest x-rays) of the remaining four cases, we could not rule out 
a sub-clinical transfusion associated circulatory overload (TACO) or transfusion related 
acute lung injury (TRALI) as a possible underlying cause [14]. Despite the use of leukocyte-
depleted RBCs in both groups, the patients assigned to a restrictive transfusion policy had a 
lower incidence of postoperative infections and respiratory complications compared to the 
patients assigned to a more liberal transfusion policy, which phenomenon we hypothesize 
to be a consequence of the transfusion policy, with no consequences on well-being. These 
data strongly suggest that use of a restrictive transfusion policy is important in blood 
management programs, and even should be the first step in implementation, aiming for 
improved patient outcome.
 In order to evaluate whether RBC transfusions contributed to well being by separating 
the effects of transfusion from the effects of the need for transfusion, we correlated QoL 
scores to RBC use. The number of RBC transfusions and the transfusion status was, after 
correction for possible confounders, not associated with QoL and fatigue scores at any time-
point. We may therefore conclude that the number of RBC transfusions or the transfusion 
status was not related to well being and functioning in the direct postoperative period. We 
previously showed no effect of anaemia on QoL in this cohort. 
 This study has some limitations. First, the study was not powered to evaluate post-
operative complications, since the prevalence of these complications is low, nor was the 
study powered to evaluate the relationship between RBC use and postoperative functioning 
and well being. Second, by reassigning the randomised groups to a “liberal” and “restrictive” 
group, the validity of the current “post-hoc” analysis might be disputed. However, since 
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the allocation was still randomised, the inference and p-values are completely valid as if it 
were a randomised allocation from the start. Therefore, the results from this study provide 
a higher level of evidence than data from prospective observational studies. Third, since 
postoperative anaemia was only moderate in our studied patients, we cannot extrapolate 
our findings to patients with more severe anaemia. 
 In conclusion, a restrictive transfusion policy was not associated with a higher 
complication rate, moreover, this policy might even result in less infections and respiratory 
complications, with no consequences on well-being. QoL scores were not associated to the 
number of RBC transfusions or to the transfusion status, suggesting that these were not of 
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aPPEndiX 
transfusion policies from the original study protocol
Hb values were originally in mmol/L (e.g. 4.0 / 5.0 / 6.0 mmol/L) which is common use in the 
Netherlands 
Protocol a: new, uniform transfusion policy (all participating hospitals)
low risk group (patients younger than 50 years of age)
Within 4 hours of surgery After 4 hours of surgery
If Hb ≥6.4 g/dL: 0 RBC If Hb ≥6.4 g/dL: 0 RBC 
4.8 - <6.4 : 1 RBC 5.6 - <6.4: 1 RBC
<4.8: 2 RBC(s)  <5.6: 2 RBC(s)
intermediate risk group (patients from 50 to 70 years of age)
Within 4 hours of surgery After 4 hours of surgery
If Hb ≥7.2 g/dL: 0 RBC If Hb ≥ 8.1g /dL: 0 RBC
6.4 - <7.2: 1 RBC  7.2 - <8.1: 1 RBC
<6.4: 2 RBC(s)  <7.2: 2 RBC(s)
high risk groupa (see below)
Within 4 hours of surgery After 4 hours of surgery
If Hb ≥8.9 g /dL: 0 RBC If Hb ≥9.7 g /dL: 0 RBC
8.1 - <8.9 : 1 RBC 8.9 - <9.7: 1 RBC
7.2 - <8.1 : 2 RBC(s)  8.1 - <8.9: 2 RBC(s)
<7.2: 3 RBC(s)  <8.1: 3 RBC(s) 
aHigh risk includes one or more of the following:
- any heart rhythm different than sinus rhythm.
- unstable cardiac ischemia (by history or ECG) 
- myocardial infarction less than 6 months 
- heart failure
- heart valve disease
- age ( from 70 years onwards).
- serious peripheral arterial disease, including large vessel surgery (aortic aneurysm, peripheral vessels).
- cerebral arterial disease (CVA or TIA in history) 
- hypertension with left ventricular hypertrophy (LVH) (shown on ECG/ echocardiogram)
- serious pulmonary disease, expressed in polyglobulism (emphysema / pulmonary fibrosis).
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Protocol B: standard care transfusion policies
*hospital number 1 (university Medical Center):
 - Peri-operative transfusion policy (day 0): 
  if Hb between 8.1 and 9.7 g /dL and dependent on blood loss: 1-2 RBC(s).
 - Post operative transfusion policy (from day 1) :
  if Hb <9.7 g /dL : 2 RBC(s), independent of age, risk status
*hospital number 2 (general hospital):
 - Peri-operative transfusion policy (day 0): 
  I keep Hb >6.4 g/dL in case of age < 60 years and ASAa class 1
  II keep Hb >8.1 g.dL in case of age ≥ 60 years and ASAa class 1, 2, 3
  III keep Hb >9.7 g/dL in case of ASAa class 4 or serious cardiopulmonary disease
aAmerican Society of Anesthesiologists
 - Post operative transfusion policy (from day 1):
  I keep Hb >9.7 g/dL in case of co-morbidity as: IC / CCU admission, uremia, serious heart-, lung- or  
  vessel disease: 
  II If no co-morbidity exists, the transfusion trigger is age-dependent:





*hospital number 3 (general hospital):
 - Peri-operative transfusion policy (day 0): 
  if Hb <9.7 g/dL and dependent on (expected) blood loss: 2 RBC(s) 
 - Post operative transfusion policy (from day 1):
  I Patients with cardiac history:
  - if Hb <9.7 g/dL: 2 RBC(s)
  II Patients without cardiac history if symptomatic (nausea, dizziness, tachycardia, general malaise,  
  paleness):
  - if Hb 7.2 g/dL – 8.1 g/dL: 2 RBC(s)
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aBStraCt 
Background: Lower limb joint replacement surgery provides a considerable improvement 
in quality of life (QoL), but is associated with peroperative blood loss, and with anemia in the 
direct postoperative period. General acceptance of low transfusion thresholds and shorter 
postoperative hospital stays will result in patients leaving hospital with low hemoglobin 
(Hb) levels. To evaluate the role of QoL scores as a possible alternative for Hb values to 
serve as a further indicator for RBC transfusion, we performed a secondary analysis of a 
previously conducted randomized clinical trial (RCT) to compare QoL and fatigue scores 
with simultaneously measured pre- and postoperative Hb levels, in total hip and knee 
arthroplasty patients. 
Methods: QoL measurement was measured preoperatively and twice up to 14 days 
postoperatively using the Functional Status Index (FSI), the Visual Analogue Score (VAS)-
Fatigue score, and the Functional Assessment of Cancer Therapy Anemia (FACT-Anemia) 
subscale. Pearson correlation coefficients between (change in) FSI, VAS-Fatigue and FACT-
Anemia subscale scores and (change in) Hb levels were calculated. Additionally, partial 
correlations were calculated and linear regression analysis was performed, correcting for 
possible confounding variables.
results: 603 patients were evaluated. All patients scored worse postoperatively, but none of 
the scores correlated with Hb values, neither after correcting for confounding factors. Even 
more, the changes between preoperative and postoperative Hb levels were not correlated 
with changes in fatigue scores. 
Conclusions: In hip- and knee-prosthesis surgery no correlation existed between 
postoperative Hb levels or acute postoperative decline in Hb values and QoL scores (FSI, 
VAS-Fatigue or FACT-Anemia). 
Lower limb joint replacement (hip- and knee-) surgery provides a considerable improvement 
in quality of life (QoL), but is associated with peroperative blood loss and with anemia in 
the direct post-operative period [1-3]. General acceptance now exists for low transfusion 
thresholds. These latter, combined with an early postoperative discharge of patients from 
the hospital, will result in patients discharged with low hemoglobin (Hb) levels, which may 
compromise revalidation. To date, two studies are available on the effects of anemia on QoL, 
especially on fatigue, in the post-operative period after total hip and knee replacement 
surgery [4,5]. However, these studies comprised less than 100 patients each, studied 
different postoperative intervals and Hb values were not always measured simultaneously 
with the questionnaires. We investigated the relationship between QoL and fatigue scores 
and Hb levels, in order to see whether these scores could serve as a further indicator for 
RBC transfusion. We used data from a large prospective, randomized study that compared 
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MatErialS and MEthOdS
Study design
Secondary analysis of a previously conducted prospective, randomized study that compared 
two different transfusion policies with the mean use of allogeneic leucocyte-depleted 
red blood cell (RBC) units as primary end point. In the original study, QoL measurement 
was pre-defined as secondary endpoint. The transfusion policies differed from a minimal 
threshold of 7.0 g/dL to a maximal threshold of 10 to 10.5 g/dL. The study included patients 
of 18 years and older scheduled for a primary or revision total hip replacement or total 
knee replacement surgery at either of three Dutch participating hospitals (Leiden University 
Medical Center, Leiden; HAGA hospital, The Hague; and Reinier de Graaf Hospital, Delft), 
during a three year period (2001-2003). Refusal of allogeneic transfusions (e.g. Jehovah’s 
witnesses) was the only exclusion criterion. 
Procedures
QoL scores were measured pre-operatively and at post-operative days +4 and + 14 using: 
1. the Functional Status Index (FSI), which is a reliable and valid functional assessment 
instrument in rheumatoid arthritis (RA) and in patients after hip fracture (scale 0-4: with 
lower scores indicating better functioning, 0=not relevant) (Appendix 1) [7, 8]. Total 
scores were recalculated to range from 0 to 100. It should be noted that in literature 
FSI scores are reported as the higher, the better. For better comparison we reversed the 
scores in opposite direction to ensure that all scores were pointed at the same direction.
2. the VAS fatigue score (scale 1-10: lower scores indicate better functioning and well-
being). For reasons of comparison, we recalculated the scores to range from 0 to 100.
3. the Functional Assessment of Cancer Therapy Anemia (FACT-Anemia) subscale (with 13 
fatigue (F) items and 7 non-fatigue (NF) items), which was validated for the association 
with Hb levels in cancer patients (scale 0-4: lower scores indicate better functioning and 
well-being) (Appendix 2) [9]. Total scores were recalculated to range from 0 to 100 for 
FACT-F and FACT-NF items. The FACT-Anemia scale was used specifically for its fatigue 
items, although its validity and reliability is not known in an orthopaedic population. 
Patients completed the first set of questionnaires preoperatively (T1). On postoperative 
days +4 (during hospitalisation) and +14 (in the outpatient setting) the patient completed 
the second (T2) and third set (T3) of questionnaires. Hb levels were measured at the same 
moment as the QoL scores were taken. Follow up ended at the outpatient clinic 14 days 
after surgery or after discharge of the patient (in case of a prolonged hospital stay of more 
than 14 days) (T3). 
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defining clinically minimal important difference (Mid) 
To evaluate responsiveness, MID was defined using anchor-based approaches, when 
available [10]. 
 Anchor-based methods assess which changes on the measurement instrument 
correspond with a minimal important change defined on the anchor. An external criterion, 
generally a global change or transition question, is used to operationalize a relevant or an 
important change. The advantage is that the concept of ‘minimal importance’ is explicitly 
defined and incorporated in these methods.
 For FACT-Fatigue and VAS fatigue scores, MID was defined as a difference in score of 
3.0 (score range 0-42) and 10 (score range 0-100), respectively [11,12]. As FACT-Fatigue 
scores were recalculated to a range from 0 to 100, MID was recalculated to a difference of 
7.1. Concerning the FSI, anchor-based estimates were not available. Therefore we used a 
difference of 0.5 SD for MID at all time points, based on distribution-based methods [13]. 
All validation studies for FSI had only been performed among rheumatoid arthritis patients 
and not always in a surgical setting, whereas for Fact-Fatigue these were all performed 
among cancer patients. 
Statistical analysis
Variables were described as mean and SD, or median and inter-quartile (IQ) range in case 
of a non-normal distribution. Pearson correlation coefficients (+ 95% confidence interval 
[CI]) were calculated for time points T1, T2 and T3, between FSI, Fact-Anemia, VAS scores 
and Hb values as well as between changes in scores and Hb levels from preoperative to 
postoperative values obtained at T2 and T3. Subgroup analysis was performed to compare 
scores between groups concerning age, gender, type of surgery, preoperatively anemia, and 
comorbidity (cardiovascular, respiratory, RA, diabetes), randomization group and numbers 
of RBC transfusions. Partial correlation coefficients were calculated, individually controlling 
for the variables mentioned. Hb levels were additionally analyzed as categorized variables 
(using tertiles: low, intermediate and high Hb groups), and mean QoL scores were compared 
between the highest and lowest group using Student’s t-tests. By linear regression analysis, 
the correlation between Hb and QoL scores was evaluated after adjusting for the same 
variables mentioned. Pre-operative anemia was based on WHO criteria [14]. P values of less 
than 0.05 were considered statistically significant.
rESultS
Baseline characteristics 
Of 619 included consecutive patients, 16 patients could not be analyzed because of the 
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withdrawn before surgery in six and charts missing in two cases. Baseline characteristics of 
the excluded group were comparable with those of the analyzed group (data not shown). 
In Table 1, characteristics of the remaining 603 included patients are shown. During surgery, 
78 patients (13%) received general anaesthesia and 525 (87%) patients received a loco-
regional technique (spinal with or without epidural anaesthesia). Median total blood loss 
was 400 mL (IQ range 0-600 mL). Overall mean RBC usage was 0.78 U/patient in the new 
uniform policy group and 0.86 U/patient in the standard care policy group (mean difference 
0.08; 95% CI, -0.3 to 0.2; p=0.53).
Qol Outcomes 
All 603 patients completed the first set (T1) of questionnaires (pre-operatively), 92% (n=554) 
completed the second set (T2) (4 days after surgery) and 81% (n=487) the third set (T3). Ten 
percent of patients (n=59) had a hospital stay of more than 14 days, with a maximum of 100 
days (median 18 days, IQ range 16-21 days). In Table 2, mean Hb levels and mean scores of 
all questionnaires are shown for all time points which show that at postoperative days 4 
and 14 patients deteriorated in all scores except the FACT-NF score. Patients with RA scored 
worse compared to the group without RA at all time points for VAS-Fatigue and FACT-
Fatigue, but mainly preoperatively (mean difference -12.4 [95% CI, -20.3 to -4.6], p=0.02 and 
-10.2 [95% CI, -15.0 to -5.4], p<0.001, respectively). Also the FSI scores were worse, but only 
preoperatively (T1) and postoperatively at T2 (mean difference at T1 of -9.3 [95% CI, -17.3 to 
-1.4], p=0.002 and at T2 of -9.3 [95% CI, -15.7 to -2.8], p=0.005, respectively). 
 At each time point, the three fatigue questionnaires correlated with variable extent: 
correlations were weak between FSI and VAS fatigue (r=0.29, [95% CI, 0.20 to 0.37], p<0.001) 
and Fact-F (r=0.39, [95% CI, 0.32 to 0.46], p<0.001), whereas a better correlation was found 
between VAS fatigue and Fact-F (r=0.70, [95% CI, 0.65 to 0.74],p<0.001). Within each type of 
questionnaire, pre-operative scores were weakly correlated with postoperative scores: for 
FSI, at T2 (r=0.41, [95% CI, 0.32 to 0.48], p<0.001) and at T3 (r=0.25, [95% CI, 0.16 to 0.34], 
p<0.001); for VAS, at T2 (r=0.43, [95% CI 0.34 to 0.51], p<0.001) and at T3 (r=0.47, [95% CI, 
0.37 to 0,56], p< 0.001); for FACT-F at T2 (r=0.40, [95% CI, 0.32 to 0.47], p<0.001) and at T3 
(r=0.41, [95% CI, 0.33 to 0.49], p<0.001) and for FACT-NF at T2 (r=0.44, [95% CI, 0.37 to 0.51], 
p<0.001) and at T3 (r=0.40, [95% CI, 0.32 to 0.48], p<0.001). 
 We found significant differences between the FSI and Fact-F scores of preoperatively 
anaemic patients (mean ± SD Hb level of 11.6 ± 0.8 g/dL) compared to pre-operatively 
nonanaemic patients (mean Hb (SD) of 14.0 (1.1) g/dL) at several time-points (not shown). 
However, these differences were small and less than the defined clinically MID.
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table 1. Baseline characteristics of 603 patients undergoing total hip or knee replacement surgery
all subjects
demographics
Age, years 70.4 (9.9)
Male/Female 202/401
Weight, kilograms 78.6 (13.3)
type of surgery 
Total hip replacement 339 (56.2)
Total knee replacement 224 (37.1)
Revision total hip replacement 34 (5.6)
Revision Total knee replacement 6 (1.0)
underlying diseases 
Rheumatoid arthritis 67 (11.1)
COPD 46 (7.6)
Hypertension 269 (44.7)
Myocardial infarction 27 (4.5)
Cardiac failure 58 (9.6)
CVA/TIA 32 (5.3)
Peripheral vascular disease 34 (5.6)
Arythmia 50 (8.3)
laboratory findings 
Pre-operative hemoglobin, g/dL 13.7 (1.3)
Pre-operative hematocrit, L/L 0.41 (0.04)
Pre-operative anemia 98 (16.3)
Continuous data are presented as mean (SD) and categorical data as number (%).
COPD=chronic obstructive pulmonary disease; CVA/TIA=cerebrovascular accident/transient ischemic attack.
table 2. Mean hemoglobin levels and score values* of the three questionnaires at the three measured 
time points (T1=preoperatively, T2= four days postoperatively, T3=14 days postoperatively / at 
discharge)a
Mean (Sd) scores of: t1 t2 t3
Hemoglobin (g/dL) 13.7 (1.3) 10.5 (1.1) 11.4 (1.2)
FSI 14.6 (17.0) 47.5 (23.0) 31.4 (19.0)

















*Range of scores of FSI, VAS and Fact-Anemia (both Fact-F and Fact-NF) questionnaires from 0 to 100.
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table 3. Correlations ( r) of Hb values with FSI, VAS, FACT-F, and FACT-NF scores on several time points 
(T1=preoperatively, T2= four days postoperatively, T3=14 days postoperatively / at discharge)












































hb levels and Qol scores
Mean ± SD postoperative Hb values on days +4 and +14/discharge were 10.5 ± 1.1 and 
11.4 ± 1.2 g/dL, respectively. Hb values were not correlated with VAS-scores and weakly 
correlated with FSI-, and FACT-Anemia scores at several time points (Figure 1A-L and Table 
3). Although some correlations were significant, these were very weak, as the magnitude 
(expressed by R2) did not exceed 0.04 (0.22 times 0.22), so at most 4% of the total variability 
in any of the four scores was explained at any time point by Hb. When Hb levels were 
categorized into three equal subgroups, significantly different scores on the FSI and Fact-F 
were seen between the lowest (mean Hb level, 12.2 g/dL) and highest Hb subgroup (mean 
Hb level, 15.1 g/dL) at T1, and on the FSI, Fact-F and VAS at T2 (mean Hb levels, respectively, 9.3 
and 11.8 g/dL), but not at T3 (mean Hb levels, respectively, 10.1 and 12.9 g/dL). Again, these 
differences were small and less than the clinically MID. Fact-NF scores showed no differences 
at any time points. No correlation of greater than 0.30 between Hb and fatigue scores was 
found, neither after individually controlling for clinical and demographic characteristics by 
partial correlation analysis nor after simultaneous correction for these variables in linear 
multivariable regression analysis. The randomization group, which included a more or less 
restrictive transfusion policy, and the number of RBC transfusions were not of any influence 
on the outcome of QoL and fatigue scores either.
Change in scores compared to (change in) hb levels
We compared changes in scores between the preoperative and postoperative follow-up 
moments T2 and T3 with the absolute Hb values at the same endpoints in accordance with 
Conlon et al, for the elderly population (aged from 65 years onwards, n=455), and found no 
62 | Chapter 4
correlation of any significance. This was also the case when we compared the change scores 
with the change in Hb values (delta Hb; Table 4A). For the total study population, the results 
were also not different (Table 4B).
table 4. Correlations between (delta) Hb level and changes of FSI, VAS and FACT scores at T1 compared 
to T2 (T2-T1) and T3 (T3-T1) including 95% CI and p-values 
Change of hb (t2) delta hb (t2-t1) hb (t3) delta hb (t3-t1)










































































































figure 1. Correlation of scores with Hb levels, measured pre-and postoperatively (A-L). Scatter plots of 
VAS-Fatigue, FSI, Fact-F and Fact-NF in relation to the Hb values at T1 (preoperatively; A-D), at T2 (4 days 
post-operatively; E-H) and at T3 (14 days post-operatively; I-L). Linear regression lines with associating 
R2 values were added.
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diSCuSSiOn
This study was based on a large orthopaedic population of more than 600 patients, in which 
Hb levels and QoL- and fatigue scores were measured at simultaneous time points. In this 
elective surgery population, symptoms of fatigue were not correlated with Hb levels at any 
time-point up to 14 days after surgery. All scores deteriorated in this early postoperative 
period. Some correlations with Hb level were significant, but these were very weak, and 
at most 4% of the total variability with a maximum of 9% in any of the four scores could 
be explained at any time point by Hb levels. After controlling for clinical and demographic 
factors, the association between Hb and QoL scores remained weak. Not even the 
randomisation group and the number of RBC transfusions influenced this outcome. Scores 
of anaemic patients were slightly worse at all time points compared to non-anemic patients, 
as well as scores of the lowest Hb group compared to the highest group, but the differences 
did not meet the definition of clinically important difference. 
 The findings are in agreement with the findings of Wallis and coworkers, who compared 
the SF-36 questionnaire and an in-house linear analogue QoL scale with Hb levels up to 
8 weeks after total hip surgery in 30 patients and found no correlation [4]. Conlon et al 
[5] found a linear correlation in the change of FACT-Anemia and SF-36 scores, taken pre-
operatively and 2 months after total hip arthroplasty, and the absolute Hb values taken 
pre-operatively and 8 days post-operatively in 87 patients. Improvement in overall SF-36 
score was 8.6 points for every Hb increase of 1 g/dL on day 8, and improvement in FACT-
Anemia score was 2.9 points for a similar Hb increase, indicating that patients with a lower 
Hb at discharge at day 8 consistently reported less improvement in QoL and fatigue than 
those discharged with a higher Hb level. Our data could not confirm this.
 Both the studies performed by Wallis et al and Conlon et al differed in design from ours 
by obtaining questionnaires at different and later postoperative time points and -more 
importantly- without a simultaneous Hb measurement. Because our follow up period ended 
at two weeks postoperatively, it is possible, that FACT-Anemia scores correlate with Hb 
values at later time points. We did not include a more prolonged follow-up, since the basic 
goal of the original study was to evaluate the effect of a restricted perioperative transfusion 
trigger on RBC use and to investigate direct postoperative effects such as hospital stay, delay 
of mobilisation and, in this report, quality of life, fatigue and function with the purpose to 
find a further indicator for RBC transfusion.
 The FACT-Anemia questionnaire was originally developed for cancer patients and seems 
less applicable to lower joint surgery patients, who generally suffer a more acute anemia 
due to intra- and postoperative blood loss as compared to anemia due to a chronic disease 
(e.g. cancer, use of chemotherapy). 
 In the immediate postoperative period, the three used questionnaires, showed 
intercorrelations between 11 and 70%, suggesting that these scoring systems measure 
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a similar construct with respect to QoL and fatigue. As the FACT-NF subscale was not 
responsive, it seems not informative in this context. 
 Although the FSI is a reliable and valid instrument to measure functional outcome in 
orthopaedic patients, this functional scale did not correlate with postoperative acute Hb 
level decrease or absolute Hb levels. Other factors in the postoperative period apparently 
overrule the inconvenience of anemia or a decrease in Hb level.
 In hip fracture patients, Carson and coworkers investigated postoperative recovery in 
relation to Hb levels and found no difference in recovery between a discharge Hb of 8 to 10 
g/dL and more than 10 g/dL [15]. Halm et al used the Functional Independence Motor (FIM) 
mobility score to measure functional mobility within 60 days follow up after hip fracture 
surgery, also found no association with pre- or post-operative Hb levels [16]. These findings 
as well as our study show that the used QoL and fatigue questionnaires, are not suitable as 
a monitor for acute postoperative anemia, at least not in the range of Hb levels observed in 
this study.
 In conclusion, we found that Hb levels do not correlate with the FSI, VAS and FACT-Anemia 
scores in the immediate postoperative period after lower limb joint replacement surgery, 
which is associated with a more acute decrease in Hb level and which is different from the 
setting of chronic anemia for which some questionnaires were developed. However, this 
does not preclude an effect after a longer postoperative interval or in patients with lower 
absolute Hb levels.
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aPPEndiX 1 
The Functional Status Index (FSI) has 11 questions. Each question is scored from 0 to 4 with 
lower scores (except for 0) indicating better functioning. 
0= this question is not relevant 
1= no help needed 
2= uses a device 
3= needs human assistance 
4= not possible due to health reasons 
1. walking 10 feet
2. getting into and out of bed
3. putting socks and shoes on
4. getting on and off the toilet
5. rising from an armless chair 
6. getting in and out of a bath/shower
7. taking a bath or shower
8. walking a block
9. .getting into a car
10. putting on pants
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aPPEndiX 2 
The FACT-Anemia questionnaire comprises of fatigue (F) items and non-fatigue (NF) items. 




2=more than a little 
3=very much
4=very strongly 
I feel fatigued (F)
I feel weak all over (F)
I feel listless (“washed out”) (F)
I feel tired (is skipped because of VAS fatigue score asked separately)
I have trouble starting things because I am tired (F)
I have trouble finishing things because I am tired (F)
I have energy (F)
I have trouble walking (NF)
I am able to do my usual things (F)
I need to sleep during the day (F)
I feel light-headed (dizzy) (NF)
I get headaches (NF) 
I have been short of breath (NF)
I have pain in my chest (NF)
I am too tired to eat (F)
I am motivated to do my usual activities (NF)
I need help doing my usual activities (F)
I am frustrated by being too tired to do the things I want to do (F)
I have limited my social activities because I am tired (F).
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aBStraCt
To determine the safety, efficacy and user-friendliness of two different postoperative 
autologous blood re-infusion systems an open, randomized, controlled study was 
performed.
 Eligible consecutive primary and revision total hip and knee replacement patients were 
randomized for one of the two systems or for a control group in which shed blood was 
not re-infused. The nursing staff scored user friendliness. Patients were monitored after re-
infusion. In all three patient groups a restrictive transfusion trigger was used.
 Sixty-nine of 70 randomized patients were evaluated. Ease of use, efficacy and safety 
of both re-infusion systems were comparable. There was no difference in allogeneic blood 
use between the groups. Thirty per cent of the patients re-infused with autologous blood 
developed a mainly mild, febrile transfusion reaction. No other adverse reactions were 
seen. Signs of coagulopathy after re-infusion were not found. In multivariate analysis 
autologous re-infusion was an independent factor associated with a shorter hospital stay. 
Both postoperative autologous blood re-infusion systems were of equal efficacy and safety. 
The contribution of autologous wound blood re-infusion to reduce allogeneic transfusions 
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After total knee or hip arthroplasty a total blood loss of 750 ml or more is common [14]. 
Postoperative re-infusion of autologous shed wound blood would be a possibility to save 
the use of allogeneic red blood cell (RBC) transfusions [12,16,17]. Preliminary studies also 
suggest a reduction in postoperative (wound) infections using autologous wound blood 
transfusions [8,12,18]. Several re-infusion devices (of which the collected blood is leukocyte 
reduced, washed or “unprocessed”) are available, but limited comparison between systems 
is available [3,10,11]. For the design of a large randomized study, investigating the value 
of several blood management interventions in orthopaedic surgery, we wanted to make 
a valid decision between commercially available postoperative autologous blood re-
infusion systems. In an open randomized, controlled study in primary and revision total hip 
replacement (THR) and total knee replacement (TKR) patients, two different postoperative 
re-infusion systems currently used in the Netherlands were compared with respect to 
efficacy, safety and user friendliness.
PatiEntS, MatErialS and MEthOdS
In 2003,  patients of 18 years and older who were scheduled for a primary or revision THR or 
TKR at the Leiden University Medical Centre (LUMC) were included for this study. All patients 
were of American Society of Anaesthesiologists (ASA) 2 or 3 category. Exclusion criteria were: 
sickle cell anaemia, cancer, bacterially contaminated wounds and participation in other 
blood management studies. Patients were randomized to three groups: A, a control group 
with a standard closed suction wound drainage system not intended for re-infusion; B, a 
re-infusion system, using continuous suction at a vacuum pressure of 120 mm Hg and just 
prior to re-infusion a double shielded 40 micron filter (Pall Lipiguard VS filter) entrapping 
lipids larger than 10 micron and 2 log of leukocytes (DONORTM system, Van Straten Medical, 
Nieuwegein, The Netherlands); C, a re-infusion system, which uses intermittent suction 
pressure by a manually expandable bag at a maximum pressure of 90 mm Hg and three 
filters: a 200 mm filter, a secondary 80 mm filter and prior to re-infusion a third 40 mm filter 
(Bellovac A.B.T.®, Astra Tech, Zoetermeer, The Netherlands). The companies of the drainage 
devices were allowed to train the nursing staff on theoretical aspects in two sessions and 
practical aspects at bedside in 4 sessions. Thereafter the companies were available for 
advice if needed. 
 The study was approved by the local Medical Ethical Committee and written informed 
consent was given by all patients. A randomisation list was generated by a statistical 
software package: preoperatively, the patient was randomly assigned to one of the three 
groups by opening a sealed envelope with the randomisation number. General anaesthesia 
or loco-regional anaesthesia was chosen based on each patients’ requirements. An 
ischaemic tourniquet was applied to all TKR patients, whereas THR patients were operated 
76 | Chapter 5
in the lateral position by a direct lateral approach to the hip. During the study a restrictive 
transfusion trigger according to the Dutch guidelines was used (CBO consensus guidelines, 
2004). No intra-operative blood saving measurements were performed. A sterile disposable 
drainage system set was intra-operatively inserted, just before suturing the wound, to drain 
wound blood. One Redon catheter was placed intra-articular. Blood collection began after 
skin closure (THR) or 15 minutes after tourniquet deflation (TKR). 
Outcome measures
Outcome measures were efficacy, safety and user-friendliness of the wound drainage 
devices. User-friendliness was scored by the nursing staff by the following questions, ranked 
on a scale from 1 to 5 (1= very difficult, 5=very easy): frequency of handling the same system 
(first time or more than once), extent of burden to the patient and the nurse, occurrence 
and chance of wrong use and user-friendliness in daily practice. Efficacy and safety were 
measured by blood loss, units of allogeneic RBCs transfused, amount of autologous 
blood re-infused, transfusion reactions, postoperative haemoglobin (Hb) level, delay 
in mobilisation beyond the routine schedule at day 3 and length of hospital stay (LOHS) 
(defined as the interval between the day of surgery until the day of discharge from the 
hospital). Infections were scored according to CDC-criteria [9], wound infections were scored 
according to Gaine et al (2000). Transfusion reactions were scored according to the Dutch 
hemovigilance criteria, including mild reactions such as a temperature rise ≥1°C. Criteria for 
discharge were according to the hospital protocol. A serious adverse event was defined as 
a transfusion reaction of the third or fourth degree (life threatening or death). Antibiotics 
and anticoagulant therapy were given according to the standard hospital protocols. Total 
amounts of shed blood were measured within and after 24 hours for group A, and within 
and after 6 hours for groups B and C, respectively, until the drain was removed.
laboratory analysis
Venous blood samples were taken pre-operatively and on day 1 after surgery for Hb 
(g dL-1), haematocrit (Hct), White Blood Cell (WBC) count (x109 L-1), Thrombocyte (Tr) count 
(x109 L-1) and LDH (U L-1). Levels of interleukin (IL)-6, IL-10 and IL-12 cytokines were measured 
by ELISA with a detection range of 1 to 50.000 pg mL-1 (Sanquin diagnostics, Amsterdam, 
the Netherlands). Percentage antitrombin activity was measured by chromogenic assay 
(Coamatic Antithrombin, Chromogenix–Instrumentation Laboratory SpA, Milan, Italy) 
on an automated coagulation analyser (STA-R®, Diagnostica Stago, Asnières sur Seine, 
France), fibrinogen (g L-1) was measured according to the Clauss method on an automated 
coagulation analyser (Electra 1800C, Medical Laboratory Automation, Inc., Pleasantville, 
NY), and D-dimers (ng mL-1) were determined by an automated immuno-analyser (VIDAS®, 
bioMérieux, Breda, the Netherlands) with a maximal measurable value of 50.000 ng mL-1. In 
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blood samples were taken immediately after re-infusion was completed. At discharge, 
patients’ Hb and Hct were measured. 
 Shed blood samples (up to a maximum of 150 ml) were taken immediately after start 
of drainage (T0), pre-filter (T1) and post-filter just before re-infusion (max. 6 hours after 
surgery) (T2). These samples were analysed for Hb, WBC count, Tr, Free Hb (mg dL-1) and LDH. 
Plasma and serum were stored at -80°C for coagulation factor and cytokine measurements. 
In addition, samples were taken for bacterial culture. 
Statistical analysis
The study size was not based on statistical power calculations, but on descriptive comparisons. 
To allow for detection of large differences between the systems, each randomisation group 
consisted of minimal 20 patients. Statistical analysis was performed in SPSS for Windows 
11.0. Frequencies were described as mean and standard deviation (SD), or median and 
range in case of a nonparametric distribution. Analysis of laboratory parameters between 
patients and other numeric endpoints was performed with the ANOVA-test and analysis 
within the patients with a paired t-test. Differences between the groups in the number 
of RBC transfusions and the total number of units RBC transfusions given were analysed 
with the non-parametric Mann-Whitney test. Categorical endpoints were tested using 
the Chi-square test or Fisher’s Exact test. LOHS was analysed as a continuous variable and 
dichotomized (< eight days and ≥ eight days). Age was analysed as a continuous variable 
and categorized into four groups (≤40, 41-65, 66-75, >75 years). End points were analysed 
univariate, and when relevant, to correct for confounding factors, multivariate analysis 
with backward conditional regression was performed. P values <0.05 were considered 
statistically significant.
rESultS
Baseline characteristics are shown in Table 1. Of 70 patients included, one patient was not 
operated, leaving 69 evaluable patients. 42 (61%) patients had a primary THR, 20 (29%) 
a primary TKR, four (6%) a revision THR and three (4%) a revision TKR. THR patients were 
underrepresented and TKR over-represented in group A as compared to the wound blood 
re-infusion groups B and C (p=0.06). Diagnosis (osteo-arthritis and rheumatoid arthritis), 
co-morbidity (arterial disease, pulmonary disease, diabetes) and use of medication were 
comparable in the three groups. 
 Concerning intra-operative parameters (Table 2), groups were comparable for surgery 
duration and blood loss. Four patients received intra-operative blood transfusions (total 
of seven units RBC’s) because of large blood loss of more than 1500 mL. No transfusion 
reactions were seen.
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table 1. Baseline characteristics
  aBC (n=69) aa (n=22) Ba (n=23) Ca (n=24)
Baseline parameters
Female (%) 62 68 61 58
Age (years) mean ± SD 60 ± 16.0 58 ± 14.3 66 ± 15.6 58 ± 17.2
Weight (kg) mean ± SD 79 ± 14.9 85 ± 21.9 77 ± 13.1 76 ± 17.1
Type of surgery
THR primary/ revision (n)b 42/4 10/1 15/2 17/1
TKR primary/ revision (n)b 20/3 8/3 6/0 6/0
Pre-operative lab
Hb (g dL-1) mean ± SD 13.7 ± 1.61c 13.7 ± 1.61 13.7 ± 1.77c 13.7 ± 1.61
Hct (L L-1) mean ± SD 0.40 ± 0.04c 0.40 ± 0.04 0.40 ± 0.04c 0.40 ± 0.04
WBC (x109 L-1) mean ± SD 7.8 ± 2.4c 8.2 ± 3.3 8.4 ± 2.0c 7.0 ± 1.2
Tr (x109 L-1) mean ± SD 274 ± 84d 291 ± 100c 281 ± 76c 252 ± 75
a A, control group; B, DONORTM group; C, Bellovac A.B.T.® group
b difference in type of surgery (n) of re-infusion groups compared to control group: P=0.06
c one missing value 
d two missing values
Questionnaires to score the user-friendliness of the drainage systems, were completed in 
28 of 30 re-infused cases (response rate of 93%). Outcome of both devices was comparable 
with a learning effect after handling the same device for more than one time (Figure 1). 
 Of 47 patients randomized for the use of a shed blood re-infusion system, 30 (64%) were 
actually re-infused (mean 401 ± 170 mL): 11 of 12 (92%) of the TKR patients (mean 591 ± 322 
mL) and 19 of 35 (54%) of THR patients (mean 290 ± 170 mL) (Table 2). Of 17 patients not 
re-infused, in 11 cases the collected volume was too low (<100 mL), four patients dropped 
out from the study due to venous access problems and in two cases accidentally a control 
drainage system was placed. No serious adverse events after re-infusion were observed. Six 
patients had mild reactions (transient fever and/or shivers) after re-infusion. 
 Of the total of 71 units RBCs transfused, 64 (90%) were given to 32 patients postoperatively 
from day +1 onwards post surgery. The main reason for postoperative transfusions was a 
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table 2. Intra- and postoperative parameters
  n aBC n aa n Ba n Ca
intra operative parameters
Duration of surgery (min) 
mean ± SD 
69 146 ± 44 22 156 ± 48 23 137 ± 42 24 145 ± 44
 THR 46 138 ± 40 11 143 ± 36 17 128 ± 37 18 145 ± 45
 TKR 23 161 ± 49 11 169 ± 55 6 163 ± 47 6 146 ± 43
Blood loss (mL) median 
(range)
69 450 (0-2400) 22 313 (0-1625) 22 500 (0-2400) 23 485 (0-1700)
 THR 44 600 (0-2400) 11 600 (250-1625) 16 563 (0-2400) 17 750 (200-1700)
 TKR 23 0 (0-835) 11 0 (0-835) 6 0 (0-500) 6 0 (0-250)
Postoperative parameters
LOHS (days) mean ± SD 8.2 ± 3.3 9.0 ± 2.8 7.8 ± 4.0 7.9 ± 3.1
 THR 7.7 ± 3.6 8.9 ± 3.4 7.4 ± 4.3 7.4 ± 2.8
 TKR 9.2 ± 2.7 9.1 ± 2.3 9.0 ± 2.4 9.5 ± 3.8
total drain production (ml) median (range) 
 THR 445 (45-1350) 538 (65-1245) 440 (100-1350) 430 (45-1230)
 TKR 963 (350-1745) 885 (455-1710) 630 (350-1150) 1443 (960-1745)
Shed blood re-infusion (ml)b
mean ± SD 30 64% 15 329 ± 274 15 472 ± 265
 THR 19 54% 9 260.0 ± 192.0 10 317.5 ± 151.5
 TKR 11 92% 6 433.3 ± 359.2 5 781.0 ± 126.3
Re-infusion reactions 30 6 4 2
intra- and postoperative allogeneic rBC transfusions
Number of units 
(% of patients)
32 (46%) 10 (45%) 13  (57%) 9  (38%)
 THR 20 (43%) 4 (36%) 10  (59%) 6 (33%)
 TKR 12 (52%) 6 (55%) 3 (50%) 3 (50%)
RBC/transfused patient 
± SD
2.2 ± 0.8 1.9 ± 0.7 2.4 ± 1.0 2.3 ± 0.7
 THR 2.3 ± 0.6 2.5 ± 0.6 2.2 ± 0.6 2.2 ± 0.4
 TKR 2.2 ± 1.2 1.5 ± 0.5 3.0 ± 0.7  2.7± 1.2
Transfusion reactions 2 1 shivers 1 shivers
Hb values (g dL-1) day+1
mean ± SD 
10.3 ± 1.45 10.5 ± 1.45 10.0 ± 1.45 10.3 ± 1.61
 at discharge mean ± SD 10.8 ± 1.29 10.6 ± 1.13 10.6 ± 1.13 10.9 ± 1.45
a A, control group; B, DONORtM group; C, Bellovac A.B.T.® group
b this concerns only groups B and C
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figure 1. Scores of questionnaire: user-friendliness (n=28).
The figure shows the mean scores of system B (DONORTM) at first time of handling (n=10)and at second 
time of handling (n=4) and of system C (Bellovac A.B.T.®) at first time of handling (n=6) and at second 
(or more) time of handling (n=8). One nurse handled system C four times. Scores: 1=very difficult; 2= 
difficult; 3=neutral; 4=easy; 5=very easy. 
Neither the percentage of patients transfused, nor the transfusion index [mean units of RBCs 
transfused per patient ( 1.0 ± 1.2 for both THR and TKR)] differed among the three groups. 
Six patients could not be mobilized on the third day after surgery: two control patients, 
three of group B and one patient of group C were delayed. Overall, the infection rate was 
13 % (9/69) and was not different between groups: urinary tract infections (n=3), superficial 
wound infections (n=2), one deep wound infection resulting in prosthesis revision surgery, 
localized infections elsewhere (n=2) and bacteraemia (n=1). 
 Mean LOHS was slightly shorter in the THR re-infusion groups B and C and significantly 
less patients had a LOHS longer than 8 days as compared to the control group. In multivariate 
analysis, re-infusion group, age group, type of surgery and gender were entered, of which 
re-infusion group and age group remained independent variables to LOHS (p=0.02; 
corrected odds ratio=0.230 for re-infusion group and p=0.002; corrected odds ratio=2.775 
for age group). 
laboratory analysis
Venous blood samples
Postoperative Hb values and Hb at discharge were similar in the groups (Table 2). In both 
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3), resulting from high D-dimer values (>50.000 ng mL-1) in the re-infused shed blood, and 
other coagulation values were comparable. In all groups, analysis of paired samples within 
the whole study group showed a significant decrease of antithrombin levels at day +1 
after surgery compared with the pre-operative samples [103.2 to 83.6 % (p<0.001)]. In the 
re-infused patients this decrease was present directly after re-infusion [101.0 to 81.6 % (p 
<0.001); n=22] and remained stable up to the first postoperative day. Fibrinogen levels in 
the re-infused patients were also significantly decreased just after re-infusion: from 4,62 to 
3,35 g L-1 (p<0.001) (n=22) and increased between time of re-infusion and day+1 (n=23): 
from 3,37 to 4,70 g L-1 (p <0.001). Fibrinogen levels at day+1 of the re-infused patients and 
the control patients were not significantly different. 
table 3. Coagulation parameters of venous blood samples




fibrinogen (g l-1) 
Mean (Sd)
Aa Day –1 104.2 (9.7) 645 (225-9578) 4.33 (1.1)
Day +1 85.9 (11.2) 1719 (695-15736) 4.67 (1.1)
Ba Day –1 103.3 (14.0) 995 (225-6247) 4.69 (1.4)
Directly after re-infusion 80.8 (10.1) 39101 (5750-50000) 3.57 (0.8)
Day +1 82.8 (13.6) 6172 (691-19224) 5.15 (1.1)
Ca Day –1 102.7 (11.5) 528 (233-6251) 4.19 (0.9)
Directly after re-infusion 80.3 (20.6) 42437 (15730-50000) 3.01 (1.1)
Day +1 82.2 (11.6) 7113 (601-17894) 4.63 (0.8)
a A: control group, B: DONORTM group, C: Bellovac-A.B.T.® group
IL-12 levels in venous blood were not different between re-infused and control patients 
(median 38 pg mL-1 (range 5-615) on day-1 and 27 pg mL-1 (range 5-559) on day +1). Pre-
operative values correlated with postoperative values (Figure 2). Measurable pre-operative 
IL-6 values (i.e. >1 pg mL-1), were present in 54% of patients (n=34) with a median of 188 pg 
mL-1 and a wide range of 5-8758. After re-infusion, the median value (n=24) increased to 
648 pg mL-1 (range 89-3512) and dropped to 361 pg mL-1 (range 48-4419) on day+1 after 
surgery (n=51) without a difference between groups. IL-10 levels were below detection 
level in 92% pre-operatively, in 72% directly after re-infusion and in 79% on day +1. The 
detectable values ranged from 4 to 126 pg mL-1.
 Patients’ LDH after re-infusion was slightly elevated (446 ± 85 U L-1). 
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figure 2. IL-12 levels of venous blood samples (pre- and postoperatively).
Shed blood samples
Whole-blood volume, Hb, Hct, platelets and haemolysis parameters of shed blood samples 
were comparable between both systems before (T1) and after filtering-just before re-
infusion (T2) (Table 4), except for leukocyte count, as the Lipiguard filter used in drainage 
system B had a modest leucocyte depleting effect: from 5.6 x 109 L-1 (T1) to 1.9 x 109 L-1 (T2). 
IL-6 levels exceeded the maximal measurable value of 50.000 pg mL-1 in 4 of 37 (11%) wound 
blood samples at T0, in 20 of 33 (61%) at T1 (after 4-6 h of collecting) and in 21 of 35 (60%) 
prior to re-infusion at T2. IL-10 levels could not be detected in 6-14% at all time points. The 
range in the other samples was 4-157 pg mL-1. Mean IL-12 levels (± SD) are shown in Table 4.
 No bacterial contamination was found. There was no relation with transfusion reactions 
and cytokine levels in the re-infused shed blood. In one case, high haemolysis parameters 
were found in association with a febrile transfusion reaction (LDH and free Hb levels of 
9890 U L-1 and 239 mmol L-1, respectively). LDH of the patient directly after re-infusion was 
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table 4. Mean shed blood values (± SD) just before re-infusion (T2).
Groups B and C shed blood values
Hb (g dL-1) 8.4 ± 1.61
Thrombocytes (x109 L-1) 40 ± 22
Free Hb (mg dL-1) 184 ± 111.2
LDH (U L-1) 2511 ± 1853
Antithrombin (%) 39 ± 12.0
IL-12 (pg mL-1) 48 ± 35.0
diSCuSSiOn
Both postoperative autologous blood re-infusion systems turned out to be user-friendly 
and feasible to use. For both drainage systems a learning effect was present. The use of 
drainage systems was more effective for TKR patients, who were re-infused in 92% of the 
cases, compared to 54% of THR patients. Clearly, in TKR patients more blood is drained post-
operatively. The overall relatively low percentage of re-infusion (60% and 63% for systems 
B and C respectively) was partly due to the use of 150 mL shed blood for study analysis and 
could increase to 75%. Approximately 50-100 mL shed blood remained in the system even 
after full re-infusion. In this pilot study, no reduction of allogeneic RBC transfusions was 
found, as was reported by others in THR patients [13]. However, our study was not powered 
for this conclusion.
 No serious adverse events were seen. In one case, a reaction occurred upon fairly 
haemolytic blood. In literature, transient fever reactions during auto-transfusion have 
been related with surgery using cement [19]. In our study, however, in only two of these six 
patients bone cement (Palacos, Biomet Merck Inc., Warsaw, IN, USA) was used. Although the 
percentage of (30%; 6 of 20) mild febrile transfusion reactions was higher than previously 
reported [2,6,7], this may be due to the inclusion of all mild febrile reactions (≥1°C rise 
in temperature). A slower pace of re-infusion might prevent such transfusion reactions. 
However, there was no relation with transfusion reactions and cytokine levels in the shed 
blood or in the patient immediately after re-infusion, despite the extreme high levels of IL-6 
in the shed blood. Preoperatively, IL-6 was undetectable in 46% of patients, but increased 
in all cases post-surgery. IL-12 values were between 0-600 pg mL-1 and not affected by 
surgery, autologous re-infusion or allogeneic transfusions (Figure 2). Although previous 
reports found an increased level of IL-10 after surgery and allogeneic transfusions might 
lead to deviation towards a T helper 2 type cytokine pattern, associated with an immune-
suppressed state and even with LOHS, in our small pilot study we could not confirm this. 
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Despite IL-10 was present in shed blood, this was not recovered in the circulation after re-
infusion. 
 A mean rise in temperature of 0,5°C immediately after re-infusion was found. Fever 
upon re-infusion has been attributed to high pro-inflammatory cytokine levels in re-infused 
blood [2]. The control group showed a similar pattern of temperature rise at this interval 
after surgery. It has been suggested that this is rather a response to the surgical procedure 
itself [11]. 
 There were no signs of triggering of diffuse intra-vascular coagulation after shed blood 
re-infusion. Antithrombin activity levels decreased after surgery by 20% and remained stable 
in the patient after re-infusion up to the first postoperative day. Postoperative fibrinogen 
levels at day +1 in the re-infused patients were not significantly different compared to 
the control group. In all patient groups, fibrinogen levels also decreased significantly after 
surgery, probably due to a dilution factor (fluid infusion) and consumption during surgery, 
and increased to a slightly higher level on day +1 due to an acute phase response. Fibrinogen 
levels were not measured in shed blood, because these values are extremely low [6,10]. 
D-dimer levels in shed blood were very high due to coagulation activation and fibrinolysis 
in the wound area, and were passively infused in the patient in case of re-infusion which 
resulted in significant elevated levels in the patient directly after re-infusion up to day 1. All 
these data suggest that re-infusion of shed blood does not induce coagulopathy. 
 Despite the fact that no difference in the allogeneic RBC transfusion rate was found, 
in the control group the LOHS was one day longer than in the re-infusion groups B and 
C. In multivariate analysis, re-infusion group remained an independent variable to LOHS. 
This finding, however, should be interpreted with caution, because our study was not 
powered for this conclusion. A reduction in LOHS was also seen by Newman et al (1997) and 
Shulman et al (2002) who both found a reduction of two days, but this was associated with 
a reduction in allogeneic RBC’s. It has been postulated that the pro-inflammatory cytokines 
in shed blood activate natural killer (NK) cells [5]. Whether and how such a stimulation of NK 
cells might have an effect on LOHS is unknown. We observed no difference in postoperative 
infections, but our study was not powered for this purpose and served as a pilot study for 
a large randomized controlled trial (International Standard Randomized Controlled Trial 
Number 96327523). 
 To conclude, the use of a postoperative autologous shed-blood re-infusion system is 
user-friendly and easily implemented in a blood management protocol. Efficacy is greatest 
in TKR patients. Concerning safety, no serious adverse events were seen. Although there 
was no blood saving, LOHS was slightly shorter in the re-infusion groups compared to the 
control group. Larger sufficiently powered studies are necessary to evaluate presumed 
reduction in allogeneic transfusions, postoperative infections and LOHS by the use of re-
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the two autologous shed blood re-infusion systems was found, the choice for a particular 
device can be based on economical aspects. 
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aBStraCt
Background: In orthopaedic surgery, re-infusion of autologous salvaged blood can be used 
as an alternative for allogeneic blood transfusion. In addition, autologous salvaged blood 
might stimulate an immune response reducing infections in the postoperative period.
Questions/purposes: We investigated whether re-infusion of washed or unwashed 
salvaged blood resulted in different cytokine gene expression (GE) profiles, indicative for 
immunomodulation, in patients after hip replacement surgery compared to the effect of 
the surgery itself. 
Methods: Observational study of patients participating in a clinical study on transfusion 
alternatives. From 11 patients, whole blood samples before and 24 hours after surgery were 
collected for GE array analysis of 114 cytokines, followed by reverse transcriptase RealTime-
PCR for selected genes in 56 patients, of which 19 received washed and 13 received 
unwashed autologous blood and 24 were control patients.
results: After surgery, IL-8, TNFsf10 and TNFsf13B showed most frequent up- and down-
regulations and were selected for PCR analysis. Overall, post-surgical inter-patient variations 
were large and exceeded the differences observed with or without autologous blood 
reinfusion. Unwashed salvaged blood re-infusion was associated with slightly more up-
regulation of TNFsf13B GE compared to controls or patients who received washed salvaged 
blood. 
Conclusion: Both autologous washed or unwashed salvaged blood re-infusion after hip 
surgery was associated with minor systemic changes in cytokine GE. The results suggest a 
more pro-inflammatory response after unwashed as compared to washed salvaged blood.
Clinical relevance: Salvaged blood re-infusion adds minor immuno-modulatory alterations 
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Allogeneic blood transfusions (ABT) in orthopaedic surgery have been associated with an 
increased risk for post-operative infections [7]. In order to diminish the use of ABT, various 
blood saving strategies are employed. In particular in orthopaedic surgery, post operative 
re-infusion of salvaged blood is an often used strategy [12,20,31]. Preliminary studies found 
a decrease of post-operative infections using salvaged blood as compared to patients 
transfused with allogeneic blood [31]. This protection against postoperative infections 
has been attributed to the stimulation of natural killer (NK) precursor cells by re-infusion 
of salvaged blood in contrast to the suppression of NK cells, which may occur after joint 
surgery and ABT [18]. 
 Salvaged blood contains cytokines and activated leukocytes (neutrophils and 
macrophages), which are attracted by the local exudate at the surgical site. As compared to 
peripheral blood values prior to surgery, several pro- and anti-inflammatory cytokine genes 
become upregulated in neutrophils present in salvaged blood during the maximally 6 hours 
allowed between collection and re-infusion [2,5,6,11,13,19,21,28]. Before re-infusion, the 
collected salvaged blood can be washed to eliminate these cytokines, or filtered to remove 
debris and (activated) leukocytes, but not cytokines [1,2]. Filtration however, may activate 
the complement system [13,19], while washing of shed blood was reported to increase 
tumor necrosis factor-α (TNF-α) [6]. 
 Re-infusion of filtered or washed salvaged blood results in a, mostly transient, increase 
of some cytokine levels in vivo (e.g. IL-6), with slight differences between the two modalities 
[1,5,18,21,28,32].
 Additionally, after re-infusion of salvaged blood transient elevations in plasma cytokine 
levels have been measured, which may be associated with fever. Approximately 30% of 
patients [28] experience mild febrile transfusion reactions after re-infusion, although after 
orthopaedic surgery without re-infusion of salvaged blood a rise in temperature has also 
been observed [14]. It is however not elucidated whether these passively administered 
factors have an effect on the host immune reactivity. We investigated a possible effect on 
the recipient immune status 24 hours after hip surgery and autologous salvaged blood 
re-infusion. We compared whether re-infusion of salvaged blood had resulted in different 
cytokine gene expression profiles compared to controls and secondly whether washed 
or unwashed salvaged blood re-infusion resulted in different cytokine gene expression 
patterns.
MatErial and MEthOdS
An observational study in elective orthopaedic hip replacement (THR) surgery patients, 
selected from a randomised controlled trial (RCT; Current Controlled Trials number, ISRCTN 
96327523; Netherlands Trial Number, NTR303) evaluating various blood management 
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strategies in orthopaedic surgery. In this study, patients were randomised for either no 
autologous re-infusion (control group), or an intra- and post-operative blood salvage system 
that washes and concentrates the collected red blood cells before return to the patient 
(OrthoPAT®, Haemonetics, Breda, Netherlands), or a post-operative re-infusion system that 
filters unwashed salvaged blood (DONOR™ system, Van Straten Medical, Nieuwegein, the 
Netherlands). Both devices are FDA-approved. The ethics committee approved the protocol 
and the amendments, and all patients provided written informed consent before enrolment. 
Details of the study and overall results are reported separately [29]. 
 From September 2006 until February 2008 pre and post operative whole blood samples 
from 56 patients undergoing elective THR surgery at the Leiden University Medical Center, 
Leiden, The Netherlands, were collected for RNA analysis. Exclusion criteria were revision 
surgery, rheumatoid arthritis and erythropoietin use. Initially, a pilot study of 11 patients 
was performed in order to select genes for additional reverse transcriptase RealTime-PCR 
(RT-PCR), which was based on gene expression changes after surgery. IL-8 data of the pilot 
study were used to calculate the necessary sample sizes (power of 90 and alpha of 0.05) to 
detect a difference in post-operative gene expression between cell saver recipients (washed 
salvaged blood) and controls (hypothesis 1), between unwashed drain reinfusion patients 
and controls (hypothesis 2) and between cell saver (washed) and unwashed drain reinfusion 
patients (hypothesis 3). These comparisons resulted in group sizes of 22 control patients, 58 
unwashed wound drain reinfusion recipients and 10 cell saver recipients. 
 Some samples were invalid for analysis, leaving a total group of 24 control patients (i.e. 
with a regular wound drain), 13 drain re-infusion patients, and 19 cell saver patients. Thus 
the sample size was adequate to evaluate hypothesis 1, but sample sizes were inadequate 
for hypotheses 2 and 3. 
 Patient whole blood samples were taken before and 24 hours after surgery. Two samples 
of 500 mL were stabilised as soon as possible with RNALater (Applied Biosystems/Ambion, 
Austin, TX USA) and stored at -40˚C. RNA extraction was performed using the RiboPure™-
blood kit (Applied Biosystems/Ambion, Austin, TX USA) according to standard protocol 
including the optional DNase treatment. RNA quantity was determined with the NanoDrop 
1000 photospectrometer (NanoDrop products, Wilmington, DE, USA). Additionally, good 
RNA integrity was verified for a random selection of samples with the Bioanalyzer (Agilent 
Technologies, Santa Clara, CA USA). Preceding experiments had shown that the quality and 
quantity of isolated RNA are not influenced by storage time up to 72 hours at 2-6˚C before 
RNA stabilisation (data not shown).
 Gene expression analysis was performed with the commercially available cytokine 
array (OHS-021, SA Biosciences™, Frederick, MD USA). This array contains 114 hybridisation 
spots for cytokines. Amplification and labelling of RNA was performed according to 
manufacturer’s protocol of the TrueAMP 2.0 kit (SA Biosciences™, Frederick, MD USA). The 
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with a ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, CA USA). Quantification of 
spot intensities was conducted using the GEArray Analysis Suite (SA Biosciences™, Frederick 
MD USA). Spot intensities were corrected for inter-array variation by subtracting the average 
value of spot intensities from all individual values per array. Gene expression values were 
expressed as ratios that compared the post surgery sample to the pre surgery sample.
 The two-step reverse transcriptase Real-Time PCR assays were developed and executed 
as described earlier [27]. All assays had a taqman® probe with FAM dye and a minor groove 
binding non-fluorescent quencher (Applied Biosystems Inc., Foster City, CA USA).
 For all patient samples, cDNA was synthesized from the extracted RNA with the 
SuperScript® II Reverse Transcriptase, using random primers (Invitrogen Corporation, 
Carlsbad, CA USA). The 7500 Fast RT-PCR instrument (Applied Biosystems Inc., Foster City, CA 
USA) was used on standard modus and standard program with the Gene Expression master 
mix (Applied Biosystems Inc., Foster City, CA USA). Each sample was run in quadruplo. A 
measurement was considered an outlier if it had a value which deviated more than 0.4 
threshold cycle (Ct) from the average of the data points and was then discarded. If a second 
outlier was detected, the entire sample was discarded, and repeated in a new run. In each 
run a reference sample, consisting of pooled cDNA of 6 healthy adult blood donors, was 
taken along in 4-fold. All RT-PCR output was corrected for the reference sample from the 
same run. Relative quantification (RQ) was calculated as post/pre operative gene expression 
ratio within each patient. 
 All data were analysed statistically with SPSS version 15.0 for windows (SPSS Inc., 
Chicago, IL USA). The fold change in gene expression after surgery was compared between 
the control, cell saver and drain groups using Mann-Whitney U tests. 
 Changes in RT-PCR gene expression were correlated with clinical variables, including 
volume of re-infusion and infection rate. For this purpose, Spearman correlations were 
performed. We considered a p-value <0.05 statistically significant. Data are expressed as 
medians with interquartile ranges (IQR).
rESultS
Patient characteristics showed no differences between the three study groups (24 control 
patients, 19 washed cell saver and 13 unwashed drain patients), except for a larger amount 
of blood loss in the drain group compared to the other groups (Table 1). Although cell saver 
recipients received smaller volumes of re-infused blood than those of unwashed drain 
blood, the amount of re-infused RBCs was comparable because of the more concentrated 
haemoglobin levels in the washed cell saver blood compared to unwashed salvaged blood.
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Age, median (IQR), years 65 (50-75) 70 (67-78) 64 (51-73)
Gender, N, Male 10 6 7
Weight, median (IQR), kg 76 (68-84) 73 (63-82) 78 (73-90)
Corticosteroids, N 1 1 0
NSAIDs, N 5 5 3
CRP, median (IQR), mg/L 3 (3-6) 3 (3-8) 5 (3-8)
BSE, median (IQR), mm/h 10 (6-30) 8 (5-29) 9 (5-14)
Surgery
Duration of surgery, median (IQR), minutes 120 (105-150) 120 (105-133) 135 (110-150)
Type prothesis, cemented 11 15 7
Total blood loss during surgery, median (IQR), mL 443 (305-673) 235 (120-400) 370 (175-725)
Post-surgery
Total blood loss post surgery, median (IQR), mL 270 (235-450) 265 (155-630) 780 (460-910)
autologous re-infusion, median (IQR), mL N.A. 115 (70-200) 340 (200-500)
Hemoglobin, day +1 median (IQR), mmol/L 6.4 (6.0-6.8) 6.5 (6.1-7.0) 6.3 (5.8-7.7)
Leukocytes, day+1 median (IQR), 109/L 8.2 (7.4-9.2) 7.9 (6.8-9.2) 9.2 (8.4-10.4)
Temperature, day +1, median (IQR), °C 38.0 (37.7-38.2) 37.9 (37.5-38.0) 37.8 (37.1-38-5)
Hospital stay, median (IQR), days 7 (6-9) 8 (7-10) 7 (6-10)
Complications up to day 14
 Infections, N 0 1 0
 Wound leakage, N 2 2 1
 Other complications, Na 4 2 0
None of the patients has had previous CVA. None of the patients received antifibrinolytic agents. NSAIDs 
were stopped 3-10 days prior to surgery. None of the patients died. N.A. not applicable. 
a Two control and two cell saver patients had cardio-vascular events. One hip dislocation and one pulmonary 
embolism occurred in the control group. 
In the pilot group of 11 patients, 44 out of 114 cytokine genes were expressed above the 
detection limit on at least one of the arrays (Figure 1A). Seventeen of these showed at least a 
2-fold change after surgery in minimally one patient (Figure1B; Table 2) of which nine genes 
were up-regulated, 3 showed down-regulations and 5 genes exhibited up-regulations in 
some, and down-regulations in other patients. The most striking responses were seen in 
the pro-inflammatory cytokines IL-8, TNF superfamily 13B (TNF sf13B) and inTNF sf10: IL-8 
showed up-regulation in 3, and was down-regulated in 3 other patients. Control patients 
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salvaged blood the gene was up- and in most patients receiving washed salvaged blood 
down-regulated. TNF super family 13B (TNFsf13B) was more than 2-fold up-regulated after 
surgery in 5 of 11 patients, and TNFsf10 was up-regulated in 3 and down-regulated in 1 
patient. The remaining 14 genes showed only changes in a single patient (n=10) or showed 
a mixed response (up- and down-regulation in different patients) and were not further 
addressed. RT-PCR in the pilot patients confirmed the array results and IL-8, TNFsf10 and 
TNFsf13B were subsequently studied in extended patient groups by RT-PCR.
figure 1. 
Ctrl=control group; CS=washed salvaged blood by cell saver; Drain=unwashed salvaged blood by 
drain reinfusion.
A: Gene expression (GE) of all genes detectable on at least one array. Red presents high GE, green is 
low GE.
B: ΔGE of all detectable genes. Both post-RBC samples are compared to the pre sample of each patient. 
Green is a down-regulation, black indicates no major changes and red represents up-regulation.
* Genes which exhibit at least a 2-fold up-regulation after surgery in at least one patient.
^ Genes exhibiting at least a 2-fold down-regulation after surgery in at least 1 patient.
“Genes exhibiting at least 2-fold up-regulation and a 2-fold down-regulation after surgery in at least 
one patient each. 
Figures were constructed with matrix2png 1.0.7 [24].
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table 2. Gene expression (GE) fold changes after surgery of the pilot group on the arrays
Control Washed salvaged blood unwashed salvaged blood
Cd40-l 0.81 0.87 0.60 0.39 1.1 0.78 0.51 0.70 0.98 0.81 0.74
flt3-l 1.3 0.75 0.64 0.70 0.92 0.87 0.65 0.45 0.97 0.64 0.76
Gdf-3 5.3 0.50 0.57 1.2 0.81 1.2 1.2 0.44 0.79 0.67 0.61
Gdf-5 1.5 1.2 3.9 0.70 1.7 1.2 1.4 1.3 1.2 1.6 2.4
il-1β 3.6 0.75 1.3 0.87 1.0 1.1 1.5 0.65 1.1 0.96 0.95
il1-f7 2.7 0.67 0.86 1.1 0.80 1.3 1.1 0.57 1.0 0.78 0.76
il-8 1.6 2.0 1.4 0.19 1.3 0.50 0.08 1.5 1.1 5.7 3.7
il-17C 2.2 0.67 0.61 1.1 0.84 1.1 1.0 0.68 1.1 0.85 0.69
il-19 3.8 0.61 0.77 0.98 0.99 1.2 1.1 0.55 1.0 0.73 0.65
laSS1 4.7 0.58 0.73 0.96 0.70 1.0 1.0 0.45 0.93 0.77 0.70
lt-β 2.0 0.95 0.85 0.78 1.6 0.87 1.0 1.0 1.2 0.82 1.1
PdGf-β 4.4 0.67 0.87 0.91 0.95 1.0 1.3 0.77 0.98 0.76 0.65
tGf-α 1.3 1.3 2.9 0.88 1.6 1.1 1.8 1.1 0.97 1.5 1.7
tnfsf9 1.0 1.4 0.58 1.1 2.1 0.59 2.6 1.0 0.76 1.1 0.29
tnfsf10 1.6 1.7 3.1 0.30 1.9 0.89 1.1 1.2 1.1 2.3 2.1
tnfsf13B 2.6 1.5 2.5 0.53 2.2 1.3 1.3 1.1 1.0 2.6 3.5
vEGf- α 0.48 1.0 0.97 1.5 0.72 0.92 0.97 0.98 1.1 1.0 0.88
All GE values are ratios of GE after surgery with or without autologous re-infusion in comparison with GE before surgery. Each 
column represents a patient. More than two-fold changes are presented in bold.
In the extended population, however, IL-8 gene expression after surgery showed large 
inter-individual differences of more than 2 logs, mostly down-regulations (Table 3; Figure 
2), in all three groups of control patients, cell saver and drain recipients. In most patients 
TNFsf10 and TNFsf13B gene expression levels were elevated after surgery. These increases 
were higher in the patients receiving unwashed salvaged blood than in control patients 
and in patients receiving washed salvaged blood, which was significant for TNFsf13B gene 
expression between drain and cell saver patients (Table 3; Figure 2). 
 None of the relevant clinical variables clearly correlated with gene expression of IL-8, 
TNFsf10 and TNFsf13B (Table 4), including volume drainage blood re-infused, neither within 









figure 2. Boxplots showing median fold changes in gene expression (GE) measured with RT-PCR. A: 
IL-8, B: TNFsf10, C: TNFsf13B. 
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table 3. Fold changes in gene expression (GE) for 3 selected cytokines with RT-PCR in 
the total group






Ctrl vs CS 
p-value
Ctrl vs drain 
p-value
CS vs drain 
p-value
N 24 19 13



























All GE values are ratios of GE after surgery with or without autologous re-infusion in comparison with GE before surgery. CS: 
cell saver etc.









Age 56 -0.238 0.078 -0.121 0.4 -0.052 0.7
Gender 56 -0.221 0.10 -0.228 0.091 -0.21 0.12
before surgery
NSAIDs 56 -0.132 0.3 -0.198 0.14 -0.035 0.8
during surgery
Duration of surgery 52 0.225 0.11 -0.115 0.4 -0.179 0.2
Blood loss during surgery 56 0.062 0.6 0.003 1.0 0.104 0.4
after surgery
Blood loss after surgery 51 0.212 0.13 0.044 0.8 0.054 0.7
Reinfusion volume 56 0.056 0.7 0.149 0. 3 0.190 0.16
Hemoglobin 56 0.141 0.3 -0.052 0.7 -0.065 0.6
Leukocytes 55 -0.012 0.9 0.273 0.044 0.272 0.045
Temperature 48   0.018 0.9 0.272 0.064 0.345 0.018
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diSCuSSiOn
Autologous salvaged blood re-infusion is a widely used alternative for allogeneic blood 
transfusions and preliminary reports claim a reduced incidence of post-operative infections 
through beneficial immunomodulation. Although salvaged blood contains cytokines and 
activated cells which are re-infused into the patient, an effect on the recipient immune system 
is however less documented. We investigated alterations in patient cytokine gene expression 
profiles in relation to autologous salvaged blood product re-infusion and secondly whether 
washing of salvaged blood made a difference. For initial selection of relevant cytokines we 
performed a pilot study investigating 114 cytokine genes on expression array in 11 patients; 
only 3 cytokines came up as candidate altered gene expressions. These were subsequently 
evaluated by PCR in an extended cohort of 56 patients. 
 Our study had some limitations. Despite homogeneity of the population, we still 
detected major inter patient variation in gene expression, for which we were unable 
to find a possible explanation. Also, not enough patients were available to comply with 
the sample sizes required to detect statistically significant differences in gene expression 
ratio’s between control and drain patients. However, as gene expression ratio’s, analysed by 
PCR, were smaller than observed on the array results, not the sample size, but the smaller 
differences in gene expression ratio’s explain the non-significant results. As only one of the 
control patients had received allogeneic RBC transfusions during or within 24 hours after 
sampling, we were not able to compare the effect of autologous re-infusion with the effect 
of allogeneic RBCs on cytokine gene expression. By only measuring before and 24 hours 
after surgery, we might have missed a peak in gene expression [3,4,16], although a previous 
study that investigated the surgery effect on cytokine gene expression showed changes 
only after 24 hours, and not at 6 hours after surgery [21]. 
 We found in the pilot study patients that IL-8, TNFsf10 and TNFsf13B showed most 
frequently up-or down-regulations. However in the larger patient population, increases 
of IL-8, TNFsf10 and -13B gene expression after surgery were less pronounced (Table 3). 
Surgery by itself had major effects on the gene expression profiles and additional effects of 
salvaged blood re-infusion were minor, although small additional up-regulation remained 
present after re-infused unwashed drain blood.
 Despite re-infusion of inflammatory cytokines in drain blood and leukocytes with 
up-regulated cytokine genes in cell saver blood, the re-infusion of this salvaged blood 
showed, after 24 hours, only minor systemic changes in cytokine gene expression in excess 
of the surgical procedure itself. Although these minor up-regulations of IL-8, TNFsf10 
and TNFsf13B involve genes which are among other effects, all associated with NK cell 
activation [10,15,18,30], the most potent NK-cell activating cytokines (IL-2, -12, -15, -18 
and interferon-α) did not show changes on the array, although their activation may have 
occurred before or after the time point of 24 hours post-surgery [33]. 
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The main function of IL-8 is neutrophil chemoattraction, but it also stimulates neutrophil 
and T-cell activity [23]. Control patients did not show changes in IL-8 gene expression, while 
patients receiving unwashed salvaged blood often showed up-regulation and patients 
receiving washed salvaged blood mostly showed down-regulation of this gene. TNFsf10 
encodes for TNF-related apoptosis inducing ligand (TRAIL), has a function in apoptosis 
induction and plays a role linking the adaptive and innate immune system [25], TNFsf13B is 
associated with proliferation of B-cells [6], also referred to as B-cell activating factor (BAFF) 
[26]. The BAFF-Receptor induces cell signalling through the IKKβ and NF-κB pathways, 
promoting transcription of IL-8, TNFsf13B and CD40L [17]. 
 The large inter-patient variation in gene expression, was not explained by (type of ) 
salvaged blood transfusion, or associated to other clinical variables including postoperative 
anaemia, leukocytosis, fever, blood loss and volume of re-infused salvaged blood. Absence 
of an association between IL-8 gene expression and re-infused volume, has been previously 
published [9]. Rather, other inter-individual (genetic) or unknown environmental factors 
may play a role.
 We found only one other study that evaluated cytokine gene expression in neutrophils 
after hip arthroplasty [11]. This study compared the neutrophils in salvaged blood to those 
in pre-surgical and post-surgical circulating blood in the same patient without re-infusion of 
the salvaged blood. The authors found that other cytokines, such as interleukin-1 receptor 
antagonist (IL1RA), interleukin-18 receptor 1 (IL18R1), macrophage migration inhibitory 
factor (MIF), and macrophage inflammatory protein 3alpha (CCL20) were upregulated both 
in the patient and in salvaged blood, whereas interleukin-8 receptor beta (IL8RB/CXCR2) 
was consistently downregulated. Our findings, reflecting the total leukocyte population, 
did not only report systemic gene expression changes after surgery, but also compared 
gene expression changes after re-infusion of washed or unwashed salvaged blood with 
the presurgical situation and control surgery patients. We found a stronger up-regulation 
of TNFsf13B after receiving autologous unwashed blood compared to controls or washed 
salvaged blood. The differences in complications can not be related to either the washed 
or unwashed re-infusion of blood, since it is a post-hoc analysis with inadequate power for 
detecting a relevant difference between the groups.
 In conclusion, inter-patient variations of unidentified cause showed more changes 
in cytokine gene expression after hip surgery than re-infusion of shed salvaged blood. 
Unwashed filtered drain blood showed more up-regulation of the pro-inflammatory 
cytokines IL-8, TNFsf10 and -13B compared to washed salvaged blood or controls. 
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aBStraCt 
Objective: To investigate the combined and separate use of erythropoietin (Epo), cell saver 
and/or postoperative drain re-infusion devices (DRAIN) as red blood cell (RBC) sparing 
alternatives. 
design: A multi-centre randomised, controlled trial.
Setting: Four hospitals in the Netherlands using a restrictive transfusion policy.
Participants: 2442 elective knee- and hip-arthroplasty patients aged 18 years and older.
interventions: Primary stratification by preoperative haemoglobin (Hb) level: stratum I, Hb 
10 to 13 g/dL (low Hb), randomised for Epo or no Epo; stratum II, Hb above 13 g/dL (normal 
Hb), ineligible for Epo. Both strata were also randomised for cell saver, DRAIN or no blood 
salvage device. 
Main outcome measure: Number of RBC transfusions.
results: Mean RBC use was 0.3 (SD 1.2) units / patient (n=2442) and 11.6% were transfused. 
Transfusion protocol adherence was above 95%. In Intention-To-Treat analysis, Epo resulted 
in a significant 50% reduction in transfused patients (OR 0.5, 95% CI 0.35 to 0.75) and a 
29% mean RBC reduction (ratio 0.71, 95% CI 0.42 to 1.13). Additional costs due to Epo were 
estimated at €785 per patient (95% CI 262 to 1309), i.e. €7300 per avoided transfusion 
(95% CI 1900 to 24000). In both strata, autologous blood re-infusion did not result in RBC 
reduction and increased costs by €378 per patient (95% CI 161 to 595). Because of significant 
heterogeneity of treatment effects, primary (n=2258) and revision (n=184) surgery patients 
were analysed separately. In stratum I the primary surgery group had a 55 % reduction in 
transfused patients (OR 0.45, 95% CI 0.28 to 0.69) and a 55 % mean RBC reduction (ratio 0.45, 
95% CI 0.29 to 0.72) by Epo, whereas autologous blood re-infusion by cell saver or DRAIN 
did not result in a significant RBC reduction in either strata. No conclusions can be drawn for 
revision surgery patients.
Conclusions: Even with a restrictive transfusion trigger, Epo contributed significantly as a 
transfusion alternative for RBC use in knee- and hip-arthroplasty patients with a low Hb, 
but at unacceptably high costs per avoided transfusion. Possibly due to the restrictive 
transfusion policy, autologous blood salvage devices were not effective in RBC reduction 
and consequently only increased costs. 
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intrOduCtiOn
To achieve optimal blood management, the use of alternatives for red blood cell (RBC) 
transfusions in orthopaedic surgery is widely accepted. However, the effect on RBC reduction 
may vary considerably (from 20 to 80%) and is related to the use of a transfusion threshold 
[1-8]. As transfusion policies have recently become more restrictive, it is questionable 
whether the currently accepted transfusion alternatives can still effectively reduce RBC use. 
Over the years, the use of pre-operative au0tologous donation (PAD) has declined due to 
logistical problems and wastage [9,10]. On the other hand, the use of Erythropoietin (Epo) 
and peri-operative autologous blood salvage have become increasingly popular worldwide 
including the Netherlands [11]. In randomised controlled studies of elective hip and 
knee surgery patients, Epo resulted in a significant reduction in mean RBC use (referred 
to as “blood-sparing”) and a significant reduction in the proportion of transfused patients 
(referred to as “transfusion-avoiding”) for up to 75%, while using a restrictive transfusion 
threshold of 8 g/dL. These studies also showed that the optimal benefit from Epo can be 
reached in patients with preoperative Hb levels between 10 to 13 g/dL in order to decrease 
RBC use [12,7,13]. 
 Using a cell saver intra-operatively, up to 70% of the shed blood can be recovered in 
orthopaedic surgery [14], which may significantly reduce RBC use [8]. Post-operative re-
infusion of autologous shed blood may also result in allogeneic RBC reduction, although 
these study results are not reported consistently [1-4;15-19]. The evidence for RBC reduction 
by autologous salvaged blood re-infusion is mostly based on small and/or underpowered 
studies often not applying a restrictive transfusion threshold. Moreover, evidence is lacking 
on the effect of combined use of transfusion alternatives. To address this issue we performed 
a multi-centre study with adequate power (90%), to investigate whether the use of Epo, the 
intra- and postoperative use of cell saver or the use of a postoperative drainage and re-
infusion device (DRAIN) as transfusion alternatives, resulted in allogeneic RBC reduction in 
patients undergoing elective knee- or hip-replacement surgery while applying a restrictive 




Patients were enrolled between May 1st, 2004 and October 1st, 2008 from four hospitals 
in the Netherlands with study closure after completed follow up on Oct 1st, 2009. The 
ethics committee at each institution approved the protocol and the amendments, and all 
patients provided written informed consent before enrolment. The study was undertaken 
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in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and local 
laws and regulations. Eligible patients were aged 18 years and older, being scheduled for a 
primary or revision hip or knee replacement. All patients received six weeks of postoperative 
anti-thrombotic prophylaxis with subcutaneous Low-Molecular Weight Heparin (LMWH) 
starting the day before surgery. Anti-platelet agents (NSAIDs, clopidogrel, acetyl salicylic 
acid) were discontinued 3 to 10 days before surgery according to the hospital protocol. Oral 
anticoagulants (acenocoumarol, phenprocoumon) were discontinued with monitoring of 
INR values, which was required to be 1.8 or lower before surgery. 
 Patients were excluded if they had: untreated hypertension (diastolic blood pressure 
>95 mm Hg); a serious disorder of the coronary, peripheral and/or carotid arteries; a recent 
myocardial infarction or CVA (within 6 months); sickle cell anaemia; a malignancy in the 
surgical area; a contra-indication for anticoagulation prophylaxis; a known allergy to Epo; 
an infected wound bed; a revision of an infected prosthesis which was being treated with 
local antibiotics (e.g. gentamycin bone cement beads); difficulty understanding the Dutch 
language (unable to give informed consent); or were pregnant or refused homologous 
blood transfusions. 
Study design 
We designed a double randomised, multi-centre trial in which the randomisation was 
stratified for hospital, type of surgery (primary/revision as well as hip/knee), and the 
preoperative haemoglobin (Hb) level in order to have a balanced randomisation. Double 
randomisation included randomisation for Epo and randomisation for autologous blood 
re-infusion by cell saver or DRAIN. By selecting this design, the three transfusion alternatives 
can be investigated in a combined setting as well as separately, and was intended to 
resemble daily practice in an optimal way. Randomisation took place in one run for all 
possible combinations using a computer generated allocation table, but is here described 
sequentially. Patients were first stratified according to the pre-operative Hb level: stratum I 
(low Hb) = Hb between 10 and 13 g/dL. These patients were randomised for Epo or no Epo. 
Stratum II (normal Hb) = Hb of 13 g/dL and higher was not eligible for Epo but continued as 
a separate non-Epo treatment group. Since knee replacement procedures were performed 
using a pneumatic tourniquet, which was deflated after wound closure, intra-operative 
use of cell saver was not applicable due to negligible intra-operative blood loss, and 
consequently knee replacement surgery patients were excluded from randomisation for 
cell saver. All patients in both strata were randomised for two (knee surgery) or three (hip 
surgery) treatment modalities: 1) an intra-and postoperative autologous re-infusion device 
(cell saver) that washed, filtered and re-infused the autologous shed blood (only in hip 
surgery), 2) a postoperative autologous re-infusion drainage system (DRAIN) that filtered 
and re-infused autologous unwashed shed blood (both knee and hip surgery) and 3) no 
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blood discarded. The randomisation resulted in the following combinations of modalities: 
cell saver+DRAIN- (only hip surgery); cell saver-DRAIN+; cell saver-DRAIN- (this group 
represents the control group). Hence the entire trial consists of nine different treatment 
modalities: six in stratum I: 1) Epo+cell saver+DRAIN-; 2) Epo+cell saver-DRAIN+; 3) Epo+cell 
saver-DRAIN-; 4) Epo-cell saver+DRAIN-; 5) Epo-cell saver-DRAIN+; 6) Epo-cell saver-DRAIN- 
(=control group) and three in stratum II: 7) Epo-cell saver+DRAIN-; 8) Epo-cell saver-DRAIN+; 
9) Epo-cell saver-DRAIN- (=control group). For each stratum a separate randomisation list 
was created, using blocks of random length to avoid predictability of the random treatment 
assignment towards the end of each block. All patients were transfused according to a 
restrictive transfusion policy as advised in the Dutch transfusion guidelines (see below) 
[20]. Preoperative anaemia was defined according to the WHO criteria [21] (for males: 
Hb <13 g/dL and for females: Hb <12 g/dL). Participating hospitals were free to choose the 
type of Epo (i.e. alpha-Epo or beta-Epo) and the post-operative drainage system, but were 
obligated to use the same type throughout the study. The type of cell saver was uniform for 
all patients.
 The transfusion protocol considered age and normal or high risk patients as triggers 
for transfusion. High risk included: incapability to enlarge cardiac output to compensate 
for anaemia, serious pulmonary disease or symptomatic cerebro-vascular disease. The 
following transfusion thresholds were used: Hb=6.4 g/dL (=4.0 mmol/L) for age <60 
years and normal risk; Hb=8.1 g/dL (=5.0 mmol/L) for age ≥60 years and normal risk; 
Hb=9.7 g/dL (=6.0 mmol/L) in case of high risk. Hb values were derived from mmol/L which 
is the standard unit to denote Hb values in the Netherlands. The protocol included a single-
unit transfusion policy (RBC units transfused one by one to reach a target Hb level above 
the defined Hb thresholds). A check for transfusion protocol adherence was included in the 
CRF by verifying the Hb, age and cardiovascular history (for risk estimation) of the patient 
for every transfusion event. The RBC units were prepared from whole blood donations. 
After centrifugation, followed by plasma- and buffycoat depletion, SAG-M (Saline, Adenine, 
Glucose, Mannitol) was added, resulting in a RBC product with a Ht between 0.50 and 
0.65 L/L (40-54 g Hb) and a total volume of 270-290 mL. A universal pre-storage leukocyte 
depletion policy was applied, resulting in a leukocyte concentration of less than 1 x 10E6 
per unit. 
 Treatment allocation was random using a uniform distribution and created a pre-
generated list of sufficient length, based on the maximum expected sample size in each 
stratum. For each subject to be randomised, a sheet of paper with all relevant stratification 
and group-allocation information was produced and placed in a sealed opaque envelope. 
Batches were created according to the stratification factors. After receiving informed 
consent, the patient was preoperatively allocated by the research nurse to one of the groups 
by opening the first sealed envelope from the appropriate stratum. The exact moment of 
opening the envelope and its associated sequence number was verified against a centrally 
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stored randomisation list to check for selection bias. Hip surgery patients who were 
randomised for cell saver were automatically assigned to postoperative autologous blood 
re-infusion, as the used cell saver collected autologous blood intra- and postoperatively. 
 In order to avoid protocol violations, clinical-site staff members, clinicians, and patients 
were aware of study group assignments. The study investigators were blinded. The chart data 
were written on the Case Report Form (CRF) by the research nurses. All written information 
was transferred from the paper CRF to the secure on-line web based data management 
system (ProMISe) of the department of Medical Statistics & BioInformatics in Leiden. A built-
in quality management system checked for irregularities, inconsistencies and coding errors 
and clarification was asked for whenever necessary. 
 The primary outcome measure was the number of allogeneic RBC transfusions. By 
comparing the mean RBC use we quantified the “blood-sparing” effect, and by comparing 
the proportion of transfused patients we quantified the ”transfusion-avoiding” effect. 
Secondary outcomes (not all reported in this manuscript) were length of hospital stay 
(days), peri- and post-operative complications up to three months after surgery, transfusion 
reactions, rehabilitation time, quality of life and costs. All primary and secondary endpoints 
were scored until 3 months after surgery. 
Procedures 
A fixed weekly dose of 40.000 IU was given to patients randomised for Epo with simultaneous 
prescription of ferrofumarate 200 mg TID (=195 mg Fe2+ a day) during three weeks before 
surgery. A total of four Epo doses were administered by subcutaneous injection on days -21, 
-14, -7 and on the day of the operation (day 0), respectively. Hb levels were determined before 
administration of the fourth dose. If the Hb level exceeded the value of 15 g/dL, the final Epo 
dose was withheld. The Epo preparations were Neorecormon® (erythropoietin-beta, Roche 
Nederland BV, Woerden, Netherlands) (three hospitals) or Eprex® (erythropoietin-alpha, 
Janssen-Cilag BV, Tilburg, Netherlands) (one hospital). A protocol violation was scored if 
patient did not receive Epo therapy at all after being randomised for Epo. If at least one 
dose was given this was not regarded as violation and patients were included in the analysis 
as treated (AT) as having received Epo.
 The OrthoPAT® cell saver (Haemonetics, Breda, Netherlands) was used for both intra-
and post-operative collection and re-infusion of autologous blood. The collected shed 
blood was washed, centrifuged and concentrated to a hematocrit of 60-80% before being 
returned to the patient. Only hip surgery patients were randomised for the use of the cell 
saver. A protocol violation was scored if the cell saver was assigned but not used. When 
the cell saver device was truly used, the patient was included in the cell saver group in the 
AT-analysis whether or not autologous blood had been given to the patient. 
 Two different DRAIN devices were used: Bellovac-ABT® (Astra-Tech, Zoetermeer, the 
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Netherlands) (two hospitals). These systems differ slightly in filtration and vacuum pressure: 
the DONORTM system uses a continuous suction at a vacuum pressure of 150 mm Hg 
and just prior to re-infusion a double shielded 40 micron filter (Pall Lipiguard VS filter) 
entrapping lipids larger than 10 micron and 2 log of leukocytes. The Bellovac-ABT® system 
uses intermittent suction pressure by a manually expandable bag at a maximum pressure 
of 90 mm Hg and three filters: a 200 micron filter, a secondary 80 micron filter and prior to 
re-infusion a third 40 micron filter. In a feasibility and efficacy study, we found both systems 
to be comparable [22]. A protocol violation was scored if the device was assigned but not 
used. When the DRAIN device was truly used, the patient was included in the DRAIN group 
in the AT- analysis whether or not autologous blood had been returned. 
 Intra-operative transfusions were prescribed by the anaesthesiologist and post-
operative transfusions by the orthopaedic surgeon. Transfusion protocol violations and 
randomisation violations were recorded.
 Serious Adverse Events (SAEs) were defined as events that occurred within one 
month after surgery, and were labelled as death, life threatening events, (prolongation 
of ) hospitalization and/or events resulting in persistent disability, and categorised into 
prosthesis related (dislocation, wound infection or deep prosthetic infection, fractures 
or limitation in movement), thrombo-embolic (deep venous thrombosis diagnosed by 
ultrasound, pulmonary emboli, stroke or transient ischemic attack, myocardial infarction, 
cardiovascular other than myocardial infarction, allergic, infection/sepsis (not prosthesis 
related), malignancy and other events. All SAEs that were reported to the central coordinator 
during the three month-follow up, were scored. 
Statistical methods 
The study was designed to have statistical power of 90% with a type I error of 5% (two-
sided test) to detect a difference of 75% in mean RBC use by Epo (the alternative to null-
hypothesis 1) and a difference of 30% in mean RBC use by autologous blood re-infusion 
by either cell saver or DRAIN (alternative to null-hypothesis 2). The study design allowed to 
investigate the Epo versus no Epo effect (comparison 1), the combined autologous versus 
no autologous effect (comparison 2) and the cell saver versus DRAIN effect (comparison 3) 
(eFigure 1 and sample size calculation online material only). Various scenario’s of literature 
based estimates of standard deviations were included as well as the possibility of severe 
treatment and stratum interactions. This required an inclusion of 2250 patients for analysis 
on an Intention-To-Treat (ITT) basis and included protection against a worst case scenario of 
high standard deviations and heterogeneity of treatment effects. Assuming a study dropout 
rate of 10%, our goal was to have 2500 patients eligible for randomisation. An interim 
analysis was carried out by an independent Data Safety Monitoring Committee (DSMC) at 
the half way mark (958 inclusions) using an alpha of 2.5% (instead of 5%). As pre-defined 
stopping criteria were not reached, neither for futility nor for efficacy, the DSMC advised to 
continue the study until its pre-specified number of patients was obtained.
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Conforming to ICH-9 guidelines, the primary analyses were performed both as ITT and As 
Treated (AT). In case of the Epo (yes/no) covariate, AT is defined as the actual administration 
of at least one dose of Epo; in case of cell saver or DRAIN it is defined as the actual use of the 
device whether or not autologous blood had been re-infused to the patient. 
 Variables were described by frequencies, by mean and SD, and by median and inter-
quartile range (IQR) in case of a non-normal distribution. Although RBC use can be severely 
non-normally distributed, we also report means (and standard deviations), since the power 
and sample size calculation was based on assumptions of these means. Ratio’s (dividing 
the mean RBC values of two randomised groups to be compared) and 95% confidence 
intervals (CI) were reported to calculate the proportional reduction between the groups. 
Confidence intervals were obtained via bootstrapping methods for these highly non-
normally distributed ratio’s (software package R, using the standard package “boot”). For 
additional non-parametric testing we used the Mann-Whitney test. When comparing 
the proportion of patients receiving RBC transfusions, a Mantel-Haenszel procedure was 
applied, using the main risk factors and stratification variables as strata. This led to an 
overall, adjusted common Odds Ratio (OR) as a comparison of the probability of “receiving 
at least one RBC unit” between the randomisation arms. A linear mixed model was used 
for the primary outcome (RBC use) as a function of the interventions, the stratification 
factors (hip versus knee and primary versus revision surgery) and their interactions with 
the intervention. In case of significant interaction, the calculations were based on separate 
subpopulations (stratified by the interacting term) as pre-specified in the protocol. In case 
of non-significant interactions, the stratification factor was retained in the model as a main 
term for adjustment. The stratification factor “centre” was included as a random effect. 
Even though we were fully aware of the non-normal distribution of the RBC use among 
the various strata and intervention groups, we reported confidence intervals based on the 
mixed models for comparison with other literature; therefore significance of differences in 
this model needs to be interpreted with caution. Each analysis of intervention effect in this 
additive framework is accompanied by a robust estimate of the treatment effect as a ratio 
and its associated confidence interval.
 After data checking the database was frozen. The conversion process transferred the 
data to a number of SPSS (version 17.0 for Windows (SPSS Inc, Chicago, IL, USA)) system files 
which were used for all analyses. The same files were used within the R software to obtain 
estimates and robust bootstrapped confidence intervals. The SPSS files were read using the 
library “foreign”. A p- value of less than 0.05 was considered statistically significant. 
Economic evaluation
Costs were estimated from a hospital perspective, with a three-months time horizon. 
Health care was valued at the 2011 price level, using market prices for Epo, cell saver and 





109Transfusion alternatives in orthopaedic surgery | 
allogeneic RBC products, ICU care, and non-ICU care (€207 per unit, €2249 and €471 per day, 
respectively) [24]. The total price per unit of RBC use was estimated at four times the product 
price (i.e. €829 per unit), according to the paper of Shander and co-workers [25]. Average 
costs were compared according to intention-to-treat, using non-parametric bootstrapping 
(programmed in Stata/IC 11.0 for Windows). If a strategy resulted in transfusion avoidance 
but with higher costs, a cost-effectiveness analysis was performed comparing the difference 
in the proportion of transfused patients to the difference in costs. Confidence intervals for 
the cost-effectiveness ratio were calculated using net benefit analysis [26].
rESultS
From May 2004 to October 2008, 3165 patients were screened for eligibility of which 
586 patients were not enrolled (Figure 1). After completion of the study in October 2009, 
2579 patients had been randomised, of which 2442 (95%) were evaluated. Of the 137 not 
evaluated patients, for the majority (82%) surgery was cancelled or performed elsewhere, 
six of whom had received at least one Epo dose. Baseline characteristics are shown in table 
1. Mean preoperative Hb at first outpatient visit was 13.8 g/dL (SD 1.3) and mean Ht 0.42 
L/L(SD 0.04). Sixty percent were hip procedures and 40% were knee procedures. Seventy 
percent was female. Revision surgery occurred in 7.5% (n=184), equally divided among the 
groups. 683 (28%) patients were eligible for Epo. In Table 2, peri-operative characteristics 
are shown. The median volumes of re-infused blood were 100 mL for cell saver [IQR 50-200 
mL] with mean Ht: 0.70 [SD 0.11] and 350 mL for DRAIN [IQR 200-500 mL] with mean Ht:0.34 
[SD 0.17]. Postoperative Hb values on day+1 were comparable in the groups with or without 
autologous blood re-infusion by cell saver or DRAIN. Revision surgery patients differed 
significantly for intra-operative blood loss, mean duration of surgery and total blood loss 
(p<0.05), but not for the mean and median re-infused volumes.
Primary endpoint
No heterogeneity was found among the four participating hospitals with respect to the 
effect-size in any comparison of the primary endpoint. Of 2442 evaluated patients, mean 
RBC use was 0.32 units (U) / patient [SD 1.2] and median use was 0 U/patient [range 0-27]. 
11.6% (n=284) of patients received in total 775 RBC transfusions (median 2U [IQR 2-2]). The 
majority of patients (n=246) were transfused postoperatively up to 14 days after surgery 
(median of 2 U [IQR 2-2]). The median RBC units used and proportion transfused patients 
are outlined in Table 2. Overall, revision surgery patients were significantly transfused more 
often (19.6%) than primary surgery patients (11%) with more RBC transfusions. In addition, 
hip surgery patients were significantly more often transfused (15%) than knee surgery 
patients (6.6%), with more transfusions as well. Due to significant interaction between 
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primary or revision surgery and the allocated treatments (Epo and cell saver and DRAIN; 





Stratum I   low Hb Stratum II    normal Hb
3165 patients assessed for eligibility
586 excluded
  362 refused to participate 
  183  not meeting inclusion criteria
  41 unknown
2579 randomized
137 not evaluated
  104 not operated or operated elsewhere 
  23 consent withdrawn
  9 still on waiting list at end of study
  1 minor surgery2442 evaluated
Stratum II  Normal Hb
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In Table 3 the intention-to-treat analysis of the effects of Epo and autologous blood re-
infusion (combined cell saver and DRAIN effect) on mean RBC units used (mean difference 
and calculated ratio’s with 95% CI) and proportion transfused patients (with OR and 95% 
CI) are outlined. To investigate the overall Epo effect in stratum I, regardless of the use of 
autologous blood, pooled estimates were calculated comparing the Epo+ and Epo- groups 
(a test for heterogeneity was not significant). The separate cell saver and DRAIN effect 
showed no difference (eTable 1).
 In the low Hb stratum (stratum I) autologous blood re-infusion neither resulted in a 
decrease of mean RBC use nor in a decrease in proportion of transfused patients in either 
the total or primary surgery subgroup. Among those randomised to receive Epo, autologous 
blood use by cell saver or DRAIN even resulted in an increase in both mean RBC use (ratio 
0.45, 95% CI 0.28 to 0.69; p<0.01) and the proportion of transfused patients (adjusted OR 
2.2, 95% CI 1.1 to 4.4; p=0.02) compared to those without blood sparing devices. This effect 
mainly occurred in the revision surgery patients. The pooled Epo effect on RBC use in the 
total, primary and revision, group, showed a transfusion avoidance in 50% of patients 
(adjusted OR 0.50, 95% CI 0.35 to 0.75; p<0.001) from 26% to 16% (10% absolute difference), 
independent of assignment to autologous blood re-infusion and a non-significant 29% 
mean RBC reduction from 0.71 to 0.50 U/patient (ratio 0.71, 95% CI 0.42 to 1.13; p=0.15). 
Among the primary surgery patients, Epo was effective in both blood sparing (55% mean 
RBC reduction; ratio 0.45, 95% CI 0.28 to 0.69; p<0.01); and transfusion avoidance (55% 
reduction in transfused patients; adjusted OR 0.45, 95% CI 0.29 to 0.72; p<0.001) from 26% 
to 14% (12% absolute difference).
 In the normal Hb stratum (II) of the total group, 8.3% of the control group was transfused 
with a mean RBC use of 0.22 U/patient. Autologous blood re-infusion using either DRAIN 
or cell saver resulted neither in a RBC sparing nor in transfusion avoidance in this stratum. 
This was similar in the primary surgery group. The revision surgery group was, however, too 
small and too heterogeneous to draw valid conclusions.
Economic evaluation
For this purpose, the total group of 2442 patients were analysed. When the operation was 
unexpectedly rescheduled to a date within three weeks after randomisation, no Epo was 
administered. As a result, 66% of the patients randomised to receive Epo actually received 
Epo, with average Epo costs of €851 per patient (table 4A, 95% CI 785 to 917). The change in 
costs for RBC use and hospital stay in stratum I was relatively small compared to the costs for 
Epo. The average total cost increase for the Epo strategy was estimated at €785 per patient 
(95% CI 262 to 1309). With a decrease in the proportion of transfused patients by 10.8% 
(from 26.4% to 15.6%), the cost difference translates to €7300 per avoided transfusion (95% 
CI 1900 to 24000).
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table 3a. ITT analysis of Epo and autologous blood re-infusion (=combined cell saver/ DRAIN) effect 
on RBC use of total group, and split by primary / revision surgery
Primary and revision surgery patients (total group)










       (%)
adjustedodds 
ratioc (95% Ci)
Stratum I no Epo
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Autologous blood (n=214)
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table 3a. (continued)
revision surgery patients















Stratum I no Epo (n=33)
Autologous blood (n=22)








27 (0.2 to 5.1) 
Stratum I with Epo (n=37)
Autologous blood (n=24)






































Abbreviations: ITT=intention to treat; Epo=erythropoietin; RBC=red blood cell; U=units; CI, confidence interval; SD=standard 
deviation. Control groups are outlined in bold.
a adjusted for revision/non-revision surgery, hospital and knee/hip surgery; confidence intervals for reference purposes only 
(assuming normality)
b ratio was defined as the quotient of mean RBC values of two groups being compared; all estimates and robust standard 
errors were obtained via bootstrapping in R
c all estimates and standard errors were obtained using the Mantel-Haenszel procedure, stratifying by the pre-specified 
stratification factors hospital and knee/hip surgery
d denotes Epo alone group. 
e adjusted for hospital and for knee/ hip surgery; confidence intervals for reference purposes only (assuming normality) 
f 12% absolute difference in transfusion avoidance
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table 3B. AT analysis of primary surgery patients (truly received Epo and truly received device)
Primary surgery patients 














Stratum I no Epo (n=410)
Autologous blood (n=240)











Stratum I with Epo (n=202)
Autologous blood (n=81)









































Abbreviations: ITT=intention to treat; Epo=erythropoietin; CS=cell saver; DR=postoperative drain re-infusion; RBC=red 
blood cell; U=units; CI=confidence interval; SD=standard deviation. Control groups are outlined in bold.
a adjusted for hospital and knee/hip surgery; confidence intervals for reference purposes only (assuming normality).
b ratio was defined as the quotient of mean RBC values of two groups being compared; all estimates and robust standard 
errors were obtained via bootstrapping in R.
c all estimates and standard errors were obtained using the Mantel-Haenszel procedure, stratifying by the pre-specified 
stratification factors hospital and knee/hip surgery.
d denotes Epo alone group. 
e of 7 patients, it was not known whether the device was truly received. 
f 2.6% absolute difference in transfusion avoidance.
Autologous blood re-infusion was associated with a significant decrease in the use of Epo 
by 4% (table 4B, 95% CI 2% to 7%) and increased the length of the non-ICU hospital stay 
by 0.56 days (95% CI 0.23 to 0.90, similar in both strata). The total cost increase for the 
autologous blood re-infusion strategy was estimated at €378 per patient (95% CI 161 to 
595), without RBC reduction.
Study protocol adherence
A total of 284 patients did not receive the intended intervention. Of the 339 patients 
assigned to Epo, 114 received no Epo (34%), 225 patients assigned to Epo received at 
least one dose and of those 97% received at least three Epo doses. Sixty-two of 484 (13%) 
assigned patients did not receive cell saver (with or without Epo) and 110 of 997 (11%) 
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not receiving the intended intervention were earlier rescheduling of surgery in case of Epo, 
technical problems with the machine (broken or incomplete device) for cell saver and not 
using the proper drain device or not placing a drain at all. 
table 4. Estimated costs by Epo among patients with low Hb (table 4A) and by autologous blood 
re-infusion among all patients (table 4B)
table 4a













































Total costs 5615 4829 785 (262; 1309)
a Volume = percentage of patients and/or mean usage
bTwo patients received Epo while not randomised for Epo
table 4B



















































Total costs 4399 4021 378 (161; 595)
a Volume=percentage of patients and/or mean usage
Transfusion protocol adherence
In over 95% of the patients, the transfusion protocol was correctly followed according to Hb, 
age and co-morbidity status ( risk evaluation) of the patient before transfusion. Transfusion 
violations were equally found in all randomisation groups.
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As Treated analysis
In table 3B the AT analysis, where the actual use of Epo and the actual use of the autologous 
blood re-infusion devices are analysed, shows the primary surgery group only. Patients who 
actually received Epo (“pooled effects with Epo” group) showed a larger reduction in mean 
RBC use of 62% (ratio 0.38, 95% CI 0.19 to 0.66) and a reduction in proportion transfused 
patients of 70% (adjusted OR 0.30, 95% CI 0.18 to 0.51). In this low Hb stratum, the actual use 
of the autologous blood re-infusion devices did not result in a mean RBC reduction or in a 
reduction in percentage transfused patients. In the patient group with normal pre-operative 
Hb levels (stratum II), a significant mean RBC reduction of 37% (ratio 0.63, 95% CI 0.42 to 
0.95) and a reduction in transfused patients of 31% (adjusted OR 0.69, 95% CI 0.47 to 1.0) 
from 8.8% to 6.2% (2.6% absolute difference) was found. The AT analysis for the revision 
surgery patients, and the AT analysis for both separate cell saver and DRAIN are presented 
in eTables 2 and 3. No significant RBC reduction was found in the revision surgery group as 
well as no difference in effect of cell saver compared to DRAIN devices.
Serious adverse events (SaEs) 
A total of 112 SAEs were reported in 103 patients (eight patients suffered 2 or more SAEs) 
(Table 5A and 5B). Eighty SAEs were registered within one month postoperatively and 32 
SAEs were reported later within the three months of follow up. Categorisation according to 
intention-to-treat analysis (table 5A) and as treated analysis (table 5B), and occurrence (less 
or more than one month after surgery) is shown. One patient did not undergo surgery and 
was not further evaluated because of a stroke after one Epo dose (Hb value of 12.2 g/dL) 
and one patient was not further evaluated due to assignment of a wrong randomisation 
number. These patients were included in table 5. Total numbers of reported SAEs by 
group are outlined. A total of 31 thrombo-embolic (TE) events occurred: nine myocardial 
infarctions (MI), twelve strokes or TIA’s, four deep venous thrombosis of the leg (diagnosed 
by ultrasound), five pulmonary emboli and one arterial occlusion of a bypass graft in the leg. 
Five TE events (three MIs and two strokes) occurred in the Epo-group (1.5%), all in patients 
with Hb levels of 12.2.g/dL or less, two of these events occurred after only one Epo dose. 
The proportion of TE events (1.5%) in the Epo-group was not significantly different from 
the non-Epo group (1.2%) (OR 1.2, 95% CI 0.46 to 3.1; p=0.72). In the as treated analysis, 
1.8% in the Epo group suffered a TE event (table 5B) increasing the OR (not significantly) 
compared to the non-Epo group to 1.5 (95% CI 0.50 to 4.2; p=0.49). Non-TE related SAEs 
were: prosthesis related (n=33) (hip dislocation (n=10), prosthesis infections (n=4) or wound 
infections (n=7), limited knee flexion needing manipulation (n=5), fracture (n=3) or non-
specified (n=4)), cardiovascular events (n=22) (arrhythmia, blood pressure instability etc), 
allergic events (n=3), non prosthesis related infections or sepsis (n=7), bleeding (n=3), 
malignancy (n=1) and other (n=12). Autologous blood re-infusion related complications 
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reported in the group that actually received Epo and DRAIN (table 5B: as treated group) 
(18%; n=9), but these were mostly non TE related. Six of them were due to cardiac failure in 
patients with a known cardiac history. One serious anaphylactic reaction occurred in the DR 
group after post-operative re-fusion of 50 mL, which was treated with adrenalin and fluid 
resuscitation, and resolved uneventfully.
diSCuSSiOn
In elective knee-and hip-arthroplasty patients, three widely used RBC transfusion 
alternatives were compared while using a baseline restrictive transfusion threshold. Only 
11.6% of all patients were transfused. Within the control groups, 23% of patients with a 
low preoperative Hb (between 10 and 13 g/dL) and 8.3% in patients with a higher Hb level 
were transfused. In patients with the low preoperative Hb level (stratum I), Epo contributed 
significantly in avoiding RBC transfusions, but not in decreasing mean RBC reduction. In 
both strata I and II, the separate and combined use of cell saver and DRAIN did not result in a 
clinically significant decrease in RBC use. Since the revision surgery group was too small and 
effects were too heterogeneous, valid conclusions could only be made for the large primary 
surgery group (93% of the total cohort). Use of Epo in primary surgery patients resulted in 
a significant 12% absolute reduction and a 55% relative reduction in transfused patients 
irrespective of the use of cell saver or drain re-infusion. These results confirmed earlier 
reports that Epo has a significant benefit as a transfusion avoiding strategy (avoidance of 
exposure to allogeneic RBC transfusions) as well as a significant blood sparing effect (mean 
units RBC reduction). Our finding that neither cell saver nor DRAIN resulted in a clinically 
relevant RBC reduction may be explained by the low volume of recovered shed blood in 
combination with the applied restrictive transfusion threshold. This finding is consistent 
with a recent survey among 20 hospitals in the United States, in which the effect of blood 
salvage programs was investigated. The authors also observed that the volume of returned 
blood in orthopaedic joint surgery was small [27]. The development of better surgical 
techniques (i.e. less extensive incisions) to minimise blood loss may also have contributed 
to this effect.
 Neither Epo nor blood salvage were cost-effective. From a hospital perspective, the 
additional costs for the Epo strategy in patients with low Hb levels were estimated at 
€785 per patient, mainly consisting of the additional Epo costs. Epo avoided a transfusion 
in about one in every nine patients, translating the cost estimate to €7300 per avoided 
transfusion. To justify such costs from a health economic perspective, transfusion would 
have to be associated with a considerable health risk. Specifically, at a cost-effectiveness 
acceptability threshold of €40.000 per quality adjusted life year, one in every hundred 
transfused patients would have to incur an average life expectancy loss of approximately 
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20 years (100 x 7300 / 40.000). According to haemovigilance registers, blood transfusion 
currently seems considerably safer than that [28]. In our trial, autologous blood re-infusion 
using cell saver or DRAIN did not reduce allogeneic RBC transfusions and from a health 
economic perspective the associated cost increase is not justified.
Strengths and limitations of the study
Our study has several strengths and limitations. Strengths were that the study was 
randomised, the study power was 90% and sufficient numbers of patients were included 
and evaluated. The design of the study was chosen to be optimally consistent with current 
clinical practice, allowing to evaluate the combined and separate effect of three types of 
transfusion alternatives. Despite this complex study design, patients were well balanced 
across the randomisation groups. Adherence to the restrictive transfusion protocol was 
over 95%. This high protocol adherence was in contrast to the non-adherence to the 
randomisation arms that occurred in all participating centres. Non-adherence to Epo 
randomisation in stratum I was high, namely 34% (n=114) and was mainly due to the surgery 
date being brought forward when surgery time became suddenly available. This resulted in 
lack of time to prescribe three weeks of Epo therapy with subsequent protocol violation in 
the assignment to Epo. This situation may be typical for the Netherlands: at the time of this 
study the waiting lists for elective orthopaedic surgery were short (less than two months). In 
the analysis of the effect of autologous re-infusion, we observed that patients randomised 
to receive autologous re-infusion showed an unexpected, statistically significant, 4% lower 
use of Epo than patients randomized not to receive autologous re-infusion (Table 4B: 
autologous versus no autologous: 8% versus 12%). This may have biased our analysis at the 
expense of autologous re-infusion. However, since the transfusion rate among patients with 
low Hb was 26%, the overall influence of this imbalance on the transfusion rate cannot have 
been more than 1% (i.e. 26% of 4%), which is insufficient to alter our negative conclusion on 
autologous re-infusion.
 Non-adherence to the cell saver and to the DRAIN was present in 13% (n=62) and 
11% (n=111) of patients, respectively. Despite use of these devices, some patients did not 
receive any autologous blood due to insufficient drainage and/or collection of shed blood. 
Of the patients who did receive the intended intervention (as treated analysis), use of Epo 
in primary surgery patients showed that RBC reduction was larger, but still did not reach 
the 75% reduction level as hypothesized. In this analysis, use of blood salvage devices did 
result in a significant decrease in RBC use in primary surgery patients, who had a normal 
preoperative Hb level. However, since the absolute reduction was only 0.08 RBC units, it is 
questionable whether this is clinically relevant.
 Another limitation of the study may be that only the study investigators were blinded 
and not the clinical team, who was informed of the assigned randomisation arm in order 
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bias, however this was not likely, since clinicians adhered to the transfusion protocol and 
violations were equal in all randomisation groups.. Furthermore, since the study was not 
powered for safety evaluation, we are unable to draw valid conclusions on the incidence of 
complications. All patients in our study received thrombosis-prophylaxis, which may have 
an effect on the low proportion of thrombo-embolic complications in the Epo group. This 
finding is in contrast to a safety study in orthopaedic spine surgery patients not receiving 
thrombosis-prophylaxis that reported a higher incidence of post-operative thrombotic 
events (deep vein thrombosis in particular) in patients after Epo treatment compared to a 
control group [29]. Finally, all transfusion trials are flawed due to the fact that randomisation 
occurs prior to surgery, while the majority of included patients do not reach the trigger for 
transfusion. This however does not invalidate in any respect the intention-to-treat approach 
[30]. 
implications for clinicians and other researchers
This study may serve as a valid estimate for the primary hip- and knee surgery population 
in the Netherlands (16.6 million inhabitants), where approximately 50.000 total hip and 
knee replacements are performed annually, which is expected to rise to over 100.000 in 
2030 [31]. Considering the fact that use of autologous blood re-infusion devices are used 
in up to 80% of Dutch hospitals (year 2007) [11], and our findings that they have no blood 
sparing benefit, omission of these devices from blood management protocols may result in 
a considerable decrease in health care costs. 
 Our results confirm that patients with a low preoperative Hb were more likely to receive 
a RBC transfusion (23% of 138 control group patients in stratum I compared to 8.3% of 
698 non-anaemic control group patients in stratum II) and the patients with overt pre-
operative anaemia according to the WHO criteria even required a RBC transfusion in 32.4% 
[32-36]. For these anaemic patients, Epo is recommended in recently published guidelines, 
after excluding treatable causes of anaemia [33]. In our study, we did not investigate the 
cost-effectiveness of Epo in the anaemic subpopulation (210 patients in this study), nor 
corrected for anaemia, and propose to wait for more data to decide on the use of Epo in this 
subpopulation. Future research to aim for optimal blood management should rather focus 
on cheaper alternatives to Epo, such as iron supplements for the anaemic patient who is 
most at risk of being transfused. 
COnCluSiOnS
In elective knee-and hip-arthroplasty patients with preoperative Hb levels between 10 
and 13 g/dL, even with a restrictive transfusion policy, Epo contributed as a significant 
transfusion alternative, but at unacceptably high costs. No clinically relevant decrease in RBC 
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use was found using autologous blood salvage by cell saver or DRAIN, which consequently 
only increased costs. These findings may have a substantial impact for current blood 
management protocols in which Epo usage and autologous blood re-infusion devices are 
frequently embedded. 
What is already known on this topic:
 – In elective hip- and knee- replacement surgery, the use of Erythropoietin (Epo) and 
autologous blood re-infusion as red blood cell alternatives are widely accepted and 
embedded in daily practice. 
 – However, the effect sizes differ in literature and are smaller when a transfusion protocol 
is present. 
 – Since transfusion protocols have become more restrictive, it is questionable whether 
these alternatives are still in place in blood management protocols.
What this study adds:
Even with a restrictive transfusion policy, Epo significantly decreased red blood cell use 
in elective knee-and hip-arthroplasty patients with a preoperative Hb value of 13 g/dL or 
less, but at unacceptably high costs. The use of cell saver or postoperative drain re-infusion 
device did not result in a red blood cell reduction and consequently only increased costs. 
 Based on costs without apparent clinical benefit, the findings of this study do not 
support the use of Epo or autologous blood re-infusion by cell saver or post-operative drain 
re-infusion device as transfusion alternatives and support the use of a restrictive transfusion 
policy in this study population.
acknowledgements
We thank all the patients who took part in this trial: Leiden University Medical Center, Leiden 
(413 patients), Albert Schweitzer Hospital, Dordrecht (957 patients). Groene Hart Hospital, 
Gouda (603 patients), Slotervaart Hospital, Amsterdam (469 patients); Tineke van der Heide, 
Debby Zweers, Gerda Kuijpers and Trudy van Boxsel for data collection; Ed de Vin for data 
managing; the medical and laboratory staff of the participating hospitals; the members of 
the Data Safety and Monitoring Committee dr. Peter Te Boekhorst, dr. Bart Burger en Theo 
Stijnen; and Áine Honohan, Thea Vliet Vlieland and Stephen Vamvakas for critical appraisal 
of the manuscript. The TOMaat study group.
Contributors
AB was principal investigator. CS, AK and RN were lead clinical investigators. CS was study 
coordinator. RB was lead investigator for statistics, study design and management. CS, RN, JH 
and AB obtained ethical approval of the study and obtained funding. AB and RN supervised 





125Transfusion alternatives in orthopaedic surgery | 
and AK participated in recruitment of centres or patients, or both. TJ was responsible for 
the design of the data base and the data (quality) management as well as basic reporting 
of data to the investigators. WH was responsible for the economic evaluation. All authors 
participated in data interpretation and in reporting of results. All authors have seen and 
approved the final version.
funding: The clinical study was supported by grant PPOC- 03-002 from Sanquin Blood 
Supply and by grant 06-601 from ZonMW. In addition, Roche and Haemonetics provided 
grants for laboratory analyses (cytokine analyses) of wound blood (not reported in this 
study). The sponsors of the study had no input in study design, data collection, data 
analysis, data interpretation, writing of the report, or the decision to submit the paper for 
publication. The corresponding author had full access to all the data in the study and had 
final responsibility for decision to submit for publication.
Financial disclosures: non reported
Ethical approval: This study was approved by the University Hospital LUMC Committee 
of Medical Ethics (CME) and by the Medical Ethics Committees of the Albert Schweitzer 
Hospital, The Groene Hart Hospital and the Slotervaart Hospital.
data sharing: Dataset is available from the corresponding author at C.So@sanquin.nl
126 | Chapter 7
rEfErEnCES
1. Thomas D, Wareham K, Cohen D, Hutchings H. Autologous blood transfusion in total knee replacement 
surgery. Br J Anaesth 2001; 86(5):669-673.
2. Shenolikar A, Wareham K, Newington D, Thomas D, Hughes J, Downes M. Cell salvage auto transfusion 
in total knee replacement surgery. Transfus Med 1997; 7(4):277-280.
3. Heddle NM, Brox WT, Klama LN, Dickson LL, Levine MN. A randomized trial on the efficacy of an 
autologous blood drainage and transfusion device in patients undergoing elective knee arthroplasty. 
Transfusion 1992; 32(8):742-746.
4. Slagis SV, Benjamin JB, Volz RG, Giordano GF. Postoperative blood salvage in total hip and knee 
arthroplasty. A randomised controlled trial. J Bone Joint Surg Br 1991; 73(4):591-594.
5. Huet C, Salmi LR, Fergusson D, Koopman-van Gemert AW, Rubens F, Laupacis A. A meta-analysis of 
the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and 
orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth 
Analg 1999; 89(4):861-869.
6. Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB et al. Transfusion thresholds 
and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 
2002;(2):CD002042.
7. Weber EW, Slappendel R, Hemon Y, Mahler S, Dalen T, Rouwet E et al. Effects of epoetin alfa on blood 
transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery 
Trial (EEST). Eur J Anaesthesiol 2005; 22(4):249-257.
8. Carless PA, Henry DA, Moxey AJ, O’Connell D, Brown T, Fergusson DA. Cell salvage for minimising 
perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2010; (4):CD001888.
9. Rock G, Berger R, Bormanis J, Giulivi A, ElSaadany S, Afzal M et al. A review of nearly two decades in an 
autologous blood programme: The rise and fall of activity. Transfus Med 2006; 16(5):307-311.
10. Boulton FE, James V. Guidelines for policies on alternatives to allogeneic blood transfusion. 1. 
Predeposit autologous blood donation and transfusion. Transfus Med 2007; 17(5):354-365.
11. Horstmann WG, Ettema HB, Verheyen CC. Dutch orthopedic blood management surveys 2002 and 
2007: an increasing use of blood-saving measures. Arch Orthop Trauma Surg 2009.
12. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative 
transfusion requirements in patients having a major orthopaedic operation. The American 
Erythropoietin Study Group. J Bone Joint Surg Am 1996; 78(1):62-72.
13. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood 
management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81(1):2-10.
14. Warner C. The use of the orthopaedic perioperative autotransfusion (OrthoPAT) system in total joint 
replacement surgery. Orthop Nurs 2001; 20(6):29-32.
15. Abuzakuk T, Senthil K, V, Shenava Y, Bulstrode C, Skinner JA, Cannon SR et al. Autotransfusion drains in 
total knee replacement. Are they alternatives to homologous transfusion? Int Orthop 2007; 31(2):235-
239.
16. Adalberth G, Bystrom S, Kolstad K, Mallmin H, Milbrink J. Postoperative drainage of knee arthroplasty is 
not necessary: a randomized study of 90 patients. Acta Orthop Scand 1998; 69(5):475-478.
17. Amin A, Watson A, Mangwani J, Nawabi D, Ahluwalia R, Loeffler M. A prospective randomised controlled 
trial of autologous retransfusion in total knee replacement. J Bone Joint Surg Br 2008; 90(4):451-454.
18. Wood GC, Kapoor A, Javed A. Autologous drains in arthroplasty a randomized control trial. J 
Arthroplasty 2008; 23(6):808-813.
19. Rollo VJ, Hozack WJ, Rothman RH, Chao W, Eng KO. Prospective randomized evaluation of blood 
salvage techniques for primary total hip arthroplasty. J Arthroplasty 1995; 10(4):532-539.





127Transfusion alternatives in orthopaedic surgery | 
21. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968; 405:5-
37.
22. So-Osman C, Nelissen RG, Eikenboom HC, Brand A. Efficacy, safety and user-friendliness of two devices 
for postoperative autologous shed red blood cell re-infusion in elective orthopaedic surgery patients: 
A randomized pilot study. Transfus Med 2006; 16(5):321-328.
23. Dutch Health Insurance Executive Board. Costs of medication. 2011. Ref Type: Generic
24. Hakkaart-van Roijen L, Tan S, Bouwmans C. Manual for Costing: Methods and Standard 
Costs for Economic Evaluations in Healthcare [in Dutch]. [Institiute for Medical Technology 
Assessment]. 2010. Erasmus Universiteit Rotterdam, Health Care Assurance Board. 
Ref Type: Generic
25. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood 
transfusions in surgical patients at four hospitals. Transfusion 2010; 50(4):753-765.
26. Zethraeus N, Johannesson M, Jonsson B, Lothgren M, Tambour M. Advantages of using the net-benefit 
approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 2003; 
21(1):39-48.
27. Waters J.H., Dyga R.M., Waters J.F.R., Yazer M.H. The volume of returned red blood cells in a large blood 
salvage program: where does it all go? Transfusion [Epub, 24 March 2011], 1-7. 2011. Ref Type: Generic
28. SHOT Steering Group. SHOT Annual Report 2010. 1-151. 2010. Ref Type: Report
29. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G. An open-label, randomized, parallel-group study 
of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal 
surgery: safety analysis. Spine (Phila Pa 1976 ) 2009; 34(23):2479-2485.
30. Vamvakas EC. Rationale for randomized controlled trials and for intention-to-treat analysis in 
transfusion medicine: are they one and the same? Vox Sang 2008; 95(3):165-173.
31. Otten R, van Roermund PM, Picavet HS. [Trends in the number of knee and hip arthroplasties: 
considerably more knee and hip prostheses due to osteoarthritis in 2030]. Ned Tijdschr Geneeskd 
2010; 154(20):A1534.
32. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark 
study. Transfusion 2007; 47(8):1468-1480.
33. Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E et al. Detection, evaluation, and 
management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. 
Br J Anaesth 2011; 106(1):13-22.
34. Keating EM, Meding JB, Faris PM, Ritter MA. Predictors of transfusion risk in elective knee surgery. Clin 
Orthop Relat Res 1998; (357):50-59.
35. Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM et al. Orthopedic 
Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective 
knee and hip arthroplasty in Europe. Transfusion 2003; 43(4):459-469.
36. Spahn DR. Anemia and Patient Blood Management in Hip and Knee Surgery: A Systematic Review of 
the Literature. Anesthesiology 2010; 1-14.
128 | Chapter 7
OnlinE-Only MatErial
Includes:
 – Sample size calculation (text)
 – eFigure 1 Statistical design of the study
 – Legend to eFigure 1
 – eTable 1 ITT analysis of separate cell saver and DRAIN effect by surgery group (primary 
or revision)
 – eTable 2 AT analysis of revision surgery patients
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SaMPlE SizE CalCulatiOn 
The actual design is made keeping in mind that theoretically there could be an interaction 
between the Epo, the cell saver and the DRAIN effect on the outcome. If such an interaction 
is clinically irrelevant (and statistically absent) power can be gained without introducing 
any bias, by making the univariate comparisons as indicated in the design chart (eFigure 1), 
through pooling the unbiased effects within two or more stratification categories, leading 
to a smaller sample size. However, we have designed the trial to have sufficient power even 
in the case of (severe) interaction, i.e. the situation in which for example the effect of “DRAIN 
with or without cell saver” versus “Neither DRAIN nor cell saver” would in itself depend on 
the Epo-stratum. If that were the case, we would have to report this effect in the three strata 
separately. It should be noted that only in our statistical design (eFigure 1) the cell saver 
device is denoted as cell saver+DRAIN+ for statistical convenience, but for convenience 
of the reader the cell saver group is denoted in the print article as cell saver+DRAIN-. 
 Likewise, the Epo versus no-Epo effect is an “intention-to-treat” estimate so one could argue 
that it is only necessary to compare both arms without regard for the other randomisation 
consequences (DRAIN and cell saver). However, the randomisation of the three components 
takes place at the same time, i.e. it is actually a randomisation into 6 different treatment 
modalities (depending on the stratification variables). Hence it would be prudent to 
anticipate a possible interaction between the Epo effect and the cell saver/DRAIN effect. In 
a worst case scenario the “pure” Epo effect could then only be estimated by comparing the 
Epo versus non-Epo in the no-DRAIN, no-cell saver situation, thus reducing the sample size 
for this comparison.
 To accommodate all these scenario’s and realizing that this clinical design should answer 
the various comparisons in one study and also if assumptions of no-interaction will turn out 
not to be met, we decided to safeguard the power of the trial such that at the end a decision 
among all scenario’s can be made with 90% power. The following assumptions are made:
1. 1/3 is eligible for Epo, randomisation for EPO is 1:1
2. Mean transfusion rate is 1.0 RBC Unit, with SD=1.4 (medium risk scenario SD=1.6, worst 
case scenario SD=1.8)
3. Power of the trial =90%
4. Hypothesis 1: Epo versus no Epo,  Hypothesis 2: DRAIN with or without cell saver versus 
none (any autologous blood re-infusion device versus no autologous re-infusion). 
Hypothesis 3: cell saver versus no cell saver in case of autologous re-infusion (intra-and 
postoperative re-infusion by cell saver versus postoperative re-infusion by DRAIN).
In case of hypothesis 1: for a 75% reduction in blood use (from 1,0 to 0,25 U RBC) 125 patients 
are needed per group. Therefore, 2 times 125 patients are needed. In a worst case scenario 
(SD= 1.8) 3 times 2 times 125=750 patients are needed.
Please note that we do not compare percentages but average amounts of blood used.
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In case of hypothesis 2 and hypothesis 3: this involves 2/3 of all patients included (sum of 
“DRAIN with cell saver” and “DRAIN without cell saver”). For a reduction of 30% in blood use 
(from 1,0 to 0,7 U RBC) we need 1000 patients in a worst-case scenario, so for this group 
it will be 3/2 times1000=1500 patients. We then protect the trial against severe clinical 
interactions between the various components of the distinguished scenario’s:
 However, in case of interaction between Epo and DRAIN/cell saver the analysis must be 
performed within the no Epo group (this consists of 5/6 of the total number of patients), so 
6/5 times 1500=1800 patient inclusions are needed. In the worst case, analysis can only be 
performed in ‘’no Epo not eligible for Epo group’’=2/3 of total inclusions, that is: 3/2 times 
1500=2250 patients. 
 Since we have more than one test involved in reaching a final recommendation for a 
scenario, multiple testing should be taken into account: to protect against multiple testing 
a Bonferroni correction is used and in case of a SD of 1.4 and 30% mean RBC reduction we 
need 1800 patient inclusions. When analysis has to be restricted to the non-Epo group we 
need 6/5 times 1800=2200 inclusions.
 In conclusion when 2250 patients are included we expect sufficient power for all 
hypotheses 1 to 3, even in a worst case scenario. When interaction is not found, then pooling 
is allowed and much less than 2250 patients are needed.
 An interim analysis will be performed at 1000 patients by an independent Data Safety 
and Monitoring Committee. Study-stop criteria are: 1. p smaller than 0.025 for the primary 
endpoint; 2. p smaller than 0.025 for less than 30% reduction by Epo and less than 15% by 














































































efigure 1. Statistical design of the study
Since the cell saver device (OrthoPAT®) collected and re-infused both intra-and postoperative wound 
blood, the DRAIN notation in combination of cell saver (cell saver+DRAIN+) denotes the use of 
the cell saver device only. This notation is used only in this figure and has been used for statistical 
purposes only to calculate sample sizes and to construct the hypotheses. The light gray arrow denotes 
hypothesis 1 (Epo versus no Epo). The dark gray arrows denote hypothesis 2 (autologous blood versus 
no autologous blood) and hypothesis 3 (cell saver device versus DRAIN device within the autologous 
blood re-infusion groups). In case of no interaction, groups were pooled. 
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etable 1. ITT analysis of separate cell saver (CS) and DRAIN (DR) effect by surgery group (primary or 
revision)
Primary surgery patients 




























1.1 (0.6 to 2.2)













1.4 (0.7 to 3.1)














1.0 (0.6 to1.7) 
revision surgery patients



























0.83 (0.12 to 6.0)













0.43 (0.07 to 2.8)














0.91 (0.25 to 3.4)
Abbreviations: ITT=intention to treat; CS=cell saver; DR=postoperative drain re-infusion; Epo=erythropoietin; RBC=red 
blood cell; U=units; CI=confidence interval; SD=standard deviation.
a adjusted for hospital and for knee/ hip surgery; confidence intervals for reference purposes only (assuming normality)
b ratio was defined as the quotient of mean RBC values of two groups being compared; all estimates and robust standard 
errors were obtained via bootstrapping in R
c all estimates and standard errors were obtained using the Mantel-Haenszel procedure, stratifying by the pre-specified 
stratification factors hospital and knee/hip surgery
d included 2 hip surgery patients with respectively 17 and 27 RBC transfusions; when analysed as treated, these patients did 
not receive the drain device and ended in the epo only group. (see eTable 3)
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etable 2. AT analysis of revision surgery patients (combined effect of cell saver and DRAIN denoted as 
autologous blood)
revision surgery patients













Stratum I no Epo (n=45)
Autologous blood (n=26)











Stratum I with Epo (n=25)
Autologous blood (n=11)





































Abbreviations: AT=as treated; RBC=red blood cell; U=units; CI=confidence interval; SD=standard deviation; 
Epo=erythropoietin. Control groups are outlined in bold
a adjusted for hospital and for knee/ hip surgery; confidence intervals for reference purposes only (assuming normality)
b ratio was defined as the quotient of mean RBC values of two groups being compared; all estimates and robust standard 
errors were obtained via bootstrapping in R
c all estimates and standard errors were obtained using the Mantel-Haenszel procedure, stratifying by the pre-specified 
stratification factors hospital and knee/hip surgery
d denotes Epo alone group. 
e in one patient it was unknown whether the device was truly received
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etable 3. AT analysis of separate cell saver (CS) and DRAIN (DR) effect by surgery group (primary or 
revision)
Primary surgery patients 

















































































































Abbreviations: AT=as treated; CS=cell saver; DR=postoperative drain re-infusion; RBC=red blood cell; U=units; CI=confidence 
interval; SD=standard deviation; Epo=erythropoietin.
a adjusted for hospital and for knee/ hip surgery; confidence intervals for reference purposes only (assuming normality)
b ratio was defined as the quotient of mean RBC values of two groups being compared; all estimates and robust standard 
errors were obtained via bootstrapping in R
c all estimates and standard errors were obtained using the Mantel-Haenszel procedure, stratifying by the pre-specified 
stratification factors hospital and knee/hip surgery
d one patient received CS (intra-operatively) AND drain (postoperatively)
 
Chapter 8
further improvement in  
Patient Blood Management 
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We showed that despite a restrictive transfusion trigger still a quarter of the patients receive 
transfusions for elective total hip- and knee surgery. Autologous re-infusion by use of a cell 
saver or a post-operative drain re-infusion device was not effective to further decrease RBC 
use. Pre-operative use of Epo, however, is an effective transfusion alternative, but against 
unacceptably high costs. Therefore, these transfusion alternatives should not be used for the 
average elective orthopaedic patient. Further improvement in Patient Blood Management 
may be gained by looking at patient-specific factors. In this chapter, risk indicators for 
receiving a red blood cell (RBC) transfusion and for adverse clinical outcome (morbidity 
and mortality) in elective hip-and knee surgery are discussed. Since preoperative anaemia 
has been identified as an independent risk indicator for blood transfusion and has been 
associated with adverse outcome, one of the strategies for optimal blood management is 
to treat preoperative anaemia in order to aim for normal Hb values before surgery. This 
is discussed in the light of future studies (i.e. more attention to the preoperative anaemic 
patient, including the evaluation of the use of intravenous iron). Finally, the issues for further 
improvement in Patient Blood Management by prognostic modelling are discussed.
riSK faCtOrS fOr tranSfuSiOn in ElECtivE hiP-and KnEE rEPlaCEMEnt 
SurGEry
The need for a red blood cell (RBC) transfusion in patients scheduled for hip or knee surgery 
may depend on several factors: surgical factors (e.g surgical time, type of surgery and 
surgical technique), patient factors (e.g. co-morbidity) and blood management protocols. 
A restrictive RBC transfusion trigger is a powerful tool to reduce RBC transfusions. This has 
been investigated in two randomised trials, reported in chapters 2,3 and 7.These studies 
showed that the majority of these patients are relatively healthy and do not need RBC 
transfusions, and subsequently should not be treated with blood sparing modalities. 
Therefore, it is necessary to look for patient characteristics that can be identified as risk 
indicators for RBC transfusions. Of all reported risk indicators, a low preoperative Hb value 
was found to be a strong independent predictor for RBC transfusions [1-7]. 
 In Table 1, other risk indicators are reported as well, but these were not identified 
consistently. Our own data showed, that patients with Hb levels of 8.1 mmol/L (=13 g/
dL) or lower, are three times more often transfused than patients with Hb levels above 8.1 
mmol/L (24% versus 8%) (the TOMaat study data). In patients with a preoperative Hb of 8.1 
mmol/L or lower, Epo reduced the transfusion rate to 12% (OR 0.50; 95% CI 0.3 to 0.7), but 
at unacceptably high costs per avoided transfusion. Studies investigating other, less costly 
alternatives for Epo, are therefore necessary. Furthermore, by identifying more predictors 
for the use of a RBC transfusion, selective application of blood saving measures to a certain 
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table 1. Preoperative risk indicators for red blood cell (RBC) transfusions in hip-and knee replacement 
surgery
author (year) type of surgery 
(numbers)
Study design risk factor 
(if available Or and Ci is included)





Preop Hb 10-13 g./dL vs >13 g/dL
Faris (1999) [6] THR/TKR (n=276) Retrospective 
Logistic regression curve







Inverse relation Hb and RBC 
transfusion: transfusion risk if  
Hb=8 g/dL 75% for women and 69% 
for men; if Hb=13 g/dL: 32%  
for women and 22% for men





10-13 g/dL OR 1.83 
<10 g/dL OR 4.17 
Age: 
65-74 OR 1.54 
75-84 OR 2.88
>85 OR 4.50
use of LMWH: OR 2.08
Guerin (2007) [4] THR and TKR (n=162) Prospective
Multivariable regression 
analysis
Preop Hb level < 13 g/dL 
Walsh (2012) [7] Revision THR (n=210) Prospective 
Multivariable regression 
analysis
Preoperative Hb (change per g/dL 
increase in Hb):
OR. 0.44 [0.33-0.58]
Weight (change per kg, increase): 
OR 0.98 [0.96-1.00]
blood loss (change per mL increase 
in blood loss): OR1.002 [1.002-1.003]
re-infusion of perioperative 
salvaged blood (yes/no): 
OR 0.31 [0.11-0.82]
Abbreviations: n=numbers; TKR=Total Knee Replacement; OR=Odds Ratio; CI=Confidence Interval; THR=Total Hip 
Replacement; LMWH= Low Molecular Weight Heparin
PrEOPErativE anaEMia aS a riSK indiCatOr fOr advErSE CliniCal 
OutCOME in ElECtivE hiP-and KnEE SurGEry
Besides having an increased transfusion risk, preoperative anaemia has also been identified 
as an independent risk indicator for mortality and morbidity after surgery. Beattie and 
co-workers reported a strong association between anaemia and peri-operative mortality 
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in a large non-cardiac surgery cohort of more than 7000 patients. However, the subgroup 
of orthopaedic surgery patients was not specified (Table 2) [8]. Musallam and co-workers 
investigated a large cohort of 227.425 patients including 69.227 anaemic patients (10.758 
were orthopaedic surgery patients), and found an increased risk for morbidity and mortality 
30 days after surgery in the anaemic patients compared to the non-anaemic patients [9]. 
This study found an increased risk for composite morbidity (e.g. myocardial infarction (MI), 
stroke, pneumonia, renal insufficiency, wound infection, sepsis, thrombo-embolism) of 
53% (OR1.53 [95% CI 1.23 to 1.90]). Complications were increased in 42% of the sample of 
10.000 anaemic orthopaedic patients .This association, however, could not be confirmed by 
Mantilla and co-workers who performed a case-control study of hip-and knee replacement 
surgery patients (50% elective, 50% emergency), and matched for type of surgery, age and 
sex [10]. The investigators found that preoperative Hb value was not a risk for mortality 
or MI, but identified other existing co-morbidities such as cardiovascular, cerebro-vascular 
or pulmonary disease as the most important risk indicators. This risk model applied to 
both emergency as well as to elective surgery subgroups. The authors discussed that 
their population included patients with a relatively high mean age (78 years) with a high 
prevalence of co-morbidities (65% cardiovascular diseases) compared to other studies. In 
an earlier and descriptive study on a large study population of 10.244 primary total hip and 
knee arthroplasty patients over a 10 year period, the same authors (Mantilla (2002) reported 
on the frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis 
and postoperative death and found a frequency of 2.2% of these complications within 30 
days after surgery, mainly in the older age group (>70 years). However they did not evaluate 
the association between these complications and anaemia [11]. 
 Since high age and co-morbidities are also identified as risk indicators for adverse 
outcome in hip fracture surgery patients, it seems that some overlap exists in risk indicators 
for patients scheduled for elective orthopaedic surgery and patients who had more acute 
orthopaedic surgery after a hip fracture (Table 3) [10,11]. These latter patients are also 
referred to as “the frail elderly” in contrast to the vital healthy elderly. The frail elderly group 
has been associated with impaired physical function, gait speed and impaired cognition 
and have a higher risk of death and disability. An alternative to identify frailty is to estimate 
the biological age of the patient, which has been performed in 1000 randomly recruited 
ambulatory 75-year old women in Sweden. In that study, the biological age was predictive 
for both future fractures (OR 7.52: oldest tertile compared to youngest tertile), and overall 
mortality (OR 3.65) [12]. 
 Anaemia may also be associated with “frailty”, and the presence of anaemia, whatever its 
cause, may well be a proxy for “the frail elderly”. So by identifying and treating the anaemic 
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table 2. Risk indicators for adverse outcome in (elective) hip-and knee replacement surgery
author 
(year)
type of surgery 
(numbers)
Study design / type of 
analysis
risk factors/ predictors




Age (>70 y) (higher frequencies)
Outcome: MI, pulmonary embolism, 
death

















Outcome: 30-day morbidity 
and mortality
Sabate (2011) [33] Non-cardiac surgery 
(n=3387) 
















Outcome: major cardiac and 
cerebrovascular events






 OR 3.27 [2.27-4.72];  
cerebrovascular disease:
OR 1.99 [1.24-3.19];  
pulmonary disease:
 OR 1.62 [1.00-2.61]
Outcome: MI, death
Abbreviations: n=numbers; Y=Years; TKR=Total Knee Replacement; THR=Total Hip Replacement; OR [CI]=Odds Ratio 
[Confidence Interval]; MI=Myocardial Infarction
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table 3. Risk indicators or predictors for adverse outcome after hip fracture surgery
author 
(year)
type of surgery 
(numbers)
Study design/ data 
analysis 
risk factor
Lu-Yao (1994) [34] Hip fractures 







 multivariable analysis 
Outcome: 90-d (here 
shown) and 3y-mortality
Age (1-y increase): OR 1.07 
[1.06-1.07] 
Male: OR 2.21 [2.04-2.40]
Nursing home OR 1.39 [1.28-1.52]
Pertrochanteric fracture site 
OR 1.18 [1.06-1.30]
Charlson* co-morbidity score  












- CHF OR 32.2 [5.4-92]
- angina 25.7 [3.6-184]
- COPD 11.1 [2.0-62]
Gruson (2002) [36] Hip fracture 






















age ≥65 years 
Prospective  
Standardised  
Mortality Ratio (SMR) 
Outcome:  
2 year-mortality
ASA 3-4 in age 65-84:
SMR 3.2
Not increased in:
ASA 1-2 and/or age >84




Case Fatality Rates (CFR)
Outcome: 30-d, 90-d  
and 365-d mortality  
(CFR)
CFR by age, and by sex:
from OR 7.2 in men 65-69y to OR 
33.7 in men >90y (30-d) compared 
to women (from OR 2.7 to OR 22.7 
(30-d);
Social class IV and V (adjusted for 
age and sex):
OR. 2.47 [1.79-3.42] (30-d)
ORs are further increased after 90-d 
and 365-d mortality
Halm (2004) [39] Hip fracture



















type of surgery 
(numbers)











Three or more co-morbidities:















Two or more co-morbidities:
OR 1.63 [ 1.15-2.32]
















Predictive preoperative risk scores 
(AUC):
Risk- VAS: 0.707 (for A) 
Charlson: 0.833 (for A)
POSSUM 0.726 (for A)












hospital, 3 m and 12 m)
Preoperative anaemia:
not predictive for mortality:  
OR 1.30 [0.96-1.76]
RBC transfusion: predictive for 
in-hospital mortality, 3-m and 12-m
*Charlson index: scores pre-operative co-morbidity as a predictor for adverse postoperative outcome
Abbreviations: n=numbers; OR=Odds Ratio [95% confidence interval]; n.s.=not significant; m=months; d=day; y=year; 
CHF=Congestive Heart Failure; COPD= Chronic Obstructive Pulmonary Disease; MMS= Minimal Mental State; ROC=Receiver 
Operation Curve; AUC=Area Under Curve; RISK-VAS=Visual Analogue Scale for Risk; POSSUM=Physiological and Operative 
Severity Score for the enUmeration of Mortality and morbidity
PrEOPErativE anaEMia in thE OldEr PatiEnt
Several surveys report a relationship of prevalence of anaemia and increasing age [13-
15] with an overall prevalence of 11% in males and of 10% in females older than 65 years 
according to the WHO criteria [16]. One-third can be explained by nutritional causes (of 
which half was due to iron deficiency), one third by Anaemia of Chronic Disorder (ACD) 
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and Unexplained Anaemia (UA) in the remaining one third of patients. These latter two 
categories of patients are characterized by low erythropoietin levels and low levels of pro-
inflammatory cytokines [17,18].
 If anaemia is due to nutritional causes, correction might be easily performed by 
supplementing the deficient components. However, if anaemia is due to ACD or UA, it may 
be necessary to find the underlying disease that causes the anaemia (e.g. kidney failure, 
malignancy). If a patient is then still eligible for elective surgery, preoperative measures to 
increase the Hb level can be considered. 
OPtiMiSinG PatiEnt BlOOd ManaGEMEnt and POStOPErativE Out-
COME By OPtiMiSinG thE PrEOPErativE hB lEvEl
Since the preoperative Hb level was consistently reported as an independent significant 
risk factor for a RBC transfusion, it was included in the workup for optimising Patient Blood 
Management [19,20]. A Patient Blood Management Protocol was developed by a NATA 
working party aiming for preoperative non-anaemic levels in the elective orthopaedic 
surgery population. Due to the elective character, the optimal preoperative treatment 
can be explored, which however can be a problem if the waiting period for surgery is less 
than 4 weeks. Use of Epo (with oral iron) to increase Hb to normal levels, is very costly. 
An alternative may be the use of IntraVenous (IV) iron, since IV iron therapy may increase 
Hb values not only in iron deficient patients, but also in patients with ACD, bypassing the 
blocking effect of hepcidin that makes iron unavailable for incorporation in red blood cells 
[21]. Whether patients with UA benefit from either IV iron or Epo therapy or are refractory to 
both treatments, is unknown and must be further evaluated. 
 The efficacy and safety of IV iron compared to oral iron, or to placebo had been studied 
in several randomised trials, and was reported in a systematic review [22]. The authors 
concluded, that ferric carboxymaltose (Ferinject) significantly increased Hb levels compared 
to placebo, oral iron and intravenous iron sucrose (Venofer). Furthermore, the use was 
comparably safe. 
 In orthopaedic surgery, no randomized trials are published that primarily evaluated 
the use of IV iron as an transfusion alternative and compared its effect to other blood 
management modalities. Of four published randomized studies using IV iron, none 
investigated RBC use as a primary outcome: three of them combined preoperative use with 
or without Epo and scored the frequency to preoperatively donated autologous blood as 
primary outcome [23-25], a fourth study evaluated postoperative use of IV iron and its effect 
on Hb recovery [26]. Another problem of these studies was the low numbers of patients.
 Since these randomized studies only investigated IV iron at a limited level and hardly 
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in the elderly population for elective hip-and knee surgery is important. For this purpose, 
a new study protocol was designed: the Preoperative Orthopaedic Patients- Iron (POP-I) 
study. 
the POP-i study
In this study, patients with a preoperative Hb value between 6.2 (10 g/dL) and 8.1 mmol/L 
(13 g/dL) will be equally randomised for IV iron therapy (ferric carboxymaltose), for Epo 
(+oral iron) and for a control group. Control patients will be supplemented with oral iron 
in case of an iron deficiency anaemia. Primary outcome is the proportion of transfused 
patients and cost-effectiveness will be evaluated. IV iron and Epo will be prescribed at least 
4 weeks before surgery and Hb levels will be monitored. With this study, we may provide 
evidence for using IV iron as a cost-effective alternative for Epo. 
 Interestingly, a same type of study is ongoing in hip fracture patients, comparing IV iron 
to IV iron+ Epo and to placebo (a multi-centre, randomised study: the PAHFRAC-01project; 
NCT01154491). 
OPtiMiSinG PatiEnt BlOOd ManaGEMEnt By dEvElOPinG a PrOGnOStiC 
MOdEl
Optimal tailor-made treatment (in Dutch: Op Maat) can be attained by developing a model 
in which several outcome results (i.e. to be transfused, or morbidity or mortality) can be 
predicted with a certain likelihood. Development of such a multivariable prognostic model 
can be performed best by using data from a prospective cohort study, although data 
from randomised intervention studies can also be used [27]. If such a model is developed 
and validated it can also be used to evaluate whether the predictors identified in elective 
orthopaedic surgery patients are valid for other patients groups, such as the “frail elderly” 
undergoing hip fracture surgery. 
 Prediction models for RBC transfusions have been proposed, but none of the models 
has been widely accepted and used. A systematic review on patient characteristics and its 
association with perioperative RBC transfusions was published by Khanna and coworkers, 
who analysed 46 studies of which 13 were among elective knee-and hip replacement surgery 
patients [28]. They found that a low preoperative Hb level was most frequently associated 
with RBC transfusions, being identified as a strong predictor in all studies. The other 
factors commonly associated with risk for transfusion in literature, were advancing age (3 
studies), female gender (6 studies), and small body size (4 studies). Only 2 non-orthopaedic 
studies validated their predictive model for RBC transfusion on other prospective data and 
confirmed robustness of their model. However, the retrospective nature (lack of data), the 
small sample sizes and heterogeneity of the studies made it impossible to use the data 
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in a combined dataset to define a clinically useful prediction model for allogeneic RBC 
transfusion. 
 Having access to reliable predictors for adverse outcome, the clinician may outweigh 
the benefit of an elective lower extremity joint replacement against the risk of an adverse 
outcome for an individual patient. The PROPER study (PROject PEroperative Risk) compared 
preoperative risk factors to postoperative adverse outcome during hospital stay in 1471 
elective general surgery and orthopaedic surgery patients, and found four predictive 
factors for adverse outcome in the overall group (orthopaedic patients were not separately 
specified): a risk-Visual Analogue Score (VAS), ASA score, age and surgical stress (a four point 
scale scoring minor to extensive procedures, to estimate the magnitude of surgical stress 
imposed upon the patient). However, a prediction model was not developed, because 
all predictors had moderate sensitivity and specificity and a too low predictive value for 
individual patient counselling [29]. 
 By using data from the 2500 randomised patients from our collected TOMaat-study 
dataset, that included more than 250 transfused patients, we aim to develop a prognostic 
model for prediction of RBC transfusions, which can further be validated in collected datasets 
from other orthopaedic surgery patients. For the prediction of adverse postoperative 
outcome, other databases will be needed to have sufficient numbers of adverse events 
for input in a model. The most important and significant predictors can then be identified, 
assigning relative weights to each predictor, and estimating the model’s predictive 
performance with adjusting the model for overfitting. Finally, validating the model will be 
done in new datasets. 
PatiEnt BlOOd ManaGEMEnt: futurE dirECtiOnS
Despite the fact that blood components are safe in the Western world, there is an ongoing 
aim for “bloodless surgery” [30,31], which refers to optimalisation of peri-operative Patient 
Blood Management. We demonstrated that in elective knee-and hip surgery, due to the 
use of a restrictive transfusion trigger and continuously improving surgical techniques, 
some transfusion alternatives are no longer effective in reducing RBC use (autologous re-
infusion devices such as cell saver or postoperative drain re-infusion devices), or are not 
cost-effectively reducing RBCs, such as Epo, and are thus not considered as appropriate 
transfusion alternatives. By identifying predictors for transfusion, the use of (other) blood 
sparing modalities may be further evaluated and applied to the high risk patients only.
 Nowadays, the scope for optimal Patient Blood Management has changed to the 
preoperative setting, in which the anaemic patient, which is a proxy for patients with some 
kind of co-morbidity, needs more thorough evaluation to prevent adverse postoperative 
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predictor for transfusion. Patients with a preoperative anaemia must be treated to increase 
Hb levels to normal, thus reducing peri-operative RBC use and possibly also reducing the 
postoperative complication rate. Use of Intravenous iron can be explored in patients with 
iron deficiency anaemia and ACD as a cost-effective alternative for Epo. 
 In conclusion, a clinically relevant prediction model with respect to allogeneic RBC 
transfusions, will support a Tailor Made (in Dutch: Transfusie Op Maat) Patient Blood 
Management strategy for a specific group of patients, in which the use of transfusion 
alternatives may be applied. By identifying predictors for worse outcome (i.e. mortality and 
high morbidity), a decision model for the clinician may assist in the decision whether the 
benefits of a joint prosthesis outweighs the risks for adverse postoperative outcome. Future 
studies must include prognostic modeling leading to optimal Patient Blood Management. 
146 | Chapter 8
rEfErEnCES
1. Gombotz H, Rehak PH, Shander A, Hofmann A: Blood use in elective surgery: the Austrian benchmark 
study. Transfusion 2007; 47(8):1468-1480.
2. Keating EM, Meding JB, Faris PM, Ritter MA: Predictors of transfusion risk in elective knee surgery. Clin 
Orthop Relat Res 1998;(357):50-59.
3. Bong MR, Patel V, Chang E, Issack PS, Hebert R, Di Cesare PE: Risks associated with blood transfusion 
after total knee arthroplasty. J Arthroplasty 2004; 19(3):281-287.
4. Guerin S, Collins C, Kapoor H, McClean I, Collins D: Blood transfusion requirement prediction in patients 
undergoing primary total hip and knee arthroplasty. Transfus Med 2007; 17(1):37-43.
5. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB: An analysis of blood 
management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81(1):2-10.
6. Faris PM, Spence RK, Larholt KM, Sampson AR, Frei D: The predictive power of baseline hemoglobin for 
transfusion risk in surgery patients. Orthopedics 1999; 22(1 Suppl):s135-s140.
7. Walsh TS, Palmer J, Watson D, Biggin K, Seretny M, Davidson H, Harkness M, Hay A: Multicentre cohort 
study of red blood cell use for revision hip arthroplasty and factors associated with greater risk of 
allogeneic blood transfusion. Br J Anaesth 2012; 108(1):63-71.
8. Beattie WS, Karkouti K, Wijeysundera DN, Tait G: Risk associated with preoperative anemia in noncardiac 
surgery: a single-center cohort study. Anesthesiology 2009; 110(3):574-581.
9. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, Khreiss M, Dahdaleh FS, 
Khavandi K, Sfeir PM, Soweid A, Hoballah JJ, Taher AT, Jamali FR: Preoperative anaemia and postoperative 
outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378(9800):1396-1407.
10. Mantilla CB, Wass CT, Goodrich KA, Johanns CJ, Kool ML, Zhu X, Corredor JA, Warner DO, Joyner MJ, 
Berry DJ, Schroeder DR, Sprung J: Risk for perioperative myocardial infarction and mortality in patients 
undergoing hip or knee arthroplasty: the role of anemia. Transfusion 2011; 51(1):82-91.
11. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL: Frequency of myocardial infarction, 
pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. 
Anesthesiology 2002; 96(5):1140-1146.
12. Gerdhem P, Ringsberg K, Akesson K, Obrant KJ: Just one look, and fractures and death can be predicted 
in elderly ambulatory women. Gerontology 2004; 50(5):309-314.
13. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC: Prevalence of anemia in persons 65 
years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 
104(8):2263-2268.
14. Salive ME, Cornoni-Huntley J, Guralnik JM, Phillips CL, Wallace RB, Ostfeld AM, Cohen HJ: Anemia and 
hemoglobin levels in older persons: relationship with age, gender, and health status. J Am Geriatr Soc 
1992; 40(5):489-496.
15. Inelmen EM, D’Alessio M, Gatto MR, Baggio MB, Jimenez G, Bizzotto MG, Enzi G: Descriptive analysis of 
the prevalence of anemia in a randomly selected sample of elderly people living at home: some results 
of an Italian multicentric study. Aging (Milano ) 1994; 6(2):81-89.
16. Nutritional anaemias. Report of a WHO scientific group: World Health Organ Tech Rep Ser 1968; 405:5-
37.
17. Ferrucci L, Guralnik JM, Bandinelli S, Semba RD, Lauretani F, Corsi A, Ruggiero C, Ershler WB, Longo 
DL: Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of 
pro-inflammatory markers. Br J Haematol 2007; 136(6):849-855.
18. Merchant AA, Roy CN: Not so benign haematology: anaemia of the elderly. Br J Haematol 2012; 
156(2):173-185.
19. Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, Fergusson DA, Gombotz H, Habler O, 
Monk TG, Ozier Y, Slappendel R, Szpalski M: Detection, evaluation, and management of preoperative 





147Further improvement in Patient Blood Management | 
20. Spahn DR: Anemia and Patient Blood Management in Hip and Knee Surgery: A Systematic Review of 
the Literature. Anesthesiology 2010;1-14.
21. Cullis JO: Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol 
2011; 154(3):289-300.
22. Moore RA, Gaskell H, Rose P, Allan J: Meta-analysis of efficacy and safety of intravenous ferric 
carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 2011; 
11:4.
23. Mercuriali F, Zanella A, Barosi G, Inghilleri G, Biffi E, Vinci A, Colotti MT: Use of erythropoietin to increase 
the volume of autologous blood donated by orthopedic patients. Transfusion 1993; 33(1):55-60.
24. Olijhoek G, Megens JG, Musto P, Nogarin L, Gassmann-Mayer C, Vercammen E, Hayes-Licitra SA: Role of 
oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-
controlled trial. Transfusion 2001; 41(7):957-963.
25. Tryba M, Messmer, McClelland, Mercuriali, Monk, D’Ambra, Gombotz: Epoetin alfa plus autologous 
blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery. Seminars 
in Hematology 1996; 33(2 SUPPL. 2):22-26.
26. Karkouti K, McCluskey SA, Ghannam M, Salpeter MJ, Quirt I, Yau TM: Intravenous iron and recombinant 
erythropoietin for the treatment of postoperative anemia. Can J Anaesth 2006; 53(1):11-19.
27. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG: Prognosis and prognostic research: what, 
why, and how? BMJ 2009; 338:b375.
28. Khanna MP, Hebert PC, Fergusson DA: Review of the clinical practice literature on patient characteristics 
associated with perioperative allogeneic red blood cell transfusion. Transfus Med Rev 2003; 17(2):110-
119.
29. Arvidsson S, Ouchterlony J, Sjostedt L, Svardsudd K: Predicting postoperative adverse events. Clinical 
efficiency of four general classification systems. The project perioperative risk. Acta Anaesthesiol 
Scand 1996; 40(7):783-791.
30. Goodnough LT, Shander A, Spence R: Bloodless medicine: clinical care without allogeneic blood 
transfusion. Transfusion 2003; 43(5):668-676.
31. Shander A: Surgery without blood. Crit Care Med 2003; 31(12 Suppl):S708-S714.
32. Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, Cremers S, Abraham 
IL: Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood 
management in elective knee and hip arthroplasty in Europe. Transfusion 2003; 43(4):459-469.
33. Sabate S, Mases A, Guilera N, Canet J, Castillo J, Orrego C, Sabate A, Fita G, Parramon F, Paniagua 
P, Rodriguez A, Sabate M: Incidence and predictors of major perioperative adverse cardiac and 
cerebrovascular events in non-cardiac surgery. Br J Anaesth 2011; 107(6):879-890.
34. Lu-Yao GL, Baron JA, Barrett JA, Fisher ES: Treatment and survival among elderly Americans with hip 
fractures: a population-based study. Am J Public Health 1994; 84(8):1287-1291.
35. Nettleman MD, Alsip J, Schrader M, Schulte M: Predictors of mortality after acute hip fracture. J Gen 
Intern Med 1996; 11(12):765-767.
36. Gruson KI, Aharonoff GB, Egol KA, Zuckerman JD, Koval KJ: The relationship between admission 
hemoglobin level and outcome after hip fracture. J Orthop Trauma 2002; 16(1):39-44.
37. Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ: Mortality risk after hip fracture. J Orthop Trauma 
2003; 17(1):53-56.
38. Roberts SE, Goldacre MJ: Time trends and demography of mortality after fractured neck of femur in an 
English population, 1968-98: database study. BMJ 2003; 327(7418):771-775.
39. Halm EA, Wang JJ, Boockvar K, Penrod J, Silberzweig SB, Magaziner J, Koval KJ, Siu AL: The effect of 
perioperative anemia on clinical and functional outcomes in patients with hip fracture. J Orthop 
Trauma 2004; 18(6):369-374.
40. Roche JJ, Wenn RT, Sahota O, Moran CG: Effect of comorbidities and postoperative complications 
on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ 2005; 
331(7529):1374.
148 | Chapter 8
41. Maxwell MJ, Moran CG, Moppett IK: Development and validation of a preoperative scoring system to 
predict 30 day mortality in patients undergoing hip fracture surgery. Br J Anaesth 2008; 101(4):511-
517.
42. Burgos E, Gomez-Arnau JI, Diez R, Munoz L, Fernandez-Guisasola J, Garcia d, V: Predictive value of six 
risk scores for outcome after surgical repair of hip fracture in elderly patients. Acta Anaesthesiol Scand 
2008; 52(1):125-131.
43. Vochteloo AJ, Borger van der Burg BL, Mertens BJ, Niggebrugge AH, de Vries MR, Tuinebreijer WE, 
Bloem RM, Nelissen RG, Pilot P: Outcome in hip fracture patients related to anemia at admission and 
allogeneic blood transfusion: an analysis of 1262 surgically treated patients. BMC Musculoskelet 
Disord 2011; 12:262.
Chapter 9
designing a strategy to implement  
cost-effective blood transfusion 
management in elective hip and  
knee arthroplasties: a study protocol
Veronique Voorn1, Perla Marang-van de Mheen1, Cynthia So-Osman2, Thea Vliet Vlieland3, Ankie 
Koopman-van Gemert4, Rob Nelissen3, Leti van Bodegom-Vos1* 
For the LISBOA study group
1 Department of Medical Decision Making, Leiden University Medical Centre, Leiden, the 
Netherlands
2 Jon J van Rood Netherlands Center for Clinical Transfusion Research, Sanquin Research, 
Leiden, the Netherlands
3 Department of Orthopedics, Leiden University Medical Centre, Leiden, the Netherlands
4 Department of Anesthesiology, Albert Schweitzer Hospital, Dordrecht, the Netherlands
Implementation Science, In press
150 | Chapter 9
aBStraCt
Background: Total hip and knee arthroplasties are two of the most commonly performed 
procedures in orthopedic surgery. Different blood-saving measures (BSMs) are used to 
reduce the often-needed allogenic blood transfusions in these procedures. A recent large 
randomized controlled trial showed it is not cost effective to use the BSMs of erythropoietin 
and perioperative autologous blood salvage in elective primary hip and knee arthroplasties. 
Despite dissemination of these study results, medical professionals keep using these BSMs. 
To actually change practice, an implementation strategy is needed that is based on a good 
understanding of target groups and settings and the psychological constructs that predict 
behavior of medical professionals. However, detailed insight into these issuses is lacking. 
Therefore, this study aims to explore which groups of professionals should be targeted at 
which settings, as well as relevant barriers and facilitators that should be taken into acount 
in the strategy to implement evidence-based, cost-effective blood transfusion management 
and to de-implement BSMs.
Methods: The study consists of three phases. First, a questionnaire survey among all 
Dutch orthopedic hospital departments and independent treatment centers (n=99) will 
be conducted to analyze current blood management practice. Second, semistructured 
interviews will be held among 10 orthopedic surgeons and 10 anesthesiologists to identify 
barriers and facilitators that are relevant for the uptake of cost-effective blood transfusion 
management. Interview questions will be based on the Theoretical Domains Interview 
framework. The interviews will be followed by a questionnaire survey among 800 medical 
professionals in orthopedics and anesthesiology (400 professionals per discipline) in which 
the identified barriers and facilitators will be ranked by frequency and importance. Finally, 
an implementation strategy will be developed based on the results from the previous 
phases, using principles of intervention mapping and an expert panel.
discussion: The developed strategy for cost-effective blood transfusion management by 
de-implementing BSMs is likely to reduce costs for elective hip and knee arthroplasties. 
In addition, this study will lead to generalized knowledge regarding relevant factors for 
the de-implementation of non-cost-effective interventions and insight in the differences 
between implementation and de-implementation strategies.
 Total hip and knee arthroplasties are two of the most commonly performed procedures 
in orthopedic surgery [1,2]. It is expected that the number of these procedures within the 
Netherlands will increase to more than 100,000 by the year 2030 [3]. During primary hip 
or knee arthroplasty, the calculated visible and invisible blood loss is 1,500 ml on average, 
followed by a drop of hemoglobin of approximately 3 g/dl [4]. This leads to high rates of 
allogenic blood transfusions up to 69% depending on the transfusion threshold [5]. Even 
though blood transfusions may be necessary, they include the risk for infections and 
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Many studies on blood-saving measures (BSMs) have therefore been performed, including 
erythropoietin (EPO) and peri-operative autologous blood salvage (intra-operative use of 
Cell Saver (CS) and a postoperative drainage and reinfusion device (DR)). Reviews showed 
that these studies had several limitations, such as a retrospective design, small patient 
numbers and poor methodological quality [5,7,8]. A multicenter randomized controlled 
trial (RCT) with adequate power (n=2,442) was therefore performed recently to test the cost 
effectiveness of using BSMs, including EPO, CS, and DR, in elective primary hip and knee 
arthroplasties [9]. It was shown that blood salvage (CS and DR) resulted in neither decreased 
mean red blood cell (RBC) use nor in a decrease in the proportion of transfused patients 
and was more expensive due to the costs of the devices used and a prolonged hospital 
stay. EPO showed a significant decrease in the proportion of transfused patients, but costs 
were considered too high. It was thus concluded that these BSMs were not cost effective in 
primary hip and knee arthroplasties [10].
 Despite this evidence about BSMs not being cost effective, medical professionals keep 
using these BSMs in daily practice. To decrease costs of care delivery to patients undergoing 
a hip or knee arthroplasty, cost-effective blood transfusion management needs to be 
implemented. However, little is known about how to effectively de-implement common 
practices. To actually change practice, a de-implementation strategy is needed that is based 
on a good understanding of target groups and settings and the barriers and facilitators 
that influence the behavior of medical professionals [10,11]. However, detailed insight into 
these factors is lacking. Psychological theories are used in understanding and predicting 
intentions and clinical behavior [12] and may help to outline an effective strategy to de-
implement these non-cost-effective BSMs.
OBJECtivE
The Leiden Implementation Study of BlOod management in hip and knee Arthroplasties 
(LISBOA) aims to explore the target groups, settings, and relevant barriers and facilitators 
that should be taken into account to develop a strategy directed at all involved medical 
professionals (target group) and their organizations to implement evidence-based, cost 
effective transfusion management and to de-implement BSMs.
To reach the aim of this study, the following research questions were formulated:
A. How often and in what settings are BSMs applied in hip and knee arthroplasties?
B. Which barriers and facilitators influence the implementation of cost-effective blood 
transfusion management and de-implementation of non-cost-effective BSMs among 
the target group, including orthopedic surgeons and anesthesiologists?
C. What is a tailored implementation strategy for the uptake of cost-effective blood 
transfusion management given the results of the first two research questions?
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MEthOdS
The study will be subdivided in three study phases to be executed in one year:
A. analysis of current blood transfusion management practice in elective primary hip and 
knee arthroplasties (months 1 to 3),
B. analysis of barriers and facilitators relevant for the implementation of cost-effective 
blood transfusion management and de-implementation of non-cost-effective BSMs 
(months 4 to 8),
C. development of an implementation strategy based on the results of phases A and B 
(months 9 to 12).
The study design, study population, analysis, and outcome measures are described per 
study phase.
PhaSE a: analySiS Of CurrEnt BlOOd tranSfuSiOn ManaGEMEnt
Study design
To analyze current blood transfusion management practice in hip and knee arthroplasties, 
a survey among all orthopedic departments of Dutch university, teaching, and general 
hospitals and independent treatment centers will be performed. A survey in the period 
1995-1997 showed that EPO was used rarely in the Netherlands at that time, in only 2% of 
all hospitals, and that CS was used in 24% of hospitals [13]. A more recent survey in 2007 
showed that approximately half of all Dutch orthopedic departments applied EPO and/
or autologous blood salvage [14]. However, these surveys neither showed how frequent 
these BSMs were applied within hospitals nor in what type of setting (university, teaching, 
or general hospital or independent treatment center). This information is needed to target 
the implementation strategy to the appropriate professionals and departments.
 The current survey will thus include questions about the type and size of the 
department, the transfusion protocol used, and the frequency of application of BSMs in 
patients within the last 12 months. Furthermore, questions will be included about the policy 
of preoperative anticoagulant use. These last questions are added to assess whether these 
protocols are related to BSM use and should be taken into account in the implementation 
strategy. The content of the survey will be developed together with an orthopedic surgeon, 
anesthesiologist, and hematologist specialized in blood transfusions. Reminders to 
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Study population
All heads of orthopedic departments of Dutch university, teaching, and general hospitals 
and independent treatment centers (n=99) will be approached to participate in the survey. 
In case of nonresponse, a different orthopedic surgeon within the same department will be 
approached.
analysis
Descriptive statistics will be used to describe current blood management practice. 
Independent t tests or Mann Whitney U tests for continuous variables and Chi-Square tests 
or Fisher’s exact tests for proportions are used to analyze differences in frequency of use 
between the different settings, department sizes, or other conditions.
Outcome measures
The main outcome measures are the percentage of orthopedic departments applying 
BSMs per size and type of setting of the orthopedic department and the frequency of BSM 
use within a department. These results are used in phase C to address the implementation 
strategy to the appropriate (groups of ) orthopedic departments. A secondary outcome 
measure is the number of days anticoagulants are stopped preoperatively. This is used to 
analyze whether this is associated with BSM use and should be taken into account in the 
implementation strategy.
PhaSE B: analySiS Of BarriErS and faCilitatOrS fOr iMPlEMEntatiOn 
Of COSt-EffECtivE BlOOd tranSfuSiOn ManaGEMEnt
Study design
Two steps will be taken to identify barriers and facilitators associated with the implementation 
of cost-effective blood transfusion management. First, semistructured interviews will be 
performed to explore all relevant barriers and facilitators for the uptake of cost-effective 
blood transfusion management. The interview questions will be based on the Theoretical 
Domains Interview (TDI) framework [15], complemented by the framework of Cabana, who 
subdivided largely similar constructs in three “sequences of behavior change” to give a good 
overview of the used constructs [16]. The TDI framework includes 12 theoretical construct 
domains derived from 33 health psychology theories (covering 128 theoretical constructs) 
that help explain clinicians’ behavior [15,17].
 Second, a survey will be held among a random sample of 400 Dutch orthopedic 
surgeons and 400 anesthesiologists to rank the barriers and facilitators identified in the 
interviews both on frequency and importance. The survey will include questions in which 
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these barriers and facilitators of the identified theoretical domains can be related to specific 
clinical behavior.
Study population
Orthopedic surgeons and anesthesiologists are key stakeholders in deciding to use allogenic 
blood transfusions only or BSMs in patients that undergo hip and knee arthroplasty. 
Based on the analysis of current practice (phase A of this study), we will select a sample of 
departments that frequently apply BSMs to identify barriers, as well as departments with 
rare use of BSMs to identify facilitators. In this selection, the setting is taken into account 
(university, teaching, or general hospital or independent treatment center). In addition, 
departments with alternative answers (e.g., the use of a different transfusion protocol) 
will be selected for interviews. In total, ten orthopedic surgeons and ten anesthesiologists 
will be interviewed to identify barriers and facilitators relevant for the uptake of a cost-
effective blood transfusion policy and their motivations to apply BSMs. Data saturation for 
the interviews is defined as three consecutive interviews without new themes emerging. If 
there is no data saturation after 10 interviews per specialism, additional interviews will be 
conducted [18]. The total number of interviews will thus be determined by the number it 
takes to reach data saturation.
 The interviews with orthopedic surgeons and anesthesiologists may reveal that other 
groups of stakeholders have an important role in deciding to use BSMs. In that case, additional 
interviews will be held with those stakeholders to elicit their views about relevant barriers 
and facilitators associated with the uptake of cost-effective transfusionmanagement. For 
the survey, a random sample (n=400) of all Dutch orthopedic surgeons listed in the registry 
of the Dutch Orthopedic Association (NOV) (n=595) and a random sample (n=400) of 
anesthesiologists listed in the registry of the Netherlands Society of Anesthesiologists (NVA) 
(n≈1200) will be approached for participation in the survey.
analysis
The interviews will be audiotaped and transcribed in full for analysis. The interview 
transcripts will be analyzed by two researchers using the TDI framework as a base [15]. 
Important theoretical domains and the barriers and facilitators within these domains will 
be coded. This qualitative analysis will be executed using the software package ATLAS.ti 
(ATLAS.ti Scientific Software Development GmBH, Berlin, Germany).
 The subsequent survey data will allow us to rank the importance of barriers and 
facilitators and their relationships with behavioral intention. These relationships will be 
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Outcome measures
The most important barriers and facilitators relevant for the uptake of cost-effective blood 
transfusion management by medical professionals will be the outcome measures from this 
phase.
PhaSE C: dEvElOPMEnt Of an EffECtivE iMPlEMEntatiOn StratEGy 
fOr COSt-EffECtivE BlOOd ManaGEMEnt
Study design
The results from the previous phases will be used to develop a tailored implementation 
strategy for cost-effective blood transfusion management for elective primary hip and knee 
arthroplasties. The results from phase A will show to which type of departments the strategy 
should be aimed. Phase B results will show the most important barriers and facilitators that 
should be taken into account in the development of the strategy.
 From the literature, it is known that, in general, multifaceted strategies are more effective 
than single strategies [19,20]. Assuming this, and our expectation that several barriers on 
different theoretical domains will be found, it is very likely that the implementation strategy 
to be developed will include several components directed at different levels (i.e., professional 
and organizational context). Furthermore, it is expected that the strategy components will 
include educational outreach or interactive educational strategy since these are known to 
be effective [20,21].
 In the development process, we will use a method based on the intervention mapping 
approach of Bartholomew et al [22]. This method begins with the creation of matrices in 
which the performance objectives are set against the top 10 ranking of factors that hinder 
or facilitate the implementation of a cost-effective transfusion policy. Subsequently, a 
brainstorming session will be held about the strategy components needed to achieve 
the performance objective, in the presence or absence of the hindering or facilitating 
factor mentioned in the matrix. The cells of the matrices will then gradually be filled with 
implementation strategy components [23]. Next, the formulated strategy components will 
be translated into practical strategies at each level (e.g., professional and organizational).
 After the implementation strategy is developed, an expert meeting will be held with 
a panel of key opinion leaders in orthopedic surgery and anesthesiology, delegates of 
blood transfusion committees, and implementation experts (n=10 to n=20) to discuss the 
strategy’s feasibility and to refine the developed implementation strategy. Their opinion 
about the strategy and their intention to use the strategy will be taken into account.
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analysis
The expert meeting will be audiotaped and transcribed. The panel members will receive 
a summary of the formulated implementation strategy and will be asked whether this 
summary is consistent with the conclusions reached in the meeting.
Outcome measures
The outcome from this phase will be a tailored implementation strategy likely to be effective 
for implementing cost effective blood transfusion management and de-implementing 
BSMs in elective primary hip and knee athroplasties.
Ethical approval
The study protocol has been presented to the Medical Ethical Committee of the Leiden 
University Medical Center. They declared ethical approval was not required under Dutch 
national law. (CME 11/104)
diSCuSSiOn
The goal of this study is to develop an implementation strategy for cost-effective blood 
transfusion management in elective hip and knee arthroplasties in which BSMs are de-
implemented. This study is the next step following a RCT on EPO and blood salvage as 
transfusion alternatives in orthopedic surgery using a restrictive transfusion policy that 
showed that use of these BSMs is not cost effective [9]. Given the number of hip and knee 
arthroplasties performed annually in the Netherlands and worldwide, and the accompanied 
blood loss and transfusion risks, implementing a cost-effective blood transfusion 
management may reduce costs.
 Several studies have been performed to develop and test implementation strategies, 
including identification of barriers that prevent implementation [10,16,19]. They all 
conclude that a prior inventory of barriers to develop a tailored implementation strategy 
is useful and can confirm whether barriers differ in different settings. Prior inventory 
thereby reduces the number of costly trials evaluating different implementation strategies 
[11,24,25]. The present study, however, focuses on de-implementation of BSMs known to 
be cost ineffective. Little is known about barriers and facilitators for de-implementation and 
whether these are similar to barriers and facilitators for implementation. The knowledge 
obtained by the present study may thus be further generalized to other practices that 
need to be de-implemented and contributes to general knowledge regarding differences 
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Strengths and limitations
Possible limitations of the study are biased results due to response bias in the phase A survey 
[26]. Nonresponse may cause an under- or overestimation of BSM use. The selection for the 
interviews in phase B is based on the results of phase A, so if non-responders have different 
intentions or experience different barriers and facilitators for the uptake of cost-effective 
blood transfusion management, this may influence the resulting barriers and facilitators.
We will try to overcome this by sending reminders by email and telephone, but this will 
not completely prevent response bias. In addition, response bias may also occur in the 
phase B survey if nonresponders to this survey rank the selected barriers and facilitators in 
a different order; this may influence the likelihood of barriers and facilitators being included 
in the implementation strategy. Again, reminders will be sent to keep bias to a minimum, 
and we will compare respondents and nonrespondents on demographic variables (e.g., 
type of hospital) to estimate how likely it is that bias may be introduced.
 A strength of this study is that it is one of the first studies to identify barriers and 
facilitators relevant for de-implementation. The study results will thus lead to generalized 
knowledge regarding factors that are important for the de-implementation of non-cost-
effective interventions and how these differ from relevant factors for implementation.
future work
The developed implementation strategy should be tested for effectiveness, feasibility, 
and costs within orthopedic practice in the Netherlands in a future study. As the current 
implementation strategy will be aimed at de-implementation of the use of EPO, CS, and DR, 
further research is needed to evaluate the cost effectiveness of other BSMs in hip and knee 
arthroplasties. Cost effective blood transfusion management implemented in this way is 
likely to improve efficiency of care.
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Summary
To minimise exposure to allogeneic blood in elective orthopaedic surgery, both restrictive 
transfusion policies as well as the use of transfusion alternatives are widely recommended. 
The first step towards optimal Patient Blood Management should be the implementation 
of a restrictive transfusion policy. With this measure, we managed to save 36% in mean RBC 
use and 13% in proportion transfused patients (chapters 2 and 3), without differences in 
quality of life (chapters 3 and 4). Because still 26% was transfused in our study (chapter 2), 
a second step was appropriate to evaluate, the additional effect on RBC use of transfusion 
alternatives. Although many studies on transfusion alternatives have been published, 
inclusion numbers were usually low and often without the use of a strict transfusion policy. 
In a pilot study, we compared different types of post-operative drain re-infusion devices for 
its efficacy and feasibility (chapter 5) and found these to be comparable. This pilot-study 
was performed in order to decide which drain device could be used in a larger study on 
transfusion alternatives, which included erythropoietin (Epo) as a preoperative modality, 
cell saver as an intra-operative modality for re-infusion of washed salvaged blood and a 
drain re-infusion device as a postoperative modality for re-infusion of unwashed salvaged 
blood. A restrictive transfusion policy was used for all patients according to the Dutch 
guidelines (chapter 7). In this study, Epo was the only effective transfusion alternative, but it 
was not cost-effective. Therefore, for optimal efficacy, the use of Epo should be discouraged 
in elective hip-and knee surgery, as well as use of devices for re-infusion of salvaged blood, 
like cell savers and post-operative drain re-infusion devices.
 Although autologous salvaged blood contains many cytokines from the wound bed 
(chapter 5), comparable changes in pro-inflammatory cytokine gene expression of IL-
8, TNFsf10 and TNFsf13 were seen in the systemic circulation of re-infused and control 
patients (chapter 6). This finding does not support the hypothesis that salvaged blood in 
general may reduce postoperative infection risk due to its immuno-modulatory properties. 
However, re-infusion of washed salvaged blood showed a lower pro-inflammatory cytokine 
profile in the patient than unwashed salvaged blood. 
 In order to aim for an optimal and Tailor Made Blood Management Program (in Dutch: 
Transfusie Op Maat) for elective orthopaedic surgery patients, we need to investigate other 
(cost-) effective modalities, as well as to distinguish the patient at risk for blood transfusions 
and for adverse outcome from the normal risk patient (chapter 8). On the other hand, we 
need to de-implement current blood management policies that use non cost-effective 
modalities, such as Epo and autologous blood re-infusion devices, starting by first exploring 
the barriers and facilitators for de-implementation (chapter 9).
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Samenvatting
Om de kans op het krijgen van een allogene bloedtransfusie in de electieve orthopaedische 
chirurgie te minimaliseren, worden zowel een restrictief transfusie beleid als het gebruik 
van transfusie alternatieven alom aanbevolen. De eerste stap naar optimaal Patient Blood 
Management zou het implementeren van een strict transfusiebeleid moeten zijn. Met deze 
maatregel, is het ons gelukt om een 36% reductie in gemiddeld Rode Bloed Cel (RBC) gebruik 
te bereiken en een daling van 13% in het aantal getransfundeerde patienten (hoofdstukken 
2 en 3), zonder aantoonbare verschillen in kwaliteit van leven (hoofdstukken 3 en 4). Omdat 
in onze studie nog steeds 26% van de patiënten getransfundeerd werd (hoofdstuk 2), 
was het een logische tweede stap om het additionele effect van transfusie alternatieven 
op RBC gebruik te evalueren. Hoewel veel is gepubliceerd over het gebruik van transfusie 
alternatieven, waren de inclusie aantallen in de studies vaak laag en werd vaak geen gebruik 
gemaakt van een restrictief transfusiebeleid. In een pilot studie vergeleken we verschillende 
typen post-operatieve drain re-infusie systemen op hun efficiëntie en gebruikersgemak en 
vonden we deze gelijkwaardig (hoofdstuk 5). Deze pilot studie was verricht om een besluit 
te kunnen nemen welk drain re-infusiesysteem geschikt zou zijn om te gebruiken in een 
grotere studie over transfusie alternatieven, waarin tegelijkertijd erythropoietine (Epo) als 
preoperatieve modaliteit, de cell saver voor re-infusie van gewassen wondbloed als intra-
operatieve modaliteit, alsook een drain re-infusie systeem voor re-infusie van ongewassen 
wondbloed als postoperatieve modaliteit, zou worden onderzocht. Bij alle patiënten 
werd een restrictief transfusie beleid volgens de huidige Nederlandse Transfusie Richtlijn 
gebruikt (hoofdstuk 7). In deze studie bleek Epo de enige effectieve bloedbesparende 
maatregel te zijn, maar was helaas niet kosten-effectief. Om een zo'n optimaal mogelijke 
kosten-effectiviteit te bereiken, dient het gebruik van Epo in de electieve heup-en knie 
vervangende chirurgie, ontmoedigd te worden, net zoals het gebruik van wondbloedre-
infusie systemen, zoals cell savers en post-operatieve drain re-infusie systemen.
 Hoewel autoloog wondbloed veel cytokines vanuit het wondbed bevat (hoofdstuk 5), 
werden vergelijkbare veranderingen in pro-inflammatoire cytokine gen expressie van IL-
8, TNFsf10 en TNFsf13 gevonden in de systemische circulatie van zowel gere-infundeerde 
patiënten als controle patiënten (hoofdstuk 6). Deze bevinding ondersteunt de hypothese 
niet dat wondbloed in het algemeen het postoperatieve infectierisico kan verlagen vanwege 
de immuno-modulatoire eigenschappen. Echter, re-infusie van gewassen wondbloed 
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Om een optimaal Bloed Management Protocol Op Maat te bereiken voor de electieve 
orthopaedische chirurgie patiënt, is het nodig om andere (kosten-) effectieve modaliteiten 
te onderzoeken, en om de risico patiënt met een verhoogde kans op het krijgen van een RBC 
transfusie en op het krijgen van complicaties, te kunnen onderscheiden van de patiënt met 
een gemiddeld risico (hoofdstuk 8). Anderzijds zouden we bestaande bloedmanagement 
protocollen waarin gebruik gemaakt wordt van niet-kosten effectieve modaliteiten, zoals 
Epo en autoloog wondbloed re-infusie systemen, onder de loep moeten nemen met als 
doel deze modaliteiten te de-implementeren. Hiervoor dienen in eerste instantie zowel 
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De auteur van dit proefschrift werd op 17 juli 1966 geboren te Jakarta, Indonesië. In 1968 
emigreerde haar familie naar Nederland. Het middelbaar onderwijs werd gevolgd aan de 
CSG Comenius te Capelle aan den IJssel, alwaar in 1984 het VWO diploma werd behaald. 
Vanaf 1984 studeerde ze geneeskunde aan de Erasmus Universiteit te Rotterdam, waar 
het artsexamen werd behaald in 1990. Na een jaar AGNIO-schap startte ze haar opleiding 
to internist in het Zuiderziekenhuis te Rotterdam (nu Maasstad-ziekenhuis) (opleider 
dr A. Berghout), welke werd afgerond in het Dijkzigt ziekenhuis, eveneens in Rotterdam 
(nu EMC-Centrum) (opleider prof. dr S.W.J. Lamberts). Na haar registratie in de Inwendige 
Geneeskunde in1998 volgde een registratie in de Hematologie (2001) (opleider prof dr B. 
Löwenberg) en een registratie in de Bloedtransfusiegeneeskunde (2003) (opleider prof dr 
A. Brand). Gedurende de opleiding tot transfusiespecialist werden de eerste stappen gezet 
voor dit proefschrift, waarin gestart werd met het opzetten van klinische studies inzake 
bloedtransfusiegebruik op de afdeling Orthopaedie met prof dr R.G.H.H. Nelissen. Sinds 
2002 is zij werkzaam bij Sanquin Bloedvoorziening op de afdeling Klinische Consultatieve 
Dienst als Bloedtransfusiespecialist. In 2008 werd het Master of Science diploma in de 
Klinische Epidemiologie behaald (VUMC, Amsterdam). 
Cynthia is in 1994 getrouwd met Ralph, anaesthesioloog-intensivist en Manager Kwaliteit 
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